<!DOCTYPE html><html  lang="en" data-capo=""><head><meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>Frontiers | Germline and Somatic BRCA1&#x2F;2 Mutations in 172 Chinese Women With Epithelial Ovarian Cancer</title>
<link rel="stylesheet" href="/ap-2024/_nuxt/entry.CWBB-NGm.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/vue-core.B-WA3Vg5.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/explainer.CMppEa5M.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleDetails.B93eTAmx.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleLayoutHeader.CKWUz2Al.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/AnnouncementCard.Db7nmstV.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/FloatingButtons.xuP8gC33.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleEvent.D0PaxIW7.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/SimilarArticles.BMee4Fk4.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleTemplateBanner.CXmOJ7NH.css">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/v1IBIWh4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/B674Mi_H.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BXedFy5e.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/eQMj-Fph.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Y8NTh2i4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUyL5Z_3.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/m8mdd2tc.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DHv8pTSw.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BHPWSuhB.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/x5HZk7Le.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CNJXQ6ZR.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dss5ciUI.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Do5q9QoL.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BhVAcJSK.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/y69VltF1.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Bw-bWKkJ.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/sQBxgu5L.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/D5YKKJGW.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CSLdjdGS.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUN89Jk2.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CCeQzihV.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DVDwh0-U.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dw4ta0fP.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CYv-CzHi.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/U-mJlaMn.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/NhyIC1F3.js">
<link rel="prefetch" as="style" crossorigin href="/ap-2024/_nuxt/ArticleHubLayout.q6CU8_bN.css">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/CKQJuUlk.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/D3plh7Cs.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/GWtHKqLR.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/DS3EY-DL.js">
<meta name="theme-color" content="#0C4DED">
<meta name="mobile-web-app-capable" content="yes">
<meta name="apple-mobile-web-app-capable" content="yes">
<script type="text/javascript" data-hid="4cd079c">window.NREUM||(NREUM={});NREUM.info = {"agent":"","beacon":"bam.nr-data.net","errorBeacon":"bam.nr-data.net","licenseKey":"598a124f17","applicationID":"586843029","agentToken":null,"applicationTime":3.333885,"transactionName":"MQcDMkECCkNSW0YMWghNLwlBDgVcWkJXAWAUC04MXBYWXlJUQUpaCAEOClwEHR9SSkYMVgoHEkkZTAJfXVscVwVUUk9WA1FdBRxeRwlZ","queueTime":0,"ttGuid":"10c3868c2dbd8f2d"}; (window.NREUM||(NREUM={})).init={privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]},feature_flags:["soft_nav"],distributed_tracing:{enabled:true}};(window.NREUM||(NREUM={})).loader_config={agentID:"594460232",accountID:"230385",trustKey:"230385",xpid:"VgUHUl5WGwYIUllWBAEFXw==",licenseKey:"598a124f17",applicationID:"586843029",browserID:"594460232"};;/*! For license information please see nr-loader-spa-1.303.0.min.js.LICENSE.txt */
(()=>{var e,t,r={384:(e,t,r)=>{"use strict";r.d(t,{NT:()=>s,US:()=>d,Zm:()=>a,bQ:()=>u,dV:()=>c,pV:()=>l});var n=r(6154),i=r(1863),o=r(1910);const s={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return n.gm.NREUM||(n.gm.NREUM={}),void 0===n.gm.newrelic&&(n.gm.newrelic=n.gm.NREUM),n.gm.NREUM}function c(){let e=a();return e.o||(e.o={ST:n.gm.setTimeout,SI:n.gm.setImmediate||n.gm.setInterval,CT:n.gm.clearTimeout,XHR:n.gm.XMLHttpRequest,REQ:n.gm.Request,EV:n.gm.Event,PR:n.gm.Promise,MO:n.gm.MutationObserver,FETCH:n.gm.fetch,WS:n.gm.WebSocket},(0,o.i)(...Object.values(e.o))),e}function u(e,t){let r=a();r.initializedAgents??={},t.initializedAt={ms:(0,i.t)(),date:new Date},r.initializedAgents[e]=t}function d(e,t){a()[e]=t}function l(){return function(){let e=a();const t=e.info||{};e.info={beacon:s.beacon,errorBeacon:s.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),c(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},782:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewTiming},860:(e,t,r)=>{"use strict";r.d(t,{$J:()=>d,K7:()=>c,P3:()=>u,XX:()=>i,Yy:()=>a,df:()=>o,qY:()=>n,v4:()=>s});const n="events",i="jserrors",o="browser/blobs",s="rum",a="browser/logs",c={ajax:"ajax",genericEvents:"generic_events",jserrors:i,logging:"logging",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",softNav:"soft_navigations",spa:"spa"},u={[c.pageViewEvent]:1,[c.pageViewTiming]:2,[c.metrics]:3,[c.jserrors]:4,[c.spa]:5,[c.ajax]:6,[c.sessionTrace]:7,[c.softNav]:8,[c.sessionReplay]:9,[c.logging]:10,[c.genericEvents]:11},d={[c.pageViewEvent]:s,[c.pageViewTiming]:n,[c.ajax]:n,[c.spa]:n,[c.softNav]:n,[c.metrics]:i,[c.jserrors]:i,[c.sessionTrace]:o,[c.sessionReplay]:o,[c.logging]:a,[c.genericEvents]:"ins"}},944:(e,t,r)=>{"use strict";r.d(t,{R:()=>i});var n=r(3241);function i(e,t){"function"==typeof console.debug&&(console.debug("New Relic Warning: https://github.com/newrelic/newrelic-browser-agent/blob/main/docs/warning-codes.md#".concat(e),t),(0,n.W)({agentIdentifier:null,drained:null,type:"data",name:"warn",feature:"warn",data:{code:e,secondary:t}}))}},993:(e,t,r)=>{"use strict";r.d(t,{A$:()=>o,ET:()=>s,TZ:()=>a,p_:()=>i});var n=r(860);const i={ERROR:"ERROR",WARN:"WARN",INFO:"INFO",DEBUG:"DEBUG",TRACE:"TRACE"},o={OFF:0,ERROR:1,WARN:2,INFO:3,DEBUG:4,TRACE:5},s="log",a=n.K7.logging},1687:(e,t,r)=>{"use strict";r.d(t,{Ak:()=>u,Ze:()=>f,x3:()=>d});var n=r(3241),i=r(7836),o=r(3606),s=r(860),a=r(2646);const c={};function u(e,t){const r={staged:!1,priority:s.P3[t]||0};l(e),c[e].get(t)||c[e].set(t,r)}function d(e,t){e&&c[e]&&(c[e].get(t)&&c[e].delete(t),p(e,t,!1),c[e].size&&h(e))}function l(e){if(!e)throw new Error("agentIdentifier required");c[e]||(c[e]=new Map)}function f(e="",t="feature",r=!1){if(l(e),!e||!c[e].get(t)||r)return p(e,t);c[e].get(t).staged=!0,h(e)}function h(e){const t=Array.from(c[e]);t.every(([e,t])=>t.staged)&&(t.sort((e,t)=>e[1].priority-t[1].priority),t.forEach(([t])=>{c[e].delete(t),p(e,t)}))}function p(e,t,r=!0){const s=e?i.ee.get(e):i.ee,c=o.i.handlers;if(!s.aborted&&s.backlog&&c){if((0,n.W)({agentIdentifier:e,type:"lifecycle",name:"drain",feature:t}),r){const e=s.backlog[t],r=c[t];if(r){for(let t=0;e&&t<e.length;++t)g(e[t],r);Object.entries(r).forEach(([e,t])=>{Object.values(t||{}).forEach(t=>{t[0]?.on&&t[0]?.context()instanceof a.y&&t[0].on(e,t[1])})})}}s.isolatedBacklog||delete c[t],s.backlog[t]=null,s.emit("drain-"+t,[])}}function g(e,t){var r=e[1];Object.values(t[r]||{}).forEach(t=>{var r=e[0];if(t[0]===r){var n=t[1],i=e[3],o=e[2];n.apply(i,o)}})}},1741:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(944),i=r(4261);class o{#e(e,...t){if(this[e]!==o.prototype[e])return this[e](...t);(0,n.R)(35,e)}addPageAction(e,t){return this.#e(i.hG,e,t)}register(e){return this.#e(i.eY,e)}recordCustomEvent(e,t){return this.#e(i.fF,e,t)}setPageViewName(e,t){return this.#e(i.Fw,e,t)}setCustomAttribute(e,t,r){return this.#e(i.cD,e,t,r)}noticeError(e,t){return this.#e(i.o5,e,t)}setUserId(e){return this.#e(i.Dl,e)}setApplicationVersion(e){return this.#e(i.nb,e)}setErrorHandler(e){return this.#e(i.bt,e)}addRelease(e,t){return this.#e(i.k6,e,t)}log(e,t){return this.#e(i.$9,e,t)}start(){return this.#e(i.d3)}finished(e){return this.#e(i.BL,e)}recordReplay(){return this.#e(i.CH)}pauseReplay(){return this.#e(i.Tb)}addToTrace(e){return this.#e(i.U2,e)}setCurrentRouteName(e){return this.#e(i.PA,e)}interaction(e){return this.#e(i.dT,e)}wrapLogger(e,t,r){return this.#e(i.Wb,e,t,r)}measure(e,t){return this.#e(i.V1,e,t)}consent(e){return this.#e(i.Pv,e)}}},1863:(e,t,r)=>{"use strict";function n(){return Math.floor(performance.now())}r.d(t,{t:()=>n})},1910:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(944);const i=new Map;function o(...e){return e.every(e=>{if(i.has(e))return i.get(e);const t="function"==typeof e&&e.toString().includes("[native code]");return t||(0,n.R)(64,e?.name||e?.toString()),i.set(e,t),t})}},2555:(e,t,r)=>{"use strict";r.d(t,{D:()=>a,f:()=>s});var n=r(384),i=r(8122);const o={beacon:n.NT.beacon,errorBeacon:n.NT.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0};function s(e){try{return!!e.licenseKey&&!!e.errorBeacon&&!!e.applicationID}catch(e){return!1}}const a=e=>(0,i.a)(e,o)},2614:(e,t,r)=>{"use strict";r.d(t,{BB:()=>s,H3:()=>n,g:()=>u,iL:()=>c,tS:()=>a,uh:()=>i,wk:()=>o});const n="NRBA",i="SESSION",o=144e5,s=18e5,a={STARTED:"session-started",PAUSE:"session-pause",RESET:"session-reset",RESUME:"session-resume",UPDATE:"session-update"},c={SAME_TAB:"same-tab",CROSS_TAB:"cross-tab"},u={OFF:0,FULL:1,ERROR:2}},2646:(e,t,r)=>{"use strict";r.d(t,{y:()=>n});class n{constructor(e){this.contextId=e}}},2843:(e,t,r)=>{"use strict";r.d(t,{u:()=>i});var n=r(3878);function i(e,t=!1,r,i){(0,n.DD)("visibilitychange",function(){if(t)return void("hidden"===document.visibilityState&&e());e(document.visibilityState)},r,i)}},3241:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(6154);const i="newrelic";function o(e={}){try{n.gm.dispatchEvent(new CustomEvent(i,{detail:e}))}catch(e){}}},3304:(e,t,r)=>{"use strict";r.d(t,{A:()=>o});var n=r(7836);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())??""}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}return""}}},3333:(e,t,r)=>{"use strict";r.d(t,{$v:()=>d,TZ:()=>n,Xh:()=>c,Zp:()=>i,kd:()=>u,mq:()=>a,nf:()=>s,qN:()=>o});const n=r(860).K7.genericEvents,i=["auxclick","click","copy","keydown","paste","scrollend"],o=["focus","blur"],s=4,a=1e3,c=2e3,u=["PageAction","UserAction","BrowserPerformance"],d={RESOURCES:"experimental.resources",REGISTER:"register"}},3434:(e,t,r)=>{"use strict";r.d(t,{Jt:()=>o,YM:()=>u});var n=r(7836),i=r(5607);const o="nr@original:".concat(i.W),s=50;var a=Object.prototype.hasOwnProperty,c=!1;function u(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");const s="-"===n.charAt(0);for(let a=0;a<t.length;a++){const c=t[a],u=e[c];l(u)||(e[c]=r(u,s?c+n:n,i,c,o))}},r.flag=o,r;function r(t,r,n,c,u){return l(t)?t:(r||(r=""),nrWrapper[o]=t,function(e,t,r){if(Object.defineProperty&&Object.keys)try{return Object.keys(e).forEach(function(r){Object.defineProperty(t,r,{get:function(){return e[r]},set:function(t){return e[r]=t,t}})}),t}catch(e){d([e],r)}for(var n in e)a.call(e,n)&&(t[n]=e[n])}(t,nrWrapper,e),nrWrapper);function nrWrapper(){var o,a,l,f;let h;try{a=this,o=[...arguments],l="function"==typeof n?n(o,a):n||{}}catch(t){d([t,"",[o,a,c],l],e)}i(r+"start",[o,a,c],l,u);const p=performance.now();let g;try{return f=t.apply(a,o),g=performance.now(),f}catch(e){throw g=performance.now(),i(r+"err",[o,a,e],l,u),h=e,h}finally{const e=g-p,t={start:p,end:g,duration:e,isLongTask:e>=s,methodName:c,thrownError:h};t.isLongTask&&i("long-task",[t,a],l,u),i(r+"end",[o,a,f],l,u)}}}function i(r,n,i,o){if(!c||t){var s=c;c=!0;try{e.emit(r,n,i,t,o)}catch(t){d([t,r,n,i],e)}c=s}}}function d(e,t){t||(t=n.ee);try{t.emit("internal-error",e)}catch(e){}}function l(e){return!(e&&"function"==typeof e&&e.apply&&!e[o])}},3606:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(9908);o.on=s;var i=o.handlers={};function o(e,t,r,o){s(o||n.d,i,e,t,r)}function s(e,t,r,i,o){o||(o="feature"),e||(e=n.d);var s=t[o]=t[o]||{};(s[r]=s[r]||[]).push([e,i])}},3738:(e,t,r)=>{"use strict";r.d(t,{He:()=>i,Kp:()=>a,Lc:()=>u,Rz:()=>d,TZ:()=>n,bD:()=>o,d3:()=>s,jx:()=>l,sl:()=>f,uP:()=>c});const n=r(860).K7.sessionTrace,i="bstResource",o="resource",s="-start",a="-end",c="fn"+s,u="fn"+a,d="pushState",l=1e3,f=3e4},3785:(e,t,r)=>{"use strict";r.d(t,{R:()=>c,b:()=>u});var n=r(9908),i=r(1863),o=r(860),s=r(8154),a=r(993);function c(e,t,r={},c=a.p_.INFO,u,d=(0,i.t)()){(0,n.p)(s.xV,["API/logging/".concat(c.toLowerCase(),"/called")],void 0,o.K7.metrics,e),(0,n.p)(a.ET,[d,t,r,c,u],void 0,o.K7.logging,e)}function u(e){return"string"==typeof e&&Object.values(a.p_).some(t=>t===e.toUpperCase().trim())}},3878:(e,t,r)=>{"use strict";function n(e,t){return{capture:e,passive:!1,signal:t}}function i(e,t,r=!1,i){window.addEventListener(e,t,n(r,i))}function o(e,t,r=!1,i){document.addEventListener(e,t,n(r,i))}r.d(t,{DD:()=>o,jT:()=>n,sp:()=>i})},3962:(e,t,r)=>{"use strict";r.d(t,{AM:()=>s,O2:()=>l,OV:()=>o,Qu:()=>f,TZ:()=>c,ih:()=>h,pP:()=>a,t1:()=>d,tC:()=>i,wD:()=>u});var n=r(860);const i=["click","keydown","submit"],o="popstate",s="api",a="initialPageLoad",c=n.K7.softNav,u=5e3,d=500,l={INITIAL_PAGE_LOAD:"",ROUTE_CHANGE:1,UNSPECIFIED:2},f={INTERACTION:1,AJAX:2,CUSTOM_END:3,CUSTOM_TRACER:4},h={IP:"in progress",PF:"pending finish",FIN:"finished",CAN:"cancelled"}},4234:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(7836),i=r(1687);class o{constructor(e,t){this.agentIdentifier=e,this.ee=n.ee.get(e),this.featureName=t,this.blocked=!1}deregisterDrain(){(0,i.x3)(this.agentIdentifier,this.featureName)}}},4261:(e,t,r)=>{"use strict";r.d(t,{$9:()=>d,BL:()=>c,CH:()=>p,Dl:()=>R,Fw:()=>w,PA:()=>v,Pl:()=>n,Pv:()=>A,Tb:()=>f,U2:()=>s,V1:()=>E,Wb:()=>T,bt:()=>y,cD:()=>b,d3:()=>x,dT:()=>u,eY:()=>g,fF:()=>h,hG:()=>o,hw:()=>i,k6:()=>a,nb:()=>m,o5:()=>l});const n="api-",i=n+"ixn-",o="addPageAction",s="addToTrace",a="addRelease",c="finished",u="interaction",d="log",l="noticeError",f="pauseReplay",h="recordCustomEvent",p="recordReplay",g="register",m="setApplicationVersion",v="setCurrentRouteName",b="setCustomAttribute",y="setErrorHandler",w="setPageViewName",R="setUserId",x="start",T="wrapLogger",E="measure",A="consent"},4387:(e,t,r)=>{"use strict";function n(e={}){return!(!e.id||!e.name)}function i(e){return"string"==typeof e&&e.trim().length<501||"number"==typeof e}function o(e,t){if(2!==t?.harvestEndpointVersion)return{};const r=t.agentRef.runtime.appMetadata.agents[0].entityGuid;return n(e)?{"mfe.id":e.id,"mfe.name":e.name,eventSource:e.eventSource,"parent.id":e.parent?.id||r}:{"entity.guid":r,appId:t.agentRef.info.applicationID}}r.d(t,{Ux:()=>o,c7:()=>n,yo:()=>i})},5205:(e,t,r)=>{"use strict";r.d(t,{j:()=>_});var n=r(384),i=r(1741);var o=r(2555),s=r(3333);const a=e=>{if(!e||"string"!=typeof e)return!1;try{document.createDocumentFragment().querySelector(e)}catch{return!1}return!0};var c=r(2614),u=r(944),d=r(8122);const l="[data-nr-mask]",f=e=>(0,d.a)(e,(()=>{const e={feature_flags:[],experimental:{allow_registered_children:!1,resources:!1},mask_selector:"*",block_selector:"[data-nr-block]",mask_input_options:{color:!1,date:!1,"datetime-local":!1,email:!1,month:!1,number:!1,range:!1,search:!1,tel:!1,text:!1,time:!1,url:!1,week:!1,textarea:!1,select:!1,password:!0}};return{ajax:{deny_list:void 0,block_internal:!0,enabled:!0,autoStart:!0},api:{get allow_registered_children(){return e.feature_flags.includes(s.$v.REGISTER)||e.experimental.allow_registered_children},set allow_registered_children(t){e.experimental.allow_registered_children=t},duplicate_registered_data:!1},browser_consent_mode:{enabled:!1},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},get feature_flags(){return e.feature_flags},set feature_flags(t){e.feature_flags=t},generic_events:{enabled:!0,autoStart:!0},harvest:{interval:30},jserrors:{enabled:!0,autoStart:!0},logging:{enabled:!0,autoStart:!0},metrics:{enabled:!0,autoStart:!0},obfuscate:void 0,page_action:{enabled:!0},page_view_event:{enabled:!0,autoStart:!0},page_view_timing:{enabled:!0,autoStart:!0},performance:{capture_marks:!1,capture_measures:!1,capture_detail:!0,resources:{get enabled(){return e.feature_flags.includes(s.$v.RESOURCES)||e.experimental.resources},set enabled(t){e.experimental.resources=t},asset_types:[],first_party_domains:[],ignore_newrelic:!0}},privacy:{cookies_enabled:!0},proxy:{assets:void 0,beacon:void 0},session:{expiresMs:c.wk,inactiveMs:c.BB},session_replay:{autoStart:!0,enabled:!1,preload:!1,sampling_rate:10,error_sampling_rate:100,collect_fonts:!1,inline_images:!1,fix_stylesheets:!0,mask_all_inputs:!0,get mask_text_selector(){return e.mask_selector},set mask_text_selector(t){a(t)?e.mask_selector="".concat(t,",").concat(l):""===t||null===t?e.mask_selector=l:(0,u.R)(5,t)},get block_class(){return"nr-block"},get ignore_class(){return"nr-ignore"},get mask_text_class(){return"nr-mask"},get block_selector(){return e.block_selector},set block_selector(t){a(t)?e.block_selector+=",".concat(t):""!==t&&(0,u.R)(6,t)},get mask_input_options(){return e.mask_input_options},set mask_input_options(t){t&&"object"==typeof t?e.mask_input_options={...t,password:!0}:(0,u.R)(7,t)}},session_trace:{enabled:!0,autoStart:!0},soft_navigations:{enabled:!0,autoStart:!0},spa:{enabled:!0,autoStart:!0},ssl:void 0,user_actions:{enabled:!0,elementAttributes:["id","className","tagName","type"]}}})());var h=r(6154),p=r(9324);let g=0;const m={buildEnv:p.F3,distMethod:p.Xs,version:p.xv,originTime:h.WN},v={consented:!1},b={appMetadata:{},get consented(){return this.session?.state?.consent||v.consented},set consented(e){v.consented=e},customTransaction:void 0,denyList:void 0,disabled:!1,harvester:void 0,isolatedBacklog:!1,isRecording:!1,loaderType:void 0,maxBytes:3e4,obfuscator:void 0,onerror:void 0,ptid:void 0,releaseIds:{},session:void 0,timeKeeper:void 0,registeredEntities:[],jsAttributesMetadata:{bytes:0},get harvestCount(){return++g}},y=e=>{const t=(0,d.a)(e,b),r=Object.keys(m).reduce((e,t)=>(e[t]={value:m[t],writable:!1,configurable:!0,enumerable:!0},e),{});return Object.defineProperties(t,r)};var w=r(5701);const R=e=>{const t=e.startsWith("http");e+="/",r.p=t?e:"https://"+e};var x=r(7836),T=r(3241);const E={accountID:void 0,trustKey:void 0,agentID:void 0,licenseKey:void 0,applicationID:void 0,xpid:void 0},A=e=>(0,d.a)(e,E),S=new Set;function _(e,t={},r,s){let{init:a,info:c,loader_config:u,runtime:d={},exposed:l=!0}=t;if(!c){const e=(0,n.pV)();a=e.init,c=e.info,u=e.loader_config}e.init=f(a||{}),e.loader_config=A(u||{}),c.jsAttributes??={},h.bv&&(c.jsAttributes.isWorker=!0),e.info=(0,o.D)(c);const p=e.init,g=[c.beacon,c.errorBeacon];S.has(e.agentIdentifier)||(p.proxy.assets&&(R(p.proxy.assets),g.push(p.proxy.assets)),p.proxy.beacon&&g.push(p.proxy.beacon),e.beacons=[...g],function(e){const t=(0,n.pV)();Object.getOwnPropertyNames(i.W.prototype).forEach(r=>{const n=i.W.prototype[r];if("function"!=typeof n||"constructor"===n)return;let o=t[r];e[r]&&!1!==e.exposed&&"micro-agent"!==e.runtime?.loaderType&&(t[r]=(...t)=>{const n=e[r](...t);return o?o(...t):n})})}(e),(0,n.US)("activatedFeatures",w.B),e.runSoftNavOverSpa&&=!0===p.soft_navigations.enabled&&p.feature_flags.includes("soft_nav")),d.denyList=[...p.ajax.deny_list||[],...p.ajax.block_internal?g:[]],d.ptid=e.agentIdentifier,d.loaderType=r,e.runtime=y(d),S.has(e.agentIdentifier)||(e.ee=x.ee.get(e.agentIdentifier),e.exposed=l,(0,T.W)({agentIdentifier:e.agentIdentifier,drained:!!w.B?.[e.agentIdentifier],type:"lifecycle",name:"initialize",feature:void 0,data:e.config})),S.add(e.agentIdentifier)}},5270:(e,t,r)=>{"use strict";r.d(t,{Aw:()=>s,SR:()=>o,rF:()=>a});var n=r(384),i=r(7767);function o(e){return!!(0,n.dV)().o.MO&&(0,i.V)(e)&&!0===e?.session_trace.enabled}function s(e){return!0===e?.session_replay.preload&&o(e)}function a(e,t){try{if("string"==typeof t?.type){if("password"===t.type.toLowerCase())return"*".repeat(e?.length||0);if(void 0!==t?.dataset?.nrUnmask||t?.classList?.contains("nr-unmask"))return e}}catch(e){}return"string"==typeof e?e.replace(/[\S]/g,"*"):"*".repeat(e?.length||0)}},5289:(e,t,r)=>{"use strict";r.d(t,{GG:()=>o,Qr:()=>a,sB:()=>s});var n=r(3878);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.sp)("load",e,t)}function s(e){if(i())return e();(0,n.DD)("DOMContentLoaded",e)}function a(e){if(i())return e();(0,n.sp)("popstate",e)}},5607:(e,t,r)=>{"use strict";r.d(t,{W:()=>n});const n=(0,r(9566).bz)()},5701:(e,t,r)=>{"use strict";r.d(t,{B:()=>o,t:()=>s});var n=r(3241);const i=new Set,o={};function s(e,t){const r=t.agentIdentifier;o[r]??={},e&&"object"==typeof e&&(i.has(r)||(t.ee.emit("rumresp",[e]),o[r]=e,i.add(r),(0,n.W)({agentIdentifier:r,loaded:!0,drained:!0,type:"lifecycle",name:"load",feature:void 0,data:e})))}},6154:(e,t,r)=>{"use strict";r.d(t,{A4:()=>a,OF:()=>d,RI:()=>i,WN:()=>h,bv:()=>o,gm:()=>s,lR:()=>f,m:()=>u,mw:()=>c,sb:()=>l});var n=r(1863);const i="undefined"!=typeof window&&!!window.document,o="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),s=i?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a="complete"===s?.document?.readyState,c=Boolean("hidden"===s?.document?.visibilityState),u=""+s?.location,d=/iPad|iPhone|iPod/.test(s.navigator?.userAgent),l=d&&"undefined"==typeof SharedWorker,f=(()=>{const e=s.navigator?.userAgent?.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),h=Date.now()-(0,n.t)()},6344:(e,t,r)=>{"use strict";r.d(t,{BB:()=>d,Qb:()=>l,TZ:()=>i,Ug:()=>s,Vh:()=>o,_s:()=>a,bc:()=>u,yP:()=>c});var n=r(2614);const i=r(860).K7.sessionReplay,o="errorDuringReplay",s=.12,a={DomContentLoaded:0,Load:1,FullSnapshot:2,IncrementalSnapshot:3,Meta:4,Custom:5},c={[n.g.ERROR]:15e3,[n.g.FULL]:3e5,[n.g.OFF]:0},u={RESET:{message:"Session was reset",sm:"Reset"},IMPORT:{message:"Recorder failed to import",sm:"Import"},TOO_MANY:{message:"429: Too Many Requests",sm:"Too-Many"},TOO_BIG:{message:"Payload was too large",sm:"Too-Big"},CROSS_TAB:{message:"Session Entity was set to OFF on another tab",sm:"Cross-Tab"},ENTITLEMENTS:{message:"Session Replay is not allowed and will not be started",sm:"Entitlement"}},d=5e3,l={API:"api",RESUME:"resume",SWITCH_TO_FULL:"switchToFull",INITIALIZE:"initialize",PRELOAD:"preload"}},6389:(e,t,r)=>{"use strict";function n(e,t=500,r={}){const n=r?.leading||!1;let i;return(...r)=>{n&&void 0===i&&(e.apply(this,r),i=setTimeout(()=>{i=clearTimeout(i)},t)),n||(clearTimeout(i),i=setTimeout(()=>{e.apply(this,r)},t))}}function i(e){let t=!1;return(...r)=>{t||(t=!0,e.apply(this,r))}}r.d(t,{J:()=>i,s:()=>n})},6630:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewEvent},6774:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.jserrors},7295:(e,t,r)=>{"use strict";r.d(t,{Xv:()=>s,gX:()=>i,iW:()=>o});var n=[];function i(e){if(!e||o(e))return!1;if(0===n.length)return!0;for(var t=0;t<n.length;t++){var r=n[t];if("*"===r.hostname)return!1;if(a(r.hostname,e.hostname)&&c(r.pathname,e.pathname))return!1}return!0}function o(e){return void 0===e.hostname}function s(e){if(n=[],e&&e.length)for(var t=0;t<e.length;t++){let r=e[t];if(!r)continue;0===r.indexOf("http://")?r=r.substring(7):0===r.indexOf("https://")&&(r=r.substring(8));const i=r.indexOf("/");let o,s;i>0?(o=r.substring(0,i),s=r.substring(i)):(o=r,s="");let[a]=o.split(":");n.push({hostname:a,pathname:s})}}function a(e,t){return!(e.length>t.length)&&t.indexOf(e)===t.length-e.length}function c(e,t){return 0===e.indexOf("/")&&(e=e.substring(1)),0===t.indexOf("/")&&(t=t.substring(1)),""===e||e===t}},7378:(e,t,r)=>{"use strict";r.d(t,{$p:()=>x,BR:()=>b,Kp:()=>R,L3:()=>y,Lc:()=>c,NC:()=>o,SG:()=>d,TZ:()=>i,U6:()=>p,UT:()=>m,d3:()=>w,dT:()=>f,e5:()=>E,gx:()=>v,l9:()=>l,oW:()=>h,op:()=>g,rw:()=>u,tH:()=>A,uP:()=>a,wW:()=>T,xq:()=>s});var n=r(384);const i=r(860).K7.spa,o=["click","submit","keypress","keydown","keyup","change"],s=999,a="fn-start",c="fn-end",u="cb-start",d="api-ixn-",l="remaining",f="interaction",h="spaNode",p="jsonpNode",g="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=(0,n.dV)().o.ST,w="-start",R="-end",x="-body",T="cb"+R,E="jsTime",A="fetch"},7485:(e,t,r)=>{"use strict";r.d(t,{D:()=>i});var n=r(6154);function i(e){if(0===(e||"").indexOf("data:"))return{protocol:"data"};try{const t=new URL(e,location.href),r={port:t.port,hostname:t.hostname,pathname:t.pathname,search:t.search,protocol:t.protocol.slice(0,t.protocol.indexOf(":")),sameOrigin:t.protocol===n.gm?.location?.protocol&&t.host===n.gm?.location?.host};return r.port&&""!==r.port||("http:"===t.protocol&&(r.port="80"),"https:"===t.protocol&&(r.port="443")),r.pathname&&""!==r.pathname?r.pathname.startsWith("/")||(r.pathname="/".concat(r.pathname)):r.pathname="/",r}catch(e){return{}}}},7699:(e,t,r)=>{"use strict";r.d(t,{It:()=>o,KC:()=>a,No:()=>i,qh:()=>s});var n=r(860);const i=16e3,o=1e6,s="SESSION_ERROR",a={[n.K7.logging]:!0,[n.K7.genericEvents]:!1,[n.K7.jserrors]:!1,[n.K7.ajax]:!1}},7767:(e,t,r)=>{"use strict";r.d(t,{V:()=>i});var n=r(6154);const i=e=>n.RI&&!0===e?.privacy.cookies_enabled},7836:(e,t,r)=>{"use strict";r.d(t,{P:()=>a,ee:()=>c});var n=r(384),i=r(8990),o=r(2646),s=r(5607);const a="nr@context:".concat(s.W),c=function e(t,r){var n={},s={},d={},l=!1;try{l=16===r.length&&u.initializedAgents?.[r]?.runtime.isolatedBacklog}catch(e){}var f={on:p,addEventListener:p,removeEventListener:function(e,t){var r=n[e];if(!r)return;for(var i=0;i<r.length;i++)r[i]===t&&r.splice(i,1)},emit:function(e,r,n,i,o){!1!==o&&(o=!0);if(c.aborted&&!i)return;t&&o&&t.emit(e,r,n);var a=h(n);g(e).forEach(e=>{e.apply(a,r)});var u=v()[s[e]];u&&u.push([f,e,r,a]);return a},get:m,listeners:g,context:h,buffer:function(e,t){const r=v();if(t=t||"feature",f.aborted)return;Object.entries(e||{}).forEach(([e,n])=>{s[n]=t,t in r||(r[t]=[])})},abort:function(){f._aborted=!0,Object.keys(f.backlog).forEach(e=>{delete f.backlog[e]})},isBuffering:function(e){return!!v()[s[e]]},debugId:r,backlog:l?{}:t&&"object"==typeof t.backlog?t.backlog:{},isolatedBacklog:l};return Object.defineProperty(f,"aborted",{get:()=>{let e=f._aborted||!1;return e||(t&&(e=t.aborted),e)}}),f;function h(e){return e&&e instanceof o.y?e:e?(0,i.I)(e,a,()=>new o.y(a)):new o.y(a)}function p(e,t){n[e]=g(e).concat(t)}function g(e){return n[e]||[]}function m(t){return d[t]=d[t]||e(f,t)}function v(){return f.backlog}}(void 0,"globalEE"),u=(0,n.Zm)();u.ee||(u.ee=c)},8122:(e,t,r)=>{"use strict";r.d(t,{a:()=>i});var n=r(944);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.R)(3);if(!t||"object"!=typeof t)return(0,n.R)(4);const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let s in o)if(void 0!==e[s])try{if(null===e[s]){r[s]=null;continue}Array.isArray(e[s])&&Array.isArray(t[s])?r[s]=Array.from(new Set([...e[s],...t[s]])):"object"==typeof e[s]&&"object"==typeof t[s]?r[s]=i(e[s],t[s]):r[s]=e[s]}catch(e){r[s]||(0,n.R)(1,e)}return r}catch(e){(0,n.R)(2,e)}}},8139:(e,t,r)=>{"use strict";r.d(t,{u:()=>f});var n=r(7836),i=r(3434),o=r(8990),s=r(6154);const a={},c=s.gm.XMLHttpRequest,u="addEventListener",d="removeEventListener",l="nr@wrapped:".concat(n.P);function f(e){var t=function(e){return(e||n.ee).get("events")}(e);if(a[t.debugId]++)return t;a[t.debugId]=1;var r=(0,i.YM)(t,!0);function f(e){r.inPlace(e,[u,d],"-",p)}function p(e,t){return e[1]}return"getPrototypeOf"in Object&&(s.RI&&h(document,f),c&&h(c.prototype,f),h(s.gm,f)),t.on(u+"-start",function(e,t){var n=e[1];if(null!==n&&("function"==typeof n||"object"==typeof n)&&"newrelic"!==e[0]){var i=(0,o.I)(n,l,function(){var e={object:function(){if("function"!=typeof n.handleEvent)return;return n.handleEvent.apply(n,arguments)},function:n}[typeof n];return e?r(e,"fn-",null,e.name||"anonymous"):n});this.wrapped=e[1]=i}}),t.on(d+"-start",function(e){e[1]=this.wrapped||e[1]}),t}function h(e,t,...r){let n=e;for(;"object"==typeof n&&!Object.prototype.hasOwnProperty.call(n,u);)n=Object.getPrototypeOf(n);n&&t(n,...r)}},8154:(e,t,r)=>{"use strict";r.d(t,{z_:()=>o,XG:()=>a,TZ:()=>n,rs:()=>i,xV:()=>s});r(6154),r(9566),r(384);const n=r(860).K7.metrics,i="sm",o="cm",s="storeSupportabilityMetrics",a="storeEventMetrics"},8374:(e,t,r)=>{r.nc=(()=>{try{return document?.currentScript?.nonce}catch(e){}return""})()},8990:(e,t,r)=>{"use strict";r.d(t,{I:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},9300:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.ajax},9324:(e,t,r)=>{"use strict";r.d(t,{AJ:()=>s,F3:()=>i,Xs:()=>o,Yq:()=>a,xv:()=>n});const n="1.303.0",i="PROD",o="CDN",s="@newrelic/rrweb",a="1.0.1"},9566:(e,t,r)=>{"use strict";r.d(t,{LA:()=>a,ZF:()=>c,bz:()=>s,el:()=>u});var n=r(6154);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function s(){const e=n.gm?.crypto||n.gm?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(30))),i.split("").map(e=>"x"===e?o(t,r++).toString(16):"y"===e?(3&o()|8).toString(16):e).join("")}function a(e){const t=n.gm?.crypto||n.gm?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(e)));const s=[];for(var a=0;a<e;a++)s.push(o(r,i++).toString(16));return s.join("")}function c(){return a(16)}function u(){return a(32)}},9908:(e,t,r)=>{"use strict";r.d(t,{d:()=>n,p:()=>i});var n=r(7836).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce((t,r)=>(i.f[r](e,t),t),[])),i.u=e=>({212:"nr-spa-compressor",249:"nr-spa-recorder",478:"nr-spa"}[e]+"-1.303.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA-1.303.0.PROD:",i.l=(r,n,o,s)=>{if(e[r])e[r].push(n);else{var a,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d<u.length;d++){var l=u[d];if(l.getAttribute("src")==r||l.getAttribute("data-webpack")==t+o){a=l;break}}if(!a){c=!0;var f={478:"sha512-Q1pLqcoiNmLHv0rtq3wFkJBA3kofBdRJl0ExDl0mTuAoCBd0qe/1J0XWrDlQKuNlUryL6aZfVkAMPLmoikWIoQ==",249:"sha512-695ZzudsxlMtHKnpDNvkMlJd3tdMtY03IQKVCw9SX12tjUC+f7Nrx5tnWO72Vg9RFf6DSY6wVmM3cEkRM12kkQ==",212:"sha512-18Gx1wIBsppcn0AnKFhwgw4IciNgFxiw3J74W393Ape+wtg4hlg7t6SBKsIE/Dk/tfl2yltgcgBFvYRs283AFg=="};(a=document.createElement("script")).charset="utf-8",i.nc&&a.setAttribute("nonce",i.nc),a.setAttribute("data-webpack",t+o),a.src=r,0!==a.src.indexOf(window.location.origin+"/")&&(a.crossOrigin="anonymous"),f[s]&&(a.integrity=f[s])}e[r]=[n];var h=(t,n)=>{a.onerror=a.onload=null,clearTimeout(p);var i=e[r];if(delete e[r],a.parentNode&&a.parentNode.removeChild(a),i&&i.forEach(e=>e(n)),t)return t(n)},p=setTimeout(h.bind(null,void 0,{type:"timeout",target:a}),12e4);a.onerror=h.bind(null,a.onerror),a.onload=h.bind(null,a.onload),c&&document.head.appendChild(a)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.p="https://js-agent.newrelic.com/",(()=>{var e={38:0,788:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise((r,i)=>n=e[t]=[r,i]);r.push(n[2]=o);var s=i.p+i.u(t),a=new Error;i.l(s,r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),s=r&&r.target&&r.target.src;a.message="Loading chunk "+t+" failed.\n("+o+": "+s+")",a.name="ChunkLoadError",a.type=o,a.request=s,n[1](a)}},"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[s,a,c]=r,u=0;if(s.some(t=>0!==e[t])){for(n in a)i.o(a,n)&&(i.m[n]=a[n]);if(c)c(i)}for(t&&t(r);u<s.length;u++)o=s[u],i.o(e,o)&&e[o]&&e[o][0](),e[o]=0},r=self["webpackChunk:NRBA-1.303.0.PROD"]=self["webpackChunk:NRBA-1.303.0.PROD"]||[];r.forEach(t.bind(null,0)),r.push=t.bind(null,r.push.bind(r))})(),(()=>{"use strict";i(8374);var e=i(9566),t=i(1741);class r extends t.W{agentIdentifier=(0,e.LA)(16)}var n=i(860);const o=Object.values(n.K7);var s=i(5205);var a=i(9908),c=i(1863),u=i(4261),d=i(3241),l=i(944),f=i(5701),h=i(8154);function p(e,t,i,o){const s=o||i;!s||s[e]&&s[e]!==r.prototype[e]||(s[e]=function(){(0,a.p)(h.xV,["API/"+e+"/called"],void 0,n.K7.metrics,i.ee),(0,d.W)({agentIdentifier:i.agentIdentifier,drained:!!f.B?.[i.agentIdentifier],type:"data",name:"api",feature:u.Pl+e,data:{}});try{return t.apply(this,arguments)}catch(e){(0,l.R)(23,e)}})}function g(e,t,r,n,i){const o=e.info;null===r?delete o.jsAttributes[t]:o.jsAttributes[t]=r,(i||null===r)&&(0,a.p)(u.Pl+n,[(0,c.t)(),t,r],void 0,"session",e.ee)}var m=i(1687),v=i(4234),b=i(5289),y=i(6154),w=i(5270),R=i(7767),x=i(6389),T=i(7699);class E extends v.W{constructor(e,t){super(e.agentIdentifier,t),this.agentRef=e,this.abortHandler=void 0,this.featAggregate=void 0,this.loadedSuccessfully=void 0,this.onAggregateImported=new Promise(e=>{this.loadedSuccessfully=e}),this.deferred=Promise.resolve(),!1===e.init[this.featureName].autoStart?this.deferred=new Promise((t,r)=>{this.ee.on("manual-start-all",(0,x.J)(()=>{(0,m.Ak)(e.agentIdentifier,this.featureName),t()}))}):(0,m.Ak)(e.agentIdentifier,t)}importAggregator(e,t,r={}){if(this.featAggregate)return;const n=async()=>{let n;await this.deferred;try{if((0,R.V)(e.init)){const{setupAgentSession:t}=await i.e(478).then(i.bind(i,8766));n=t(e)}}catch(e){(0,l.R)(20,e),this.ee.emit("internal-error",[e]),(0,a.p)(T.qh,[e],void 0,this.featureName,this.ee)}try{if(!this.#t(this.featureName,n,e.init))return(0,m.Ze)(this.agentIdentifier,this.featureName),void this.loadedSuccessfully(!1);const{Aggregate:i}=await t();this.featAggregate=new i(e,r),e.runtime.harvester.initializedAggregates.push(this.featAggregate),this.loadedSuccessfully(!0)}catch(e){(0,l.R)(34,e),this.abortHandler?.(),(0,m.Ze)(this.agentIdentifier,this.featureName,!0),this.loadedSuccessfully(!1),this.ee&&this.ee.abort()}};y.RI?(0,b.GG)(()=>n(),!0):n()}#t(e,t,r){if(this.blocked)return!1;switch(e){case n.K7.sessionReplay:return(0,w.SR)(r)&&!!t;case n.K7.sessionTrace:return!!t;default:return!0}}}var A=i(6630),S=i(2614);class _ extends E{static featureName=A.T;constructor(e){var t;super(e,A.T),this.setupInspectionEvents(e.agentIdentifier),t=e,p(u.Fw,function(e,r){"string"==typeof e&&("/"!==e.charAt(0)&&(e="/"+e),t.runtime.customTransaction=(r||"http://custom.transaction")+e,(0,a.p)(u.Pl+u.Fw,[(0,c.t)()],void 0,void 0,t.ee))},t),this.importAggregator(e,()=>i.e(478).then(i.bind(i,1983)))}setupInspectionEvents(e){const t=(t,r)=>{t&&(0,d.W)({agentIdentifier:e,timeStamp:t.timeStamp,loaded:"complete"===t.target.readyState,type:"window",name:r,data:t.target.location+""})};(0,b.sB)(e=>{t(e,"DOMContentLoaded")}),(0,b.GG)(e=>{t(e,"load")}),(0,b.Qr)(e=>{t(e,"navigate")}),this.ee.on(S.tS.UPDATE,(t,r)=>{(0,d.W)({agentIdentifier:e,type:"lifecycle",name:"session",data:r})})}}var O=i(384);var N=i(2843),I=i(3878),P=i(782);class j extends E{static featureName=P.T;constructor(e){super(e,P.T),y.RI&&((0,N.u)(()=>(0,a.p)("docHidden",[(0,c.t)()],void 0,P.T,this.ee),!0),(0,I.sp)("pagehide",()=>(0,a.p)("winPagehide",[(0,c.t)()],void 0,P.T,this.ee)),this.importAggregator(e,()=>i.e(478).then(i.bind(i,9917))))}}class k extends E{static featureName=h.TZ;constructor(e){super(e,h.TZ),y.RI&&document.addEventListener("securitypolicyviolation",e=>{(0,a.p)(h.xV,["Generic/CSPViolation/Detected"],void 0,this.featureName,this.ee)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,6555)))}}var C=i(6774),L=i(3304);class H{constructor(e,t,r,n,i){this.name="UncaughtError",this.message="string"==typeof e?e:(0,L.A)(e),this.sourceURL=t,this.line=r,this.column=n,this.__newrelic=i}}function M(e){return U(e)?e:new H(void 0!==e?.message?e.message:e,e?.filename||e?.sourceURL,e?.lineno||e?.line,e?.colno||e?.col,e?.__newrelic,e?.cause)}function K(e){const t="Unhandled Promise Rejection: ";if(!e?.reason)return;if(U(e.reason)){try{e.reason.message.startsWith(t)||(e.reason.message=t+e.reason.message)}catch(e){}return M(e.reason)}const r=M(e.reason);return(r.message||"").startsWith(t)||(r.message=t+r.message),r}function D(e){if(e.error instanceof SyntaxError&&!/:\d+$/.test(e.error.stack?.trim())){const t=new H(e.message,e.filename,e.lineno,e.colno,e.error.__newrelic,e.cause);return t.name=SyntaxError.name,t}return U(e.error)?e.error:M(e)}function U(e){return e instanceof Error&&!!e.stack}function F(e,t,r,i,o=(0,c.t)()){"string"==typeof e&&(e=new Error(e)),(0,a.p)("err",[e,o,!1,t,r.runtime.isRecording,void 0,i],void 0,n.K7.jserrors,r.ee),(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,r.ee)}var W=i(4387),B=i(993),V=i(3785);function G(e,{customAttributes:t={},level:r=B.p_.INFO}={},n,i,o=(0,c.t)()){(0,V.R)(n.ee,e,t,r,i,o)}function z(e,t,r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.hG,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function Z(e,t,r,i,o=(0,c.t)()){const{start:s,end:d,customAttributes:f}=t||{},h={customAttributes:f||{}};if("object"!=typeof h.customAttributes||"string"!=typeof e||0===e.length)return void(0,l.R)(57);const p=(e,t)=>null==e?t:"number"==typeof e?e:e instanceof PerformanceMark?e.startTime:Number.NaN;if(h.start=p(s,0),h.end=p(d,o),Number.isNaN(h.start)||Number.isNaN(h.end))(0,l.R)(57);else{if(h.duration=h.end-h.start,!(h.duration<0))return(0,a.p)(u.Pl+u.V1,[h,e,i],void 0,n.K7.genericEvents,r.ee),h;(0,l.R)(58)}}function q(e,t={},r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.fF,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function X(e){p(u.eY,function(t){return Y(e,t)},e)}function Y(e,t,r){const i={};(0,l.R)(54,"newrelic.register"),t||={},t.eventSource="MicroFrontendBrowserAgent",t.licenseKey||=e.info.licenseKey,t.blocked=!1,t.parent=r||{};let o=()=>{};const s=e.runtime.registeredEntities,u=s.find(({metadata:{target:{id:e,name:r}}})=>e===t.id);if(u)return u.metadata.target.name!==t.name&&(u.metadata.target.name=t.name),u;const d=e=>{t.blocked=!0,o=e};e.init.api.allow_registered_children||d((0,x.J)(()=>(0,l.R)(55))),(0,W.c7)(t)||d((0,x.J)(()=>(0,l.R)(48,t))),(0,W.yo)(t.id)&&(0,W.yo)(t.name)||d((0,x.J)(()=>(0,l.R)(48,t)));const f={addPageAction:(r,n={})=>m(z,[r,{...i,...n},e],t),log:(r,n={})=>m(G,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),measure:(r,n={})=>m(Z,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),noticeError:(r,n={})=>m(F,[r,{...i,...n},e],t),register:(t={})=>m(Y,[e,t],f.metadata.target),recordCustomEvent:(r,n={})=>m(q,[r,{...i,...n},e],t),setApplicationVersion:e=>g("application.version",e),setCustomAttribute:(e,t)=>g(e,t),setUserId:e=>g("enduser.id",e),metadata:{customAttributes:i,target:t}},p=()=>(t.blocked&&o(),t.blocked);p()||s.push(f);const g=(e,t)=>{p()||(i[e]=t)},m=(t,r,i)=>{if(p())return;const o=(0,c.t)();(0,a.p)(h.xV,["API/register/".concat(t.name,"/called")],void 0,n.K7.metrics,e.ee);try{return e.init.api.duplicate_registered_data&&"register"!==t.name&&t(...r,void 0,o),t(...r,i,o)}catch(e){(0,l.R)(50,e)}};return f}class J extends E{static featureName=C.T;constructor(e){var t;super(e,C.T),t=e,p(u.o5,(e,r)=>F(e,r,t),t),function(e){p(u.bt,function(t){e.runtime.onerror=t},e)}(e),function(e){let t=0;p(u.k6,function(e,r){++t>10||(this.runtime.releaseIds[e.slice(-200)]=(""+r).slice(-200))},e)}(e),X(e);try{this.removeOnAbort=new AbortController}catch(e){}this.ee.on("internal-error",(t,r)=>{this.abortHandler&&(0,a.p)("ierr",[M(t),(0,c.t)(),!0,{},e.runtime.isRecording,r],void 0,this.featureName,this.ee)}),y.gm.addEventListener("unhandledrejection",t=>{this.abortHandler&&(0,a.p)("err",[K(t),(0,c.t)(),!1,{unhandledPromiseRejection:1},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),y.gm.addEventListener("error",t=>{this.abortHandler&&(0,a.p)("err",[D(t),(0,c.t)(),!1,{},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,2176)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var Q=i(8990);let ee=1;function te(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===y.gm?0:(0,Q.I)(e,"nr@id",function(){return ee++})}function re(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,L.A)(e).length}catch(e){return}}}var ne=i(8139),ie=i(7836),oe=i(3434);const se={},ae=["open","send"];function ce(e){var t=e||ie.ee;const r=function(e){return(e||ie.ee).get("xhr")}(t);if(void 0===y.gm.XMLHttpRequest)return r;if(se[r.debugId]++)return r;se[r.debugId]=1,(0,ne.u)(t);var n=(0,oe.YM)(r),i=y.gm.XMLHttpRequest,o=y.gm.MutationObserver,s=y.gm.Promise,a=y.gm.setInterval,c="readystatechange",u=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],d=[],f=y.gm.XMLHttpRequest=function(e){const t=new i(e),o=r.context(t);try{r.emit("new-xhr",[t],o),t.addEventListener(c,(s=o,function(){var e=this;e.readyState>3&&!s.resolved&&(s.resolved=!0,r.emit("xhr-resolved",[],e)),n.inPlace(e,u,"fn-",b)}),(0,I.jT)(!1))}catch(e){(0,l.R)(15,e);try{r.emit("internal-error",[e])}catch(e){}}var s;return t};function h(e,t){n.inPlace(t,["onreadystatechange"],"fn-",b)}if(function(e,t){for(var r in e)t[r]=e[r]}(i,f),f.prototype=i.prototype,n.inPlace(f.prototype,ae,"-xhr-",b),r.on("send-xhr-start",function(e,t){h(e,t),function(e){d.push(e),o&&(p?p.then(v):a?a(v):(g=-g,m.data=g))}(t)}),r.on("open-xhr-start",h),o){var p=s&&s.resolve();if(!a&&!s){var g=1,m=document.createTextNode(g);new o(v).observe(m,{characterData:!0})}}else t.on("fn-end",function(e){e[0]&&e[0].type===c||v()});function v(){for(var e=0;e<d.length;e++)h(0,d[e]);d.length&&(d=[])}function b(e,t){return t}return r}var ue="fetch-",de=ue+"body-",le=["arrayBuffer","blob","json","text","formData"],fe=y.gm.Request,he=y.gm.Response,pe="prototype";const ge={};function me(e){const t=function(e){return(e||ie.ee).get("fetch")}(e);if(!(fe&&he&&y.gm.fetch))return t;if(ge[t.debugId]++)return t;function r(e,r,n){var i=e[r];"function"==typeof i&&(e[r]=function(){var e,r=[...arguments],o={};t.emit(n+"before-start",[r],o),o[ie.P]&&o[ie.P].dt&&(e=o[ie.P].dt);var s=i.apply(this,r);return t.emit(n+"start",[r,e],s),s.then(function(e){return t.emit(n+"end",[null,e],s),e},function(e){throw t.emit(n+"end",[e],s),e})})}return ge[t.debugId]=1,le.forEach(e=>{r(fe[pe],e,de),r(he[pe],e,de)}),r(y.gm,"fetch",ue),t.on(ue+"end",function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(ue+"done",[null,r],n)}else t.emit(ue+"done",[e],n)}),t}var ve=i(7485);class be{constructor(e){this.agentRef=e}generateTracePayload(t){const r=this.agentRef.loader_config;if(!this.shouldGenerateTrace(t)||!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var s=(0,e.ZF)(),a=(0,e.el)(),c=Date.now(),u={spanId:s,traceId:a,timestamp:c};return(t.sameOrigin||this.isAllowedOrigin(t)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(s,a),u.traceContextStateHeader=this.generateTraceContextStateHeader(s,c,n,i,o)),(t.sameOrigin&&!this.excludeNewrelicHeader()||!t.sameOrigin&&this.isAllowedOrigin(t)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(s,a,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof y.gm?.btoa))return null;var s={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(s.d.tk=o),btoa((0,L.A)(s))}shouldGenerateTrace(e){return this.agentRef.init?.distributed_tracing?.enabled&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var t=!1;const r=this.agentRef.init?.distributed_tracing;if(e.sameOrigin)t=!0;else if(r?.allowed_origins instanceof Array)for(var n=0;n<r.allowed_origins.length;n++){var i=(0,ve.D)(r.allowed_origins[n]);if(e.hostname===i.hostname&&e.protocol===i.protocol&&e.port===i.port){t=!0;break}}return t}excludeNewrelicHeader(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.exclude_newrelic_header}useNewrelicHeaderForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!1!==e.cors_use_newrelic_header}useTraceContextHeadersForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.cors_use_tracecontext_headers}}var ye=i(9300),we=i(7295);function Re(e){return"string"==typeof e?e:e instanceof(0,O.dV)().o.REQ?e.url:y.gm?.URL&&e instanceof URL?e.href:void 0}var xe=["load","error","abort","timeout"],Te=xe.length,Ee=(0,O.dV)().o.REQ,Ae=(0,O.dV)().o.XHR;const Se="X-NewRelic-App-Data";class _e extends E{static featureName=ye.T;constructor(e){super(e,ye.T),this.dt=new be(e),this.handler=(e,t,r,n)=>(0,a.p)(e,t,r,n,this.ee);try{const e={xmlhttprequest:"xhr",fetch:"fetch",beacon:"beacon"};y.gm?.performance?.getEntriesByType("resource").forEach(t=>{if(t.initiatorType in e&&0!==t.responseStatus){const r={status:t.responseStatus},i={rxSize:t.transferSize,duration:Math.floor(t.duration),cbTime:0};Oe(r,t.name),this.handler("xhr",[r,i,t.startTime,t.responseEnd,e[t.initiatorType]],void 0,n.K7.ajax)}})}catch(e){}me(this.ee),ce(this.ee),function(e,t,r,i){function o(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},t.latestLongtaskEnd=0,e.addEventListener("load",function(r){A(t,e)},(0,I.jT)(!1)),y.lR||e.addEventListener("progress",function(e){t.lastSize=e.loaded},(0,I.jT)(!1))}function s(e){this.params={method:e[0]},Oe(this,e[1]),this.metrics={}}function u(t,r){e.loader_config.xpid&&this.sameOrigin&&r.setRequestHeader("X-NewRelic-ID",e.loader_config.xpid);var n=i.generateTracePayload(this.parsedOrigin);if(n){var o=!1;n.newrelicHeader&&(r.setRequestHeader("newrelic",n.newrelicHeader),o=!0),n.traceContextParentHeader&&(r.setRequestHeader("traceparent",n.traceContextParentHeader),n.traceContextStateHeader&&r.setRequestHeader("tracestate",n.traceContextStateHeader),o=!0),o&&(this.dt=n)}}function d(e,r){var n=this.metrics,i=e[0],o=this;if(n&&i){var s=re(i);s&&(n.txSize=s)}this.startTime=(0,c.t)(),this.body=i,this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof r.onload)&&"function"==typeof o.end)&&o.end(r)}catch(e){try{t.emit("internal-error",[e])}catch(e){}}};for(var a=0;a<Te;a++)r.addEventListener(xe[a],this.listener,(0,I.jT)(!1))}function l(e,t,r){this.cbTime+=e,t?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof r.onload||"function"!=typeof this.end||this.end(r)}function f(e,t){var r=""+te(e)+!!t;this.xhrGuids&&!this.xhrGuids[r]&&(this.xhrGuids[r]=!0,this.totalCbs+=1)}function p(e,t){var r=""+te(e)+!!t;this.xhrGuids&&this.xhrGuids[r]&&(delete this.xhrGuids[r],this.totalCbs-=1)}function g(){this.endTime=(0,c.t)()}function m(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-added",[e[1],e[2]],r)}function v(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-removed",[e[1],e[2]],r)}function b(e,t,r){t instanceof Ae&&("onload"===r&&(this.onload=!0),("load"===(e[0]&&e[0].type)||this.onload)&&(this.xhrCbStart=(0,c.t)()))}function w(e,r){this.xhrCbStart&&t.emit("xhr-cb-time",[(0,c.t)()-this.xhrCbStart,this.onload,r],r)}function R(e){var t,r=e[1]||{};if("string"==typeof e[0]?0===(t=e[0]).length&&y.RI&&(t=""+y.gm.location.href):e[0]&&e[0].url?t=e[0].url:y.gm?.URL&&e[0]&&e[0]instanceof URL?t=e[0].href:"function"==typeof e[0].toString&&(t=e[0].toString()),"string"==typeof t&&0!==t.length){t&&(this.parsedOrigin=(0,ve.D)(t),this.sameOrigin=this.parsedOrigin.sameOrigin);var n=i.generateTracePayload(this.parsedOrigin);if(n&&(n.newrelicHeader||n.traceContextParentHeader))if(e[0]&&e[0].headers)a(e[0].headers,n)&&(this.dt=n);else{var o={};for(var s in r)o[s]=r[s];o.headers=new Headers(r.headers||{}),a(o.headers,n)&&(this.dt=n),e.length>1?e[1]=o:e.push(o)}}function a(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,c.t)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r=this.opts||{},n=this.target;Oe(this,Re(n));var i=(""+(n&&n instanceof Ee&&n.method||r.method||"GET")).toUpperCase();this.params.method=i,this.body=r.body,this.txSize=re(r.body)||0}function T(e,t){if(this.endTime=(0,c.t)(),this.params||(this.params={}),(0,we.iW)(this.params))return;let i;this.params.status=t?t.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(i=+this.rxSize);const o={txSize:this.txSize,rxSize:i,duration:(0,c.t)()-this.startTime};r("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,n.K7.ajax)}function E(e){const t=this.params,i=this.metrics;if(!this.ended){this.ended=!0;for(let t=0;t<Te;t++)e.removeEventListener(xe[t],this.listener,!1);t.aborted||(0,we.iW)(t)||(i.duration=(0,c.t)()-this.startTime,this.loadCaptureCalled||4!==e.readyState?null==t.status&&(t.status=0):A(this,e),i.cbTime=this.cbTime,r("xhr",[t,i,this.startTime,this.endTime,"xhr"],this,n.K7.ajax))}}function A(e,r){e.params.status=r.status;var i=function(e,t){var r=e.responseType;return"json"===r&&null!==t?t:"arraybuffer"===r||"blob"===r||"json"===r?re(e.response):"text"===r||""===r||void 0===r?re(e.responseText):void 0}(r,e.lastSize);if(i&&(e.metrics.rxSize=i),e.sameOrigin&&r.getAllResponseHeaders().indexOf(Se)>=0){var o=r.getResponseHeader(Se);o&&((0,a.p)(h.rs,["Ajax/CrossApplicationTracing/Header/Seen"],void 0,n.K7.metrics,t),e.params.cat=o.split(", ").pop())}e.loadCaptureCalled=!0}t.on("new-xhr",o),t.on("open-xhr-start",s),t.on("open-xhr-end",u),t.on("send-xhr-start",d),t.on("xhr-cb-time",l),t.on("xhr-load-added",f),t.on("xhr-load-removed",p),t.on("xhr-resolved",g),t.on("addEventListener-end",m),t.on("removeEventListener-end",v),t.on("fn-end",w),t.on("fetch-before-start",R),t.on("fetch-start",x),t.on("fn-start",b),t.on("fetch-done",T)}(e,this.ee,this.handler,this.dt),this.importAggregator(e,()=>i.e(478).then(i.bind(i,3845)))}}function Oe(e,t){var r=(0,ve.D)(t),n=e.params||e;n.hostname=r.hostname,n.port=r.port,n.protocol=r.protocol,n.host=r.hostname+":"+r.port,n.pathname=r.pathname,e.parsedOrigin=r,e.sameOrigin=r.sameOrigin}const Ne={},Ie=["pushState","replaceState"];function Pe(e){const t=function(e){return(e||ie.ee).get("history")}(e);return!y.RI||Ne[t.debugId]++||(Ne[t.debugId]=1,(0,oe.YM)(t).inPlace(window.history,Ie,"-")),t}var je=i(3738);function ke(e){p(u.BL,function(t=Date.now()){const r=t-y.WN;r<0&&(0,l.R)(62,t),(0,a.p)(h.XG,[u.BL,{time:r}],void 0,n.K7.metrics,e.ee),e.addToTrace({name:u.BL,start:t,origin:"nr"}),(0,a.p)(u.Pl+u.hG,[r,u.BL],void 0,n.K7.genericEvents,e.ee)},e)}const{He:Ce,bD:Le,d3:He,Kp:Me,TZ:Ke,Lc:De,uP:Ue,Rz:Fe}=je;class We extends E{static featureName=Ke;constructor(e){var t;super(e,Ke),t=e,p(u.U2,function(e){if(!(e&&"object"==typeof e&&e.name&&e.start))return;const r={n:e.name,s:e.start-y.WN,e:(e.end||e.start)-y.WN,o:e.origin||"",t:"api"};r.s<0||r.e<0||r.e<r.s?(0,l.R)(61,{start:r.s,end:r.e}):(0,a.p)("bstApi",[r],void 0,n.K7.sessionTrace,t.ee)},t),ke(e);if(!(0,R.V)(e.init))return void this.deregisterDrain();const r=this.ee;let o;Pe(r),this.eventsEE=(0,ne.u)(r),this.eventsEE.on(Ue,function(e,t){this.bstStart=(0,c.t)()}),this.eventsEE.on(De,function(e,t){(0,a.p)("bst",[e[0],t,this.bstStart,(0,c.t)()],void 0,n.K7.sessionTrace,r)}),r.on(Fe+He,function(e){this.time=(0,c.t)(),this.startPath=location.pathname+location.hash}),r.on(Fe+Me,function(e){(0,a.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,n.K7.sessionTrace,r)});try{o=new PerformanceObserver(e=>{const t=e.getEntries();(0,a.p)(Ce,[t],void 0,n.K7.sessionTrace,r)}),o.observe({type:Le,buffered:!0})}catch(e){}this.importAggregator(e,()=>i.e(478).then(i.bind(i,6974)),{resourceObserver:o})}}var Be=i(6344);class Ve extends E{static featureName=Be.TZ;#n;recorder;constructor(e){var t;let r;super(e,Be.TZ),t=e,p(u.CH,function(){(0,a.p)(u.CH,[],void 0,n.K7.sessionReplay,t.ee)},t),function(e){p(u.Tb,function(){(0,a.p)(u.Tb,[],void 0,n.K7.sessionReplay,e.ee)},e)}(e);try{r=JSON.parse(localStorage.getItem("".concat(S.H3,"_").concat(S.uh)))}catch(e){}(0,w.SR)(e.init)&&this.ee.on(u.CH,()=>this.#i()),this.#o(r)&&this.importRecorder().then(e=>{e.startRecording(Be.Qb.PRELOAD,r?.sessionReplayMode)}),this.importAggregator(this.agentRef,()=>i.e(478).then(i.bind(i,6167)),this),this.ee.on("err",e=>{this.blocked||this.agentRef.runtime.isRecording&&(this.errorNoticed=!0,(0,a.p)(Be.Vh,[e],void 0,this.featureName,this.ee))})}#o(e){return e&&(e.sessionReplayMode===S.g.FULL||e.sessionReplayMode===S.g.ERROR)||(0,w.Aw)(this.agentRef.init)}importRecorder(){return this.recorder?Promise.resolve(this.recorder):(this.#n??=Promise.all([i.e(478),i.e(249)]).then(i.bind(i,4866)).then(({Recorder:e})=>(this.recorder=new e(this),this.recorder)).catch(e=>{throw this.ee.emit("internal-error",[e]),this.blocked=!0,e}),this.#n)}#i(){this.blocked||(this.featAggregate?this.featAggregate.mode!==S.g.FULL&&this.featAggregate.initializeRecording(S.g.FULL,!0,Be.Qb.API):this.importRecorder().then(()=>{this.recorder.startRecording(Be.Qb.API,S.g.FULL)}))}}var Ge=i(3962);function ze(e){const t=e.ee.get("tracer");function r(){}p(u.dT,function(e){return(new r).get("object"==typeof e?e:{})},e);const i=r.prototype={createTracer:function(r,i){var o={},s=this,d="function"==typeof i;return(0,a.p)(h.xV,["API/createTracer/called"],void 0,n.K7.metrics,e.ee),e.runSoftNavOverSpa||(0,a.p)(u.hw+"tracer",[(0,c.t)(),r,o],s,n.K7.spa,e.ee),function(){if(t.emit((d?"":"no-")+"fn-start",[(0,c.t)(),s,d],o),d)try{return i.apply(this,arguments)}catch(e){const r="string"==typeof e?new Error(e):e;throw t.emit("fn-err",[arguments,this,r],o),r}finally{t.emit("fn-end",[(0,c.t)()],o)}}}};["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach(t=>{p.apply(this,[t,function(){return(0,a.p)(u.hw+t,[(0,c.t)(),...arguments],this,e.runSoftNavOverSpa?n.K7.softNav:n.K7.spa,e.ee),this},e,i])}),p(u.PA,function(){e.runSoftNavOverSpa?(0,a.p)(u.hw+"routeName",[performance.now(),...arguments],void 0,n.K7.softNav,e.ee):(0,a.p)(u.Pl+"routeName",[(0,c.t)(),...arguments],this,n.K7.spa,e.ee)},e)}class Ze extends E{static featureName=Ge.TZ;constructor(e){if(super(e,Ge.TZ),ze(e),!y.RI||!(0,O.dV)().o.MO)return;const t=Pe(this.ee);try{this.removeOnAbort=new AbortController}catch(e){}Ge.tC.forEach(e=>{(0,I.sp)(e,e=>{s(e)},!0,this.removeOnAbort?.signal)});const r=()=>(0,a.p)("newURL",[(0,c.t)(),""+window.location],void 0,this.featureName,this.ee);t.on("pushState-end",r),t.on("replaceState-end",r),(0,I.sp)(Ge.OV,e=>{s(e),(0,a.p)("newURL",[e.timeStamp,""+window.location],void 0,this.featureName,this.ee)},!0,this.removeOnAbort?.signal);let n=!1;const o=new((0,O.dV)().o.MO)((e,t)=>{n||(n=!0,requestAnimationFrame(()=>{(0,a.p)("newDom",[(0,c.t)()],void 0,this.featureName,this.ee),n=!1}))}),s=(0,x.s)(e=>{(0,a.p)("newUIEvent",[e],void 0,this.featureName,this.ee),o.observe(document.body,{attributes:!0,childList:!0,subtree:!0,characterData:!0})},100,{leading:!0});this.abortHandler=function(){this.removeOnAbort?.abort(),o.disconnect(),this.abortHandler=void 0},this.importAggregator(e,()=>i.e(478).then(i.bind(i,4393)),{domObserver:o})}}var qe=i(7378);const Xe={},Ye=["appendChild","insertBefore","replaceChild"];function Je(e){const t=function(e){return(e||ie.ee).get("jsonp")}(e);if(!y.RI||Xe[t.debugId])return t;Xe[t.debugId]=!0;var r=(0,oe.YM)(t),n=/[?&](?:callback|cb)=([^&#]+)/,i=/(.*)\.([^.]+)/,o=/^(\w+)(\.|$)(.*)$/;function s(e,t){if(!e)return t;const r=e.match(o),n=r[1];return s(r[3],t[n])}return r.inPlace(Node.prototype,Ye,"dom-"),t.on("dom-start",function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var o=(a=e.src,c=a.match(n),c?c[1]:null);var a,c;if(!o)return;var u=function(e){var t=e.match(i);if(t&&t.length>=3)return{key:t[2],parent:s(t[1],window)};return{key:e,parent:window}}(o);if("function"!=typeof u.parent[u.key])return;var d={};function l(){t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}function f(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",l,(0,I.jT)(!1)),e.addEventListener("error",f,(0,I.jT)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])}),t}const $e={};function Qe(e){const t=function(e){return(e||ie.ee).get("promise")}(e);if($e[t.debugId])return t;$e[t.debugId]=!0;var r=t.context,n=(0,oe.YM)(t),i=y.gm.Promise;return i&&function(){function e(r){var o=t.context(),s=n(r,"executor-",o,null,!1);const a=Reflect.construct(i,[s],e);return t.context(a).getCtx=function(){return o},a}y.gm.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return i.toString()},Object.setPrototypeOf(e,i),["all","race"].forEach(function(r){const n=i[r];e[r]=function(e){let i=!1;[...e||[]].forEach(e=>{this.resolve(e).then(s("all"===r),s(!1))});const o=n.apply(this,arguments);return o;function s(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}}),["resolve","reject"].forEach(function(r){const n=i[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}}),e.prototype=i.prototype;const o=i.prototype.then;i.prototype.then=function(...e){var i=this,s=r(i);s.promise=i,e[0]=n(e[0],"cb-",s,null,!1),e[1]=n(e[1],"cb-",s,null,!1);const a=o.apply(this,e);return s.nextPromise=a,t.emit("propagate",[i,!0],a,!1,!1),a},i.prototype.then[oe.Jt]=o,t.on("executor-start",function(e){e[0]=n(e[0],"resolve-",this,null,!1),e[1]=n(e[1],"resolve-",this,null,!1)}),t.on("executor-err",function(e,t,r){e[1](r)}),t.on("cb-end",function(e,r,n){t.emit("propagate",[n,!0],this.nextPromise,!1,!1)}),t.on("propagate",function(e,r,n){if(!this.getCtx||r){const r=this,n=e instanceof Promise?t.context(e):null;let i;this.getCtx=function(){return i||(i=n&&n!==r?"function"==typeof n.getCtx?n.getCtx():n:r,i)}}})}(),t}const et={},tt="setTimeout",rt="setInterval",nt="clearTimeout",it="-start",ot=[tt,"setImmediate",rt,nt,"clearImmediate"];function st(e){const t=function(e){return(e||ie.ee).get("timer")}(e);if(et[t.debugId]++)return t;et[t.debugId]=1;var r=(0,oe.YM)(t);return r.inPlace(y.gm,ot.slice(0,2),tt+"-"),r.inPlace(y.gm,ot.slice(2,3),rt+"-"),r.inPlace(y.gm,ot.slice(3),nt+"-"),t.on(rt+it,function(e,t,n){e[0]=r(e[0],"fn-",null,n)}),t.on(tt+it,function(e,t,n){this.method=n,this.timerDuration=isNaN(e[1])?0:+e[1],e[0]=r(e[0],"fn-",this,n)}),t}const at={};function ct(e){const t=function(e){return(e||ie.ee).get("mutation")}(e);if(!y.RI||at[t.debugId])return t;at[t.debugId]=!0;var r=(0,oe.YM)(t),n=y.gm.MutationObserver;return n&&(window.MutationObserver=function(e){return this instanceof n?new n(r(e,"fn-")):n.apply(this,arguments)},MutationObserver.prototype=n.prototype),t}const{TZ:ut,d3:dt,Kp:lt,$p:ft,wW:ht,e5:pt,tH:gt,uP:mt,rw:vt,Lc:bt}=qe;class yt extends E{static featureName=ut;constructor(e){if(super(e,ut),ze(e),!y.RI)return;try{this.removeOnAbort=new AbortController}catch(e){}let t,r=0;const n=this.ee.get("tracer"),o=Je(this.ee),s=Qe(this.ee),u=st(this.ee),d=ce(this.ee),l=this.ee.get("events"),f=me(this.ee),h=Pe(this.ee),p=ct(this.ee);function g(e,t){h.emit("newURL",[""+window.location,t])}function m(){r++,t=window.location.hash,this[mt]=(0,c.t)()}function v(){r--,window.location.hash!==t&&g(0,!0);var e=(0,c.t)();this[pt]=~~this[pt]+e-this[mt],this[bt]=e}function b(e,t){e.on(t,function(){this[t]=(0,c.t)()})}this.ee.on(mt,m),s.on(vt,m),o.on(vt,m),this.ee.on(bt,v),s.on(ht,v),o.on(ht,v),this.ee.on("fn-err",(...t)=>{t[2]?.__newrelic?.[e.agentIdentifier]||(0,a.p)("function-err",[...t],void 0,this.featureName,this.ee)}),this.ee.buffer([mt,bt,"xhr-resolved"],this.featureName),l.buffer([mt],this.featureName),u.buffer(["setTimeout"+lt,"clearTimeout"+dt,mt],this.featureName),d.buffer([mt,"new-xhr","send-xhr"+dt],this.featureName),f.buffer([gt+dt,gt+"-done",gt+ft+dt,gt+ft+lt],this.featureName),h.buffer(["newURL"],this.featureName),p.buffer([mt],this.featureName),s.buffer(["propagate",vt,ht,"executor-err","resolve"+dt],this.featureName),n.buffer([mt,"no-"+mt],this.featureName),o.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),b(f,gt+dt),b(f,gt+"-done"),b(o,"new-jsonp"),b(o,"jsonp-end"),b(o,"cb-start"),h.on("pushState-end",g),h.on("replaceState-end",g),window.addEventListener("hashchange",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",function(){g(0,r>1)},(0,I.jT)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,5592)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var wt=i(3333);class Rt extends E{static featureName=wt.TZ;constructor(e){super(e,wt.TZ);const t=[e.init.page_action.enabled,e.init.performance.capture_marks,e.init.performance.capture_measures,e.init.user_actions.enabled,e.init.performance.resources.enabled];var r;r=e,p(u.hG,(e,t)=>z(e,t,r),r),function(e){p(u.fF,(t,r)=>q(t,r,e),e)}(e),ke(e),X(e),function(e){p(u.V1,(t,r)=>Z(t,r,e),e)}(e);const o=e.init.feature_flags.includes("user_frustrations");let s;if(y.RI&&o&&(me(this.ee),ce(this.ee),s=Pe(this.ee)),y.RI){if(e.init.user_actions.enabled&&(wt.Zp.forEach(e=>(0,I.sp)(e,e=>(0,a.p)("ua",[e],void 0,this.featureName,this.ee),!0)),wt.qN.forEach(e=>{const t=(0,x.s)(e=>{(0,a.p)("ua",[e],void 0,this.featureName,this.ee)},500,{leading:!0});(0,I.sp)(e,t)}),o)){function c(t){const r=(0,ve.D)(t);return e.beacons.includes(r.hostname+":"+r.port)}function d(){s.emit("navChange")}y.gm.addEventListener("error",()=>{(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.ee.on("open-xhr-start",(e,t)=>{c(e[1])||t.addEventListener("readystatechange",()=>{2===t.readyState&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)})}),this.ee.on("fetch-start",e=>{e.length>=1&&!c(Re(e[0]))&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)}),s.on("pushState-end",d),s.on("replaceState-end",d),window.addEventListener("hashchange",d,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",d,(0,I.jT)(!0,this.removeOnAbort?.signal))}if(e.init.performance.resources.enabled&&y.gm.PerformanceObserver?.supportedEntryTypes.includes("resource")){new PerformanceObserver(e=>{e.getEntries().forEach(e=>{(0,a.p)("browserPerformance.resource",[e],void 0,this.featureName,this.ee)})}).observe({type:"resource",buffered:!0})}}try{this.removeOnAbort=new AbortController}catch(l){}this.abortHandler=()=>{this.removeOnAbort?.abort(),this.abortHandler=void 0},t.some(e=>e)?this.importAggregator(e,()=>i.e(478).then(i.bind(i,8019))):this.deregisterDrain()}}var xt=i(2646);const Tt=new Map;function Et(e,t,r,n){if("object"!=typeof t||!t||"string"!=typeof r||!r||"function"!=typeof t[r])return(0,l.R)(29);const i=function(e){return(e||ie.ee).get("logger")}(e),o=(0,oe.YM)(i),s=new xt.y(ie.P);s.level=n.level,s.customAttributes=n.customAttributes;const a=t[r]?.[oe.Jt]||t[r];return Tt.set(a,s),o.inPlace(t,[r],"wrap-logger-",()=>Tt.get(a)),i}var At=i(1910);class St extends E{static featureName=B.TZ;constructor(e){var t;super(e,B.TZ),t=e,p(u.$9,(e,r)=>G(e,r,t),t),function(e){p(u.Wb,(t,r,{customAttributes:n={},level:i=B.p_.INFO}={})=>{Et(e.ee,t,r,{customAttributes:n,level:i})},e)}(e),X(e);const r=this.ee;["log","error","warn","info","debug","trace"].forEach(e=>{(0,At.i)(y.gm.console[e]),Et(r,y.gm.console,e,{level:"log"===e?"info":e})}),this.ee.on("wrap-logger-end",function([e]){const{level:t,customAttributes:n}=this;(0,V.R)(r,e,n,t)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,5288)))}}new class extends r{constructor(e){var t;(super(),y.gm)?(this.features={},(0,O.bQ)(this.agentIdentifier,this),this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(_),this.runSoftNavOverSpa=[...this.desiredFeatures].some(e=>e.featureName===n.K7.softNav),(0,s.j)(this,e,e.loaderType||"agent"),t=this,p(u.cD,function(e,r,n=!1){if("string"==typeof e){if(["string","number","boolean"].includes(typeof r)||null===r)return g(t,e,r,u.cD,n);(0,l.R)(40,typeof r)}else(0,l.R)(39,typeof e)},t),function(e){p(u.Dl,function(t){if("string"==typeof t||null===t)return g(e,"enduser.id",t,u.Dl,!0);(0,l.R)(41,typeof t)},e)}(this),function(e){p(u.nb,function(t){if("string"==typeof t||null===t)return g(e,"application.version",t,u.nb,!1);(0,l.R)(42,typeof t)},e)}(this),function(e){p(u.d3,function(){e.ee.emit("manual-start-all")},e)}(this),function(e){p(u.Pv,function(t=!0){if("boolean"==typeof t){if((0,a.p)(u.Pl+u.Pv,[t],void 0,"session",e.ee),e.runtime.consented=t,t){const t=e.features.page_view_event;t.onAggregateImported.then(e=>{const r=t.featAggregate;e&&!r.sentRum&&r.sendRum()})}}else(0,l.R)(65,typeof t)},e)}(this),this.run()):(0,l.R)(21)}get config(){return{info:this.info,init:this.init,loader_config:this.loader_config,runtime:this.runtime}}get api(){return this}run(){try{const e=function(e){const t={};return o.forEach(r=>{t[r]=!!e[r]?.enabled}),t}(this.init),t=[...this.desiredFeatures];t.sort((e,t)=>n.P3[e.featureName]-n.P3[t.featureName]),t.forEach(t=>{if(!e[t.featureName]&&t.featureName!==n.K7.pageViewEvent)return;if(this.runSoftNavOverSpa&&t.featureName===n.K7.spa)return;if(!this.runSoftNavOverSpa&&t.featureName===n.K7.softNav)return;const r=function(e){switch(e){case n.K7.ajax:return[n.K7.jserrors];case n.K7.sessionTrace:return[n.K7.ajax,n.K7.pageViewEvent];case n.K7.sessionReplay:return[n.K7.sessionTrace];case n.K7.pageViewTiming:return[n.K7.pageViewEvent];default:return[]}}(t.featureName).filter(e=>!(e in this.features));r.length>0&&(0,l.R)(36,{targetFeature:t.featureName,missingDependencies:r}),this.features[t.featureName]=new t(this)})}catch(e){(0,l.R)(22,e);for(const e in this.features)this.features[e].abortHandler?.();const t=(0,O.Zm)();delete t.initializedAgents[this.agentIdentifier]?.features,delete this.sharedAggregator;return t.ee.get(this.agentIdentifier).abort(),!1}}}({features:[_e,_,j,We,Ve,k,J,Rt,St,Ze,yt],loaderType:"spa"})})()})();</script>
<link rel="icon" type="image/png" sizes="16x16" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png">
<meta name="apple-mobile-web-app-title" content="Frontiers | Articles">
<link rel="manifest" href="/manifest.json">
<link rel="canonical" href="https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00295/full">
<meta property="description" name="description" content="ObjectiveDespite several nationwide cohort studies on germline BRCA1/2 mutations and several small cohort studies on somatic BRCA1/2 mutations in Chinese epi...">
<meta property="og:title" name="title" content="Frontiers | Germline and Somatic BRCA1/2 Mutations in 172 Chinese Women With Epithelial Ovarian Cancer">
<meta property="og:description" name="description" content="ObjectiveDespite several nationwide cohort studies on germline BRCA1/2 mutations and several small cohort studies on somatic BRCA1/2 mutations in Chinese epi...">
<meta name="keywords" content="epithelial ovarian cancer,BRCA mutations,germline mutations,somatic mutations,Progression-free survival,overall survival">
<meta property="og:site_name" name="site_name" content="Frontiers">
<meta property="og:image" name="image" content="https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g001.jpg">
<meta property="og:type" name="type" content="article">
<meta property="og:url" name="url" content="https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00295/full">
<meta name="twitter:card" content="summary_large_image">
<meta name="citation_volume" content="10">
<meta name="citation_journal_title" content="Frontiers in Oncology">
<meta name="citation_publisher" content="Frontiers">
<meta name="citation_journal_abbrev" content="Front. Oncol.">
<meta name="citation_issn" content="2234-943X">
<meta name="citation_doi" content="10.3389/fonc.2020.00295">
<meta name="citation_firstpage" content="526265">
<meta name="citation_language" content="English">
<meta name="citation_title" content="Germline and Somatic BRCA1/2 Mutations in 172 Chinese Women With Epithelial Ovarian Cancer">
<meta name="citation_keywords" content="epithelial ovarian cancer; BRCA mutations; germline mutations; somatic mutations; Progression-free survival; overall survival">
<meta name="citation_abstract" content="ObjectiveDespite several nationwide cohort studies on germline BRCA1/2 mutations and several small cohort studies on somatic BRCA1/2 mutations in Chinese epithelial ovarian cancer (EOC) patients, little is known about the impact of these findings on survival outcomes in this population. In this study of 172 retrospectively recruited Chinese EOC patients, germline and somatic BRCA1/2 mutations and their value for predicting survival outcomes were evaluated.MethodsUnselected patients who visited the study center from January 1, 2011, to January 1, 2015, were recruited and asked to provide peripheral blood samples for this study if they were pathologically confirmed to have primary EOC. All patients received staging surgeries or debulking surgeries systemic platinum-based chemotherapy, and the patients were then followed up to December 1, 2017. DNA was extracted from formalin-fixed, paraffin-embedded (FFPE) sections and peripheral blood and sequenced for somatic and germline testing, respectively. The demographic and clinicopathological characteristics of the patients were collected to analyze the distribution of BRCA mutations in subgroups. Survival outcomes were compared among various BRCA mutation statuses using univariate and multivariate models.ResultsIn 59 (34.1%) patients, 64 variants were identified, including variants of unknown signicance (VUS) in 19 patients (11.0%) and pathogenic or likely pathogenic variants in a partially overlapping set of 41 patients (23.8%). Germline BRCA mutations, somatic BRCA mutations, BRCA1 mutations in general, and BRCA2 mutations in general were found in 35 (20.3%), 7 (4.1%), 28 (16.3%) and 13 (7.6%) patients, respectively. Five recurrent mutations were identified. Personal and family cancer history as well as hereditary breast and ovarian cancer (HBOC) criteria were associated with deleterious BRCA mutations both overall and in the germline specifically, whereas only age at diagnosis of EOC was associated with somatic BRCA mutations. In univariate and Cox regression analyses, patients with BRCA1/2 mutations in general had significant improvements in progression-free survival (PFS) and overall survival (OS).ConclusionsIn Chinese EOC patients, the distributions and risk factors associated with germline and somatic BRCA1/2 were similar to those previously reported in international studies. Deleterious BRCA mutations in general were associated with improved survival outcomes in this cohort.">
<meta name="citation_article_type" content="Original Research">
<meta name="citation_pdf_url" content="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00295/pdf">
<meta name="citation_xml_url" content="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00295/xml">
<meta name="citation_fulltext_world_readable" content="yes">
<meta name="citation_online_date" content="2020/02/20">
<meta name="citation_publication_date" content="2020/03/10">
<meta name="citation_author" content="You, Yan ">
<meta name="citation_author_institution" content="Department of Pathology, Molecular Pathology Research Center, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, China">
<meta name="citation_author" content="Li, Lei ">
<meta name="citation_author_institution" content="Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, China">
<meta name="citation_author" content="Lu, Junliang ">
<meta name="citation_author_institution" content="Department of Pathology, Molecular Pathology Research Center, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, China">
<meta name="citation_author" content="Wu, Huanwen ">
<meta name="citation_author_institution" content="Department of Pathology, Molecular Pathology Research Center, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, China">
<meta name="citation_author" content="Wang, Jing ">
<meta name="citation_author_institution" content="Department of Pathology, Molecular Pathology Research Center, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, China">
<meta name="citation_author" content="Gao, Jie ">
<meta name="citation_author_institution" content="Department of Pathology, Molecular Pathology Research Center, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, China">
<meta name="citation_author" content="Wu, Ming ">
<meta name="citation_author_institution" content="Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, China">
<meta name="citation_author" content="Liang, Zhiyong ">
<meta name="citation_author_institution" content="Department of Pathology, Molecular Pathology Research Center, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, China">
<meta name="dc.identifier" content="doi:10.3389/fonc.2020.00295">
<script type="application/ld+json">{"@context":"https://schema.org","@type":"ScholarlyArticle","headline":"Germline and Somatic BRCA1/2 Mutations in 172 Chinese Women With Epithelial Ovarian Cancer","author":[{"@type":"Person","name":"Yan You","affiliation":["Department of Pathology, Molecular Pathology Research Center, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, China"]},{"@type":"Person","name":"Lei Li","affiliation":["Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, China"]},{"@type":"Person","name":"Junliang Lu","affiliation":["Department of Pathology, Molecular Pathology Research Center, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, China"]},{"@type":"Person","name":"Huanwen Wu","affiliation":["Department of Pathology, Molecular Pathology Research Center, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, China"]},{"@type":"Person","name":"Jing Wang","affiliation":["Department of Pathology, Molecular Pathology Research Center, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, China"]},{"@type":"Person","name":"Jie Gao","affiliation":["Department of Pathology, Molecular Pathology Research Center, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, China"]},{"@type":"Person","name":"Ming Wu","affiliation":["Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, China"]},{"@type":"Person","name":"Zhiyong Liang","affiliation":["Department of Pathology, Molecular Pathology Research Center, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, China"]}],"datePublished":"2020-03-10","dateModified":"2025-11-25","publisher":{"@type":"Organization","name":"Frontiers"},"isPartOf":{"@type":"PublicationIssue","datePublished":"2020","isPartOf":{"@type":"PublicationVolume","volumeNumber":"10","isPartOf":{"@type":"Periodical","name":"Frontiers in Oncology"}}},"citation":["https://doi.org/10.3389/fonc.2020.00295"],"inLanguage":"en"}</script>
<script type="module" src="/ap-2024/_nuxt/v1IBIWh4.js" crossorigin></script>
<script id="unhead:payload" type="application/json">{"title":"Frontiers | Articles"}</script></head><body  class="body--v3"><div id="__nuxt"><!--[--><!----><div theme="purple"><nav class="Ibar"><div class="Ibar__main"><div class="Ibar__wrapper"><button class="Ibar__burger" aria-label="Open Menu" data-event="iBar-btn-openMenu"></button><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/oncology" class="Ibar__journalName" data-event="iBar-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Oncology</span></div></div></a><div class="Ibar__dropdown--aboutUs" parent-data-event="iBar"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=57&amp;specialtyid=0&amp;entitytype=2&amp;entityid=451" data-event="iBar-a-submit">Submit your research</a><div class="Ibar__spacer"></div><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><div><div class="Ibar__menu Ibar__menu--journal"><div class="Ibar__menu__header"><div class="Ibar__logo"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div></div><button class="Ibar__close" aria-label="Close Menu" data-event="iBarMenu-btn-closeMenu"></button></div><div class="Ibar__menu__wrapper"><div class="Ibar__menu__journal"><a href="//www.frontiersin.org/journals/oncology" data-event="iBarMenu-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Oncology</span></div></div></a><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/breast-cancer" data-event="iBarJournal-sections-a_id_500">Breast Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-cell-signaling" data-event="iBarJournal-sections-a_id_2606">Cancer Cell Signaling</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_513">Cancer Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-genetics" data-event="iBarJournal-sections-a_id_506">Cancer Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-imaging-and-image-directed-interventions" data-event="iBarJournal-sections-a_id_515">Cancer Imaging and Image-directed Interventions</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-immunity-and-immunotherapy" data-event="iBarJournal-sections-a_id_527">Cancer Immunity and Immunotherapy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-metabolism" data-event="iBarJournal-sections-a_id_1510">Cancer Metabolism</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-molecular-targets-and-therapeutics" data-event="iBarJournal-sections-a_id_507">Cancer Molecular Targets and Therapeutics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cardio-oncology" data-event="iBarJournal-sections-a_id_1513">Cardio-Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-colorectal-cancer" data-event="iBarJournal-sections-a_id_2413">Gastrointestinal Cancers: Colorectal Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-gastric-and-esophageal-cancers" data-event="iBarJournal-sections-a_id_2415">Gastrointestinal Cancers: Gastric and Esophageal Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-hepato-pancreatic-biliary-cancers" data-event="iBarJournal-sections-a_id_2414">Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/genitourinary-oncology" data-event="iBarJournal-sections-a_id_503">Genitourinary Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gynecological-oncology" data-event="iBarJournal-sections-a_id_2079">Gynecological Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/head-and-neck-cancer" data-event="iBarJournal-sections-a_id_517">Head and Neck Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/hematologic-malignancies" data-event="iBarJournal-sections-a_id_505">Hematologic Malignancies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/molecular-and-cellular-oncology" data-event="iBarJournal-sections-a_id_508">Molecular and Cellular Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/neuro-oncology-and-neurosurgical-oncology" data-event="iBarJournal-sections-a_id_150">Neuro-Oncology and Neurosurgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pediatric-oncology" data-event="iBarJournal-sections-a_id_509">Pediatric Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pharmacology-of-anti-cancer-drugs" data-event="iBarJournal-sections-a_id_192">Pharmacology of Anti-Cancer Drugs</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/radiation-oncology" data-event="iBarJournal-sections-a_id_511">Radiation Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/skin-cancer" data-event="iBarJournal-sections-a_id_1630">Skin Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/surgical-oncology" data-event="iBarJournal-sections-a_id_512">Surgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/thoracic-oncology" data-event="iBarJournal-sections-a_id_502">Thoracic Oncology</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div></div><div class="Ibar__dropdown--aboutUs" parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><!----><!----><!----><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=57&amp;specialtyid=0&amp;entitytype=2&amp;entityid=451" data-event="iBarMenu-a-submit">Submit your research</a></div></div></div><!--[--><div class="Ibar__journal Ibar__journal--main"><div class="Ibar__wrapper Ibar__wrapper--journal"><a href="//www.frontiersin.org/journals/oncology" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Oncology</span></div></div></a><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/breast-cancer" data-event="iBarJournal-sections-a_id_500">Breast Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-cell-signaling" data-event="iBarJournal-sections-a_id_2606">Cancer Cell Signaling</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_513">Cancer Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-genetics" data-event="iBarJournal-sections-a_id_506">Cancer Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-imaging-and-image-directed-interventions" data-event="iBarJournal-sections-a_id_515">Cancer Imaging and Image-directed Interventions</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-immunity-and-immunotherapy" data-event="iBarJournal-sections-a_id_527">Cancer Immunity and Immunotherapy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-metabolism" data-event="iBarJournal-sections-a_id_1510">Cancer Metabolism</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-molecular-targets-and-therapeutics" data-event="iBarJournal-sections-a_id_507">Cancer Molecular Targets and Therapeutics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cardio-oncology" data-event="iBarJournal-sections-a_id_1513">Cardio-Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-colorectal-cancer" data-event="iBarJournal-sections-a_id_2413">Gastrointestinal Cancers: Colorectal Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-gastric-and-esophageal-cancers" data-event="iBarJournal-sections-a_id_2415">Gastrointestinal Cancers: Gastric and Esophageal Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-hepato-pancreatic-biliary-cancers" data-event="iBarJournal-sections-a_id_2414">Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/genitourinary-oncology" data-event="iBarJournal-sections-a_id_503">Genitourinary Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gynecological-oncology" data-event="iBarJournal-sections-a_id_2079">Gynecological Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/head-and-neck-cancer" data-event="iBarJournal-sections-a_id_517">Head and Neck Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/hematologic-malignancies" data-event="iBarJournal-sections-a_id_505">Hematologic Malignancies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/molecular-and-cellular-oncology" data-event="iBarJournal-sections-a_id_508">Molecular and Cellular Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/neuro-oncology-and-neurosurgical-oncology" data-event="iBarJournal-sections-a_id_150">Neuro-Oncology and Neurosurgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pediatric-oncology" data-event="iBarJournal-sections-a_id_509">Pediatric Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pharmacology-of-anti-cancer-drugs" data-event="iBarJournal-sections-a_id_192">Pharmacology of Anti-Cancer Drugs</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/radiation-oncology" data-event="iBarJournal-sections-a_id_511">Radiation Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/skin-cancer" data-event="iBarJournal-sections-a_id_1630">Skin Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/surgical-oncology" data-event="iBarJournal-sections-a_id_512">Surgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/thoracic-oncology" data-event="iBarJournal-sections-a_id_502">Thoracic Oncology</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div></div></div><div class="Ibar__journal Ibar__journal--mix"><div class="Ibar__wrapper Ibar__wrapper--journal"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/oncology" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Oncology</span></div></div></a><div class="Ibar__spacer"></div><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/breast-cancer" data-event="iBarJournal-sections-a_id_500">Breast Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-cell-signaling" data-event="iBarJournal-sections-a_id_2606">Cancer Cell Signaling</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_513">Cancer Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-genetics" data-event="iBarJournal-sections-a_id_506">Cancer Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-imaging-and-image-directed-interventions" data-event="iBarJournal-sections-a_id_515">Cancer Imaging and Image-directed Interventions</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-immunity-and-immunotherapy" data-event="iBarJournal-sections-a_id_527">Cancer Immunity and Immunotherapy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-metabolism" data-event="iBarJournal-sections-a_id_1510">Cancer Metabolism</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-molecular-targets-and-therapeutics" data-event="iBarJournal-sections-a_id_507">Cancer Molecular Targets and Therapeutics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cardio-oncology" data-event="iBarJournal-sections-a_id_1513">Cardio-Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-colorectal-cancer" data-event="iBarJournal-sections-a_id_2413">Gastrointestinal Cancers: Colorectal Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-gastric-and-esophageal-cancers" data-event="iBarJournal-sections-a_id_2415">Gastrointestinal Cancers: Gastric and Esophageal Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-hepato-pancreatic-biliary-cancers" data-event="iBarJournal-sections-a_id_2414">Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/genitourinary-oncology" data-event="iBarJournal-sections-a_id_503">Genitourinary Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gynecological-oncology" data-event="iBarJournal-sections-a_id_2079">Gynecological Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/head-and-neck-cancer" data-event="iBarJournal-sections-a_id_517">Head and Neck Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/hematologic-malignancies" data-event="iBarJournal-sections-a_id_505">Hematologic Malignancies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/molecular-and-cellular-oncology" data-event="iBarJournal-sections-a_id_508">Molecular and Cellular Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/neuro-oncology-and-neurosurgical-oncology" data-event="iBarJournal-sections-a_id_150">Neuro-Oncology and Neurosurgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pediatric-oncology" data-event="iBarJournal-sections-a_id_509">Pediatric Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pharmacology-of-anti-cancer-drugs" data-event="iBarJournal-sections-a_id_192">Pharmacology of Anti-Cancer Drugs</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/radiation-oncology" data-event="iBarJournal-sections-a_id_511">Radiation Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/skin-cancer" data-event="iBarJournal-sections-a_id_1630">Skin Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/surgical-oncology" data-event="iBarJournal-sections-a_id_512">Surgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/thoracic-oncology" data-event="iBarJournal-sections-a_id_502">Thoracic Oncology</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=57&amp;specialtyid=0&amp;entitytype=2&amp;entityid=451" data-event="iBarJournal-a-submit"><span>Submit</span><span>your research</span></a><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><!--]--></nav><div class="ArticlePage"><!--[--><div class="Layout Layout--withAside Layout--withIbarMix"><div class="Alert Alert--info Alert--noInfo ArticleTemplateBanner"><div class="Alert__icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" width="24px" class="FeedbackIcon"><path fill="#fff" d="M10 10h28v28H10z"></path><path fill="var(--blue50)" d="M24 2.88a21.12 21.12 0 1 0 0 42.24 21.12 21.12 0 0 0 0-42.24ZM22.08 13.4a.96.96 0 0 1 .96-.96h1.92a.96.96 0 0 1 .96.96v1.92a.96.96 0 0 1-.96.96h-1.92a.96.96 0 0 1-.96-.96V13.4Zm5.76 21.2a.96.96 0 0 1-.96.97h-5.76a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h.96v-7.68h-.96a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h3.84a.96.96 0 0 1 .96.96v10.56h.96a.96.96 0 0 1 .96.96v1.92Z"></path></svg></div><div class="Alert__main"><p class="Alert__message">Your new experience awaits. Try the new design now and help us make it even better</p><!--[--><button type="button" class="Button Button--outline Button--grey80 Button--small ArticleTemplateBanner__switchButton" data-event="btn-action"><span>Switch to the new experience</span></button><!--]--><!----></div><ol class="Alert__info"><!--[--><!--]--></ol></div><!----><main class="Layout__main"><!----><div class="ArticleDetails"><div class="ArticleLayoutHeader"><div class="ArticleLayoutHeader__info"><p class="ArticleLayoutHeader__info__title">ORIGINAL RESEARCH article</p><p class="ArticleLayoutHeader__info__journalDate"><span>Front. Oncol.</span><span>, 10 March 2020</span></p><p class="ArticleLayoutHeader__info__journalDate"> Sec. Women&#39;s Cancer</p><p class="ArticleLayoutHeader__info__doiVolume"><span>Volume 10 - 2020 | </span><a class="ArticleLayoutHeader__info__doi" href="https://doi.org/10.3389/fonc.2020.00295">https://doi.org/10.3389/fonc.2020.00295</a></p><!----></div><!----><!----></div><div class="ArticleDetails__main__content"><div class="ArticleDetails__main__content__main ArticleDetails__main__content__main--fullArticle"><div class="JournalAbstract"><div class="JournalAbstract__titleWrapper"><h1>Germline and Somatic <i>BRCA1/2</i> Mutations in 172 Chinese Women With Epithelial Ovarian Cancer</h1><!----></div><!----></div><div class="JournalFullText"><div class="JournalAbstract">
<a id="h1" name="h1"></a>
<div class="authors"><span class="author-wrapper notranslate">
<a href="https://loop.frontiersin.org/people/708236" class="user-id-708236"><img class="pr5" src="https://loop.frontiersin.org/images/profile/708236/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="
Yan You&#x;">Yan You</a><sup>1</sup><sup>&#x02020;</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/802691" class="user-id-802691"><img class="pr5" src="https://loop.frontiersin.org/images/profile/802691/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Lei Li&#x;">Lei Li</a><sup>2</sup><sup>&#x02020;</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/881070" class="user-id-881070"><img class="pr5" src="https://loop.frontiersin.org/images/profile/881070/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Junliang Lu&#x;">Junliang Lu</a><sup>1</sup><sup>&#x02020;</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Huanwen Wu" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Huanwen Wu<sup>1</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Jing Wang" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Jing Wang<sup>1</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Jie Gao" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Jie Gao<sup>1</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/920530" class="user-id-920530"><img class="pr5" src="https://loop.frontiersin.org/images/profile/920530/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Ming Wu&#xA;">Ming Wu</a><sup>2</sup><sup>&#x0002A;</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Zhiyong Liang&#xA;" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Zhiyong Liang<sup>1</sup><sup>&#x0002A;</sup></span></div>
<ul class="notes">
<li><span><sup>1</sup></span>Department of Pathology, Molecular Pathology Research Center, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, Beijing, China</li>
<li><span><sup>2</sup></span>Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, Beijing, China</li>
</ul>
<p class="mb15"><strong>Objective:</strong> Despite several nationwide cohort studies of germline <i>BRCA1/2</i> mutations and several small cohort studies of somatic <i>BRCA1/2</i> mutations in Chinese epithelial ovarian cancer (EOC) patients, little is known about the impact of these findings on survival outcomes in this population. In this study of 172 retrospectively recruited Chinese EOC patients, germline and somatic <i>BRCA1/2</i> mutations and their value for predicting survival outcomes were evaluated.</p>
<p class="mb15"><strong>Methods:</strong> Unselected patients who visited the study center from January 1, 2011, to January 1, 2015, were recruited and asked to provide peripheral blood samples for this study if they were pathologically confirmed to have primary EOC. All patients received staging surgeries or debulking surgeries involving systemic platinum-based chemotherapy, and the patients were then followed up to December 1, 2017. DNA was extracted from formalin-fixed, paraffin-embedded (FFPE) sections and peripheral blood and sequenced for somatic and germline testing, respectively. The demographic and clinicopathological characteristics of the patients were collected to analyze the distribution of <i>BRCA</i> mutations in subgroups. Survival outcomes were compared among various <i>BRCA</i> mutation statuses using univariate and multivariate models.</p>
<p class="mb15"><strong>Results:</strong> In 58 (33.7%) patients, 63 variants were identified, including variants of unknown significance (VUS) in 18 patients (10.5%) and pathogenic or likely pathogenic variants in a partially overlapping set of 41 patients (23.8%). Germline <i>BRCA</i> mutations, somatic <i>BRCA</i> mutations, <i>BRCA1</i> mutations in general, and <i>BRCA2</i> mutations in general were found in 35 (20.3%), 7 (4.1%), 28 (16.3%), and 13 (7.6%) patients, respectively. Five recurrent mutations were identified. Personal and family cancer histories as well as hereditary breast and ovarian cancer (HBOC) criteria were associated with deleterious <i>BRCA</i> mutations both overall and in the germline specifically, whereas only age at diagnosis of EOC was associated with somatic <i>BRCA</i> mutations. In univariate and Cox regression analyses, patients with <i>BRCA1/2</i> mutations in general had significant improvements in progression-free survival (PFS) and overall survival (OS).</p>
<p class="mb0"><strong>Conclusions:</strong> In Chinese EOC patients, the distributions and risk factors associated with germline and somatic <i>BRCA1/2</i> mutations were similar to those previously reported in international studies. Deleterious <i>BRCA</i> mutations in general were associated with improved survival outcomes in this cohort.</p>
<div class="clear"></div>
</div>
<div class="JournalFullText">
<a id="h2" name="h2"></a><h2>Introduction</h2>
<p class="mb15">Ovarian cancer is the third most common gynecological malignancy and the leading cause of mortality in female cancers (<a href="#B1">1</a>), representing 1.3% of all new cancer cases in the United States in 2018 (<a href="#B2">2</a>). In China, the prevalence of ovarian cancer has increased in the past decade, with 52,100 new cases and 22,500 related deaths in 2015 (<a href="#B3">3</a>). Ovarian cancers are a heterogeneous group of malignancies varying in etiology and molecular biology. Approximately 90% of cases belong to the epithelial type [epithelial ovarian cancer (EOC)], with the most common being high-grade serous carcinoma (HGSC). A majority of EOC patients are diagnosed at advanced stages and have a poor prognosis. As with other malignancies, the tumorigenesis of EOC is a process that drives normal cells toward a malignant state and can involve both somatic (acquired) and germline (inherited) mutations (<a href="#B4">4</a>, <a href="#B5">5</a>). Large-scale cancer sequencing data from cases in The Cancer Genome Atlas (TCGA) revealed that ovarian cancer has the highest prevalence of susceptibility-associated genes (<a href="#B6">6</a>). In previous reports, &#x0007E;5 to 10% of invasive EOC cases were hereditary (<a href="#B7">7</a>&#x02013;<a href="#B10">10</a>). In addition, inherited ovarian cancer may present as hereditary breast and ovarian cancer (HBOC) (<a href="#B11">11</a>, <a href="#B12">12</a>). However, in recent reports, &#x0007E;20% or more of all EOCs have been identified to be associated with germline mutations (<a href="#B13">13</a>&#x02013;<a href="#B16">16</a>). Most cases of inherited susceptibility to EOC are primarily related to germline mutations of <i>BRCA1</i> and <i>BRCA2</i>, which account for about 80% of hereditary ovarian cancers (<a href="#B17">17</a>&#x02013;<a href="#B19">19</a>). Mutant <i>BRCA</i> is an indispensable founding mutation in EOC (<a href="#B20">20</a>). Knowledge of the pathogenic molecular mechanism and genetic mutations involved in EOC has promoted genetic counseling and testing as well as potential intervention (<a href="#B21">21</a>). The emergence of poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors (PARPis) has necessitated genetic testing (<a href="#B22">22</a>). However, there is controversy regarding the optimum testing strategy (<a href="#B23">23</a>&#x02013;<a href="#B25">25</a>). Information on <i>BRCA1/2</i> germline mutations has predictive value for the platinum sensitivity of tumors and the survival outcomes of patients (<a href="#B26">26</a>&#x02013;<a href="#B28">28</a>). In a study by Pennington et al. (<a href="#B28">28</a>) compared to germline <i>BRCA1/2</i> mutations, somatic <i>BRCA1/2</i> mutations had a similar positive impact on overall survival (OS) and platinum responsiveness. On the other hand, in recent reports, homologous recombination deficiency has gained in importance, in addition to the BRCA mutations, on the targeted treatment (<a href="#B23">23</a>, <a href="#B29">29</a>), chemotherapy (<a href="#B30">30</a>, <a href="#B31">31</a>), and prognosis (<a href="#B32">32</a>, <a href="#B33">33</a>) in EOC patients.</p>
<p class="mb15">Despite several national cohort studies of <i>BRCA</i> germline mutations in China (<a href="#B16">16</a>, <a href="#B34">34</a>, <a href="#B35">35</a>) and in Japan (<a href="#B24">24</a>), no study has attempted to reveal the association between mutations and treatment effects or survival outcomes in Chinese EOC patients. The specific impact of somatic mutations on EOC cohorts is also not well-explored. In our previous report (<a href="#B36">36</a>), no significant outcomes were discovered due to the limited sample size and short follow-up period.</p>
<p class="mb0">In the present report, we aimed to determine the frequencies of germline and somatic <i>BRCA1/2</i> mutations in a single study center based on pathological findings from primary samples or surgical tissues. The mutation status was analyzed in the context of various demographic and clinicopathological characteristics, such as personal and family cancer history as well as histological subtypes. The impact of mutation status on sensitivity to platinum-based chemotherapy and on patient survival outcomes was also described in univariate and multivariate models.</p>
<a id="h3" name="h3"></a><h2>Materials and Methods</h2>
<h3 class="pt0">Study Subjects</h3>
<p class="mb0">Unselected patients who visited the study center from January 1, 2011, to January 1, 2015, and were diagnosed with EOC were recruited for this study. Once the pathological examination confirmed EOC, the patients were asked to provide samples of peripheral blood for germline testing if they met the following inclusion criteria: (1) age 18 years or older; (2) pathologically confirmed EOC (including EOC, carcinoma of the fallopian tube and primary peritoneal carcinoma); (3) receipt of comprehensive staging surgery or debulking surgery and systemic platinum-based chemotherapy; (4) sufficient formalin-fixed, paraffin-embedded (FFPE) sections for somatic testing, which could be performed between any two systematic chemotherapy treatments; these tissues could be collected by core biopsy or by laparoscopy for patients prepared for neoadjuvant chemotherapy or by laparotomic sampling for patients of primary staging or cytoreductive surgeries; (5) willingness to provide signed consent in advance of the trial; and (6) provision of peripheral blood for germline testing. Patients not meeting all of these inclusion criteria were excluded. Basic patient information regarding age at diagnosis, neoplasm staging and histopathological type was retrieved from medical records. This study was approved by the Institutional Review Board (IRB) of the study center (Registration No. ZS-1245). The Chinese Human Genetic Resources Management Office of the National Ministry of Science and Technology also approved this study (registration No. [2017]1901, <a href="http://www.most.gov.cn/bszn/new/rlyc/jgcx/index.htm">http://www.most.gov.cn/bszn/new/rlyc/jgcx/index.htm</a>). As previously mentioned, all patients gave informed consent before enrollment.</p>
<h3>Treatment and Follow-Up</h3>
<p class="mb15">All patients received staging surgeries or primary or interval debulking surgeries along with systematic chemotherapy, which was initiated with platinum-based chemotherapy. Demographic data and medical history, including the date of diagnosis, were retrieved from the patients&#x00027; medical records. Data regarding histological classification and grading were obtained from the electronic pathology database at the study center. Staging was determined by the International Federation of Gynecology and Obstetrics (FIGO) 2014 staging system (<a href="#B37">37</a>). Personal and family cancer histories were addressed, especially personal breast cancer history and the aspects of cancer history specified by the &#x0201C;Criteria for further genetic risk evaluation&#x0201D; from the National Comprehensive Cancer Network (NCCN) HBOC guideline of &#x0201C;Genetic/Familial High-Risk Assessment: Breast and Ovarian&#x0201D; (<a href="#B38">38</a>).</p>
<p class="mb0">Tumors were sorted into the following categories depending on their response to platinum-based chemotherapy: (1) platinum sensitive, if the time between administration and first relapse of the disease was more than 6 months; (2) platinum resistant, if the patient had a relapse 4 weeks to 6 months after administration; or (3) refractory, if the disease relapsed within 4 weeks under platinum-based agents. Follow-ups were conducted for all enrolled patients until December 1, 2017, or death. Disease relapse or progression was determined by medical imaging, serology, or histology. Progression-free survival (PFS) was defined as the time span between initial diagnosis and disease relapse or progression, while OS was defined as the time span between initial diagnosis and patient death.</p>
<h3>Analysis of Germline and Somatic <i>BRCA1/2</i> Mutational Status</h3>
<p class="mb15">For germline <i>BRCA1/2</i> analyses, DNA was extracted from 200 &#x003BC;l of peripheral blood with the QIAamp DNA Blood Mini Kit (QIAGEN, Hilden, Germany). For somatic <i>BRCA1/2</i> analysis, 10 FFPE sections measuring five micrometers in thickness and taken from representative blocks were made for each case. The cancerous region was then marked by two experienced pathologists (YY and HW) and macro-dissected following deparaffinization using xylene. DNA was then extracted from the tumor tissue using the QIAamp DNA FFPE Tissue Kit (QIAGEN, Hilden, Germany).</p>
<p class="mb15">Sequencing libraries were prepared using an Oncomine <i>BRCA</i> research assay (Thermo Fisher, Waltham, Massachusetts, USA); the libraries were then subjected to emulsion PCR using the Ion OneTouch 2 System and sequenced on an Ion Torrent Personal Genome Machine sequencer to a median of 500X depth for germline mutations and 1000X for somatic mutations according to the manufacturer&#x00027;s instructions. Upon completion, the raw data were sent through a pipeline customized by Life Technologies. The parameters for variation calling are available (in JSON format) upon request. The sequences covered all exons of the <i>BRCA1</i> and <i>BRCA2</i> genes as well as &#x000B1;20 bp flanking regions to enable the detection of variations affecting potential splice sites. However, due to its high cost, we did not include multiplex ligation-dependent probe amplification (MLPA) in the tests for <i>BRCA1/2</i>.</p>
<p class="mb0">The identified <i>BRCA1/2</i> variations were classified according to the 2015 American College of Medical Genetics and Genomics (ACMG) guidelines (<a href="#B39">39</a>). Pathogenic and likely pathogenic mutations were regarded as deleterious mutations.</p>
<h3>Statistical Analysis</h3>
<p class="mb0">Comparisons of continuous variables were conducted with parametric methods if the assumption of normality was met. Non-normally distributed variables and categorical data were compared between patients with and without specific deleterious mutations by using non-parametric tests. Kaplan&#x02013;Meier survival curves were generated, and proportional hazards models were used to estimate the hazard ratios (HRs) and 95% confidence intervals (95% CIs) for the effects of deleterious mutations on PFS and OS. A multivariable analysis of disease-free survival was performed with adjustment for the important baseline risk factors of major histological subtype (HGSC vs. others), age at diagnosis, and stage (stage I&#x02013;II vs. III&#x02013;IV). Unless otherwise stated, all analyses used a two-sided significance level of 0.05 and were conducted with Statistical Product and Service Solutions (SPSS) Statistics 20.0 software (IBM Corporation, Armonk, NY, USA).</p>
<a id="h4" name="h4"></a><h2>Results</h2>
<h3 class="pt0">Demographic and Clinicopathological Characteristics of Ovarian Cancer Patients</h3>
<p class="mb0">The demographic and clinicopathological characteristics of the patients are listed in <a href="#T1">Table 1</a>. In total, 172 patients were recruited and had final genetic testing outcomes. The median age at diagnosis in the cohort was 52.5 years (range 18&#x02013;81). Most cases were ovarian carcinomas (168 cases, 97.7%), stage III-IV (140 cases, 81.4%), and HGSC (138 cases, 80.2%). Based on personal and family cancer history, 31 patients met the HBOC criteria. No patients had ever received PARPi treatment. Progression and mortality occurred in 106 (61.6%) and 50 (29.1%) patients, and the median PFS and OS were 23 months (range 0&#x02013;68) and 39 (12&#x02013;93) months, respectively.</p>
<div class="DottedLine"></div>
<div class="Imageheaders">TABLE 1</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-t001.jpg" name="Table1" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-t001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-t001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-t001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-t001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-t001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-t001.jpg" alt="www.frontiersin.org" id="T1" loading="lazy">
  </picture>
</a>
<p><strong>Table 1</strong>. The clinicopathological characteristics and survival outcomes of the patients.</p>
</div>
<div class="clear"></div>
<div class="DottedLine"></div>
<h3>Mutation Analysis</h3>
<p class="mb0">In 58 (33.7%) patients, 63 variants were identified, including variants of unknown significance (VUS) in 18 patients (10.5%) and pathogenic or likely pathogenic variants in a partially overlapping set of 41 patients (23.8%) (<a href="#F1">Figure 1</a>). Germline <i>BRCA</i> mutations, somatic <i>BRCA</i> mutations, BRCA1 mutations in general, and <i>BRCA2</i> mutations in general were found in 35 (20.3%), 7 (4.1%), 28 (16.3%), and 13 (7.6%) patients, respectively. The mutation details are listed in <a href="#SM1">Supplement Table 1</a>. Likely pathogenic or pathogenic mutations consisted of 19 (46.3%) frameshift deletions, 4 (9.8%) frameshift insertions, 12 (29.3%) non-sense mutations, 4 (9.8%) splice-site mutations, and 2 (4.9%) missense mutations.</p>
<div class="DottedLine"></div>
<div class="Imageheaders">FIGURE 1</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g001.jpg" name="figure1" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g001.jpg" alt="www.frontiersin.org" id="F1" loading="lazy">
  </picture>
</a>
<p><strong>Figure 1</strong>. <i>BRCA1</i> <strong>(A)</strong> and <i>BRCA2</i> <strong>(B)</strong> pathogenic mutation loci.</p>
</div>
<div class="clear"></div>
<div class="DottedLine"></div>
<p class="mt15 w100pc float_left">As shown in <a href="#T2">Table 2</a> and <a href="#SM1">Supplement Table 1</a>, 35 (19.7%) and seven (4.1%) patients had at least one germline and somatic deleterious mutation, respectively; 28 (16.3%) and 13 (7.6%) patients harbored at least one deleterious mutation of <i>BRCA1</i> and <i>BRCA2</i>, respectively. Two (1.2%), 5 (2.9%), and 2 (1.2%) patients carried dual germline/somatic mutations; dual germline and dual somatic mutations classified as VUS; and dual likely pathogenic and pathogenic mutations, respectively. In cases No. 063 and No. 068, the distance between the co-occurring mutations exceeded the amplicon length; therefore, we were unable to determine whether these mutations were in cis or in trans. The criteria for reclassification were unmet for these mutations. In case No. 032, the patient harbored one likely pathogenic germline variant and one somatic pathogenic variant (<a href="#SM1">Supplement Table 1</a>).</p>
<div class="DottedLine"></div>
<div class="Imageheaders">TABLE 2</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-t002.jpg" name="Table2" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-t002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-t002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-t002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-t002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-t002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-t002.jpg" alt="www.frontiersin.org" id="T2" loading="lazy">
  </picture>
</a>
<p><strong>Table 2</strong>. Distributions of pathogenic or likely pathogenic mutations in the overall and subgroup populations.</p>
</div>
<div class="clear"></div>
<div class="DottedLine"></div>
<p class="mb0 w100pc float_left mt15">Five recurrent mutations were identified in the cohort. Three pathogenic mutations occurred in two patients (<i>BRCA1</i> c.5470_5477delATTGGGCA, <i>BRCA1</i> c.66dup, and <i>BRCA2</i> c.1963delC). Two VUS missense mutations (<i>BRCA2</i> c.1568A&#x0003E;G and <i>BRCA2</i> c.6325G&#x0003E;A) appeared in three and four patients, respectively. All recurrent mutations were in the germline except for <i>BRCA2</i> c.1964delC.</p>
<h3>Deleterious <i>BRCA</i> Mutations and Clinicopathological Characteristics</h3>
<p class="mb0">As shown in <a href="#T2">Table 2</a>, FIGO stages had no significant association with deleterious mutations of <i>BRCA</i> genes in general or of <i>BRCA1</i> or <i>BRCA2</i> in particular. Personal and family cancer history and HBOC criteria were associated with overall and germline <i>BRCA</i> mutations. HBOC criteria were also associated with overall <i>BRCA1</i> and <i>BRCA2</i> mutations. For somatic <i>BRCA</i> mutations, only age at diagnosis had a significant impact, while for germline <i>BRCA</i> mutations, histological subtype also had a significant impact. However, only overall deleterious <i>BRCA</i> mutations had a significant impact on sensitivity to platinum-based chemotherapy (<a href="#T2">Table 2</a>).</p>
<h3>Survival Analyses</h3>
<p class="mb0">The survival outcomes associated with various deleterious <i>BRCA</i> mutations are shown in <a href="#F2">Figures 2</a>, <a href="#F3">3</a> and <a href="#SM1">Supplement Table 2</a>. In univariate and Cox regression analyses, patients with overall <i>BRCA1/2</i> mutations had significant improvements in PFS and OS (<a href="#F2">Figure 2</a>, <a href="#SM1">Supplement Table 2</a>). Overall, germline <i>BRCA1/2</i> mutations were associated with significant improvement in OS but not PFS. Overall, <i>BRCA2</i> mutations were associated with significantly improved OS in the Cox regression model. Somatic <i>BRCA1/2</i> and overall <i>BRCA1</i> had no significant impact on survival outcomes. However, in the subgroup analysis of HGSC patients (<i>n</i> = 138), various mutation statuses had no significant impact on survival outcomes, except that overall <i>BRCA</i> mutations affected PFS (<a href="#SM1">Supplement Table 2</a>).</p>
<div class="DottedLine"></div>
<div class="Imageheaders">FIGURE 2</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g002.jpg" name="figure2" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g002.jpg" alt="www.frontiersin.org" id="F2" loading="lazy">
  </picture>
</a>
<p><strong>Figure 2</strong>. Survival outcomes of various <i>BRCA</i> aberrations according to Kaplan&#x02013;Meier analysis. <strong>(A)</strong> Progression-free survival (PFS) with and without deleterious <i>BRCA1/2</i> mutations. <strong>(B)</strong> PFS with and without deleterious <i>BRCA1</i> mutations. <strong>(C)</strong> PFS with and without deleterious <i>BRCA2</i> mutations. <strong>(D)</strong> Overall survival (OS) with and without deleterious <i>BRCA1/2</i> mutations. <strong>(E)</strong> OS with and without deleterious <i>BRCA1</i> mutations. <strong>(F)</strong> OS with and without deleterious <i>BRCA2</i> mutations.</p>
</div>
<div class="clear"></div>
<div class="DottedLine mb15"></div>
<div class="Imageheaders">FIGURE 3</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g003.jpg" name="figure3" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g003.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g003.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g003.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g003.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g003.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g003.jpg" alt="www.frontiersin.org" id="F3" loading="lazy">
  </picture>
</a>
<p><strong>Figure 3</strong>. Survival outcomes of germline and somatic <i>BRCA</i> aberrations according to Kaplan&#x02013;Meier analysis. <strong>(A)</strong> Progression-free survival (PFS) with and without deleterious germline <i>BRCA1/2</i> mutations. <strong>(B)</strong> Overall survival (OS) with and without deleterious germline <i>BRCA1/2</i> mutations. <strong>(C)</strong> PFS with and without deleterious somatic <i>BRCA1/2</i> mutations. <strong>(D)</strong> OS with and without deleterious somatic <i>BRCA1/2</i> mutations.</p>
</div>
<div class="clear"></div>
<div class="DottedLine"></div>
<a id="h5" name="h5"></a><h2>Discussion</h2>
<p class="mb15">To our knowledge, this study is the first to describe the positive impact of <i>BRCA</i> mutation status on survival outcomes in a Chinese EOC cohort. In our study, overall <i>BRCA</i> mutations, germline <i>BRCA</i> mutations, and overall <i>BRCA2</i> mutations were all associated with improved survival outcomes, as in previous reports (<a href="#B27">27</a>, <a href="#B28">28</a>, <a href="#B40">40</a>&#x02013;<a href="#B42">42</a>). We did not find a significant impact of germline mutations on PFS or a significant impact of somatic mutations on PFS or OS. The limited sample size was probably the main reason. As shown in <a href="#T2">Table 2</a>, HGSC patients harbored more deleterious <i>BRCA1/2</i> and <i>BRCA1</i> mutations than patients with other subtypes, and the BRCAness phenotype was independently associated with improved OS in HGSC patients (<a href="#B43">43</a>). However, in our study, the effects of sample size were so obvious that HGSC patients, the majority of the cohort, had no significant associations between mutation status and survival outcome (<a href="#SM1">Supplement Table 2</a>). A larger cohort of Chinese EOC patients (NCT03015376) would provide more details and profound perspectives on such issues. The improved survival outcomes were likely caused by a higher sensitivity to platinum in patients with deleterious mutations than in those without such mutations, as revealed in the Pennington et al. (<a href="#B28">28</a>) study.</p>
<p class="mb15">Overall, we found that germline and somatic <i>BRCA1/2</i> mutations had prevalence rates of 20.3 and 4.1%, respectively. Disparities in both germline and somatic testing exist (<a href="#B44">44</a>, <a href="#B45">45</a>). Regarding other Chinese studies, our germline mutation prevalence approximated the values reported by Li et al. (1331 cases, 22.4%) (<a href="#B16">16</a>). Wang et al. (481 cases, 19.6%) (<a href="#B46">46</a>), Shi et al. (916 cases, 17.0%), and a meta-analysis (21.8%) (<a href="#B47">47</a>), but it was significantly lower than the value reported by Wu et al. (826 cases, 28.4%) (<a href="#B35">35</a>). Our somatic <i>BRCA1/2</i> mutation prevalence was similar to those in two small cohort studies, which reported prevalence values of 4.0% (2/50) (<a href="#B48">48</a>) and 6.4% (4/62) (<a href="#B36">36</a>). These differences may originate from the selection of subjects and the database used for analysis. As addressed in a recently published meta-analysis (<a href="#B47">47</a>), the variant profile in ethnically Chinese people was distinctive from those in other ethnic groups with no distinct founder pathogenic variants. However, this conclusion should be treated cautiously. China needs a uniform platform such as TCGA to further promote genomic testing. Chinese healthcare providers, including gynecologists, still have greatly divergent opinions and suggestions about genetic testing for gynecologic oncology, and these positions are also significantly different from the requirements and recommendations in the guidelines and consensus statements (<a href="#B49">49</a>&#x02013;<a href="#B51">51</a>).</p>
<p class="mb15">There are several issues worth considering in relation to the selection bias in this report. In our study, HGSC had a significantly higher frequency of overall <i>BRCA1/2</i> and <i>BRCA1</i> mutations than other subtypes. These tumors displayed defective homologous recombination due to germline and somatic <i>BRCA</i> mutations, epigenetic inactivation of <i>BRCA</i> and abnormalities in DNA repair genes (<a href="#B9">9</a>, <a href="#B13">13</a>, <a href="#B14">14</a>). The quality of the data that can be obtained from FFPE tissues as opposed to fresh tissues needs clarification. The fact that the distribution of somatic mutations was consistent with other Chinese studies (<a href="#B36">36</a>, <a href="#B48">48</a>) and with a Polish study using FFPE tissues from HGSC patients (<a href="#B52">52</a>) could guarantee the quality of our sample preparation. It was suggested that an adjusted targeted capture-based enrichment protocol was superior to commonly applied multiplex PCR-based protocols for reliable <i>BRCA1/2</i> variant detection, including CNV detection, using FFPE tumor samples (<a href="#B53">53</a>). As previously reported, the prevalence of <i>BRCA1/2</i> mutations in patients with peritoneal carcinoma or fallopian tube carcinoma is comparable to that in EOC patients (<a href="#B54">54</a>). Therefore, we did not perform a subgroup analysis of these three site-specific cancers. We also did not evaluate the impact of neoadjuvant therapy on prognosis by <i>BRCA</i> status since primary debulking surgery seems to ensure a longer PFS than neoadjuvant chemotherapy alone in women with the <i>BRCA</i> wild-type genotype (<a href="#B55">55</a>). However, patients with pathogenic mutations in <i>BRCA</i> may benefit from intraperitoneal therapy (<a href="#B56">56</a>). Finally, no patients in our study had ever utilized PARPis. The high cost of genetic testing is an important barrier to universal performance. However, somatic and germline mutations and expression loss of <i>BRCA1/2</i> are sufficiently common in ovarian cancer to warrant assessment for the prediction of treatment benefit in clinical trials of PARPis (<a href="#B57">57</a>).</p>
<p class="mb0">We reported the previously unknown association between <i>BRCA</i> mutation and survival outcomes in Chinese EOC patients, which was the most important strength of our study. However, the present study has several limitations. We did not exploit all mechanisms of <i>BRCA1/2</i> regulation, such as large gene rearrangements and epigenetic modifications. Second, the present study population did not include a sufficient sample of histological subtypes other than HGSC; this limitation impairs the ability to capture the mutational landscape of these tumors. Third, as reported previously (<a href="#B58">58</a>&#x02013;<a href="#B61">61</a>). a multigene panel for germline and/or somatic testing would probably be cost effective, providing a substantial rate of clinically actionable pathogenic variants (<a href="#B62">62</a>). There is a potential benefit to be gained from rescreening with a multigene panel in patients who previously underwent non-informative genetic screening (<a href="#B63">63</a>). On the other hand, up to 50% of ovarian HGSC patients may exhibit homologous recombination defects (<a href="#B64">64</a>), which are associated with the indication of PARPis as maintenance therapy, even in newly diagnosed EOC patients (<a href="#B23">23</a>, <a href="#B25">25</a>, <a href="#B29">29</a>). These advancements in genetic and genomic testing in EOC will promote further exploration in the future. Importantly, we did not include the MLPA analysis in our study, which is also very important for the evaluation of BRCAness (<a href="#B43">43</a>, <a href="#B65">65</a>). The lack of MLPA obviously decreases the deleterious mutation frequency in patients with EOC or breast cancer and causes bias regarding the association between BRCAness and survival prognosis (<a href="#B66">66</a>). We did not include <i>BRCA</i> methylation in the study. However, unlike <i>BRCA</i> mutation, <i>BRCA1</i> methylation was not associated with improved survival or greater sensitivity to platinum chemotherapy (<a href="#B67">67</a>). Last but not least, a discussion of cosegregation analysis and potential interventions (such as NCT03294343 and NCT04190667) should be provided to all patients with deleterious mutations.</p>
<a id="h6" name="h6"></a><h2>Conclusions</h2>
<p class="mb0">In conclusion, we reported the prevalence of germline and somatic <i>BRCA1/2</i> mutations in an unselected Chinese EOC cohort comprising 172 patients. Germline mutations were associated with cancer history, especially the aspects relevant to the HBOC criteria. Somatic mutations were associated only with age at diagnosis of EOC. In our study, overall deleterious <i>BRCA</i> mutations predicted increased sensitivity to platinum-based chemotherapy and significantly improved survival outcomes. A larger cohort must be examined with multigene panel testing and even the homologous recombination deficiency model to clarify the indications for PARPis.</p>
<a id="h7" name="h7"></a><h2>Data Availability Statement</h2>
<p class="mb0">All datasets generated for this study are included in the article/<a href="#h12">Supplementary Material</a>.</p>
<a id="h8" name="h8"></a><h2>Ethics Statement</h2>
<p class="mb0">The Institutional Review Board of Peking Union Medical College Hospital approved this study (No. HS-1245). In addition, the Chinese Human Genetic Resources Management Office of the National Ministry of Science and Technology approved this study (registration no. [2017]1901, <a href="http://www.most.gov.cn/bszn/new/rlyc/jgcx/index.htm">http://www.most.gov.cn/bszn/new/rlyc/jgcx/index.htm</a>).</p>
<a id="h9" name="h9"></a><h2>Author Contributions</h2>
<p class="mb0">MW and ZL conceived of the original idea for the study, interpreted the results, carried out the statistical analysis, edited the paper, and acted as overall guarantors. YY, LL, and JL obtained ethical approval, contributed to the preparation of the data set, interpreted the results, and contributed to drafts of the paper. HW, JW, and JG contributed to the study design and interpretation of the results and commented on drafts of the paper. Specifically, colleagues from the Department of Obstetrics and Gynecology were in charge of the diagnosis, treatment, and follow-up of the patients, while colleagues from the Department of Pathology were in charge of the pathological evaluation and molecular diagnosis.</p>
<a id="h10" name="h10"></a><h2>Funding</h2>
<p class="mb0">This study was supported by the Chinese Academy of Medical Sciences Initiative for Innovative Medicine (CAMS-2017-I2M-1-002 and CAMS-2016-I2M-1-002), by the National Science-Technology Support Plan Projects (2015BAI13B04), and by the National Natural Science Foundation of China (81602162). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p>
<a id="h11" name="h11"></a><h2>Conflict of Interest</h2>
<p class="mb0">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
<a id="h12" name="h12"></a><h2>Supplementary Material</h2>
<p class="mb0" id="SM1">The Supplementary Material for this article can be found online at: <a href="https://www.frontiersin.org/articles/10.3389/fonc.2020.00295/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fonc.2020.00295/full#supplementary-material</a></p>
<a id="h13" name="h13"></a><h2>References</h2>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B1" id="B1"></a> 1. Tangjitgamol S, Manusirivithaya S, Laopaiboon M, Lumbiganon P. Interval debulking surgery for advanced epithelial ovarian cancer: a Cochrane systematic review. <i>Gynecol Oncol.</i> (2009) 112:257&#x02013;64. doi: 10.1016/j.ygyno.2008.09.041</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=19017548" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.ygyno.2008.09.041" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S.+Tangjitgamol&#x00026;author=S.+Manusirivithaya&#x00026;author=M.+Laopaiboon&#x00026;author=P.+Lumbiganon+&#x00026;publication_year=2009&#x00026;title=Interval+debulking+surgery+for+advanced+epithelial+ovarian+cancer%3A+a+Cochrane+systematic+review&#x00026;journal=Gynecol+Oncol.&#x00026;volume=112&#x00026;pages=257-64" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B2" id="B2"></a> 2. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. <i>CA Cancer J Clin.</i> (2017) 67:7&#x02013;30. doi: 10.3322/caac.21387</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=28055103" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3322/caac.21387" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=RL.+Siegel&#x00026;author=KD.+Miller&#x00026;author=A.+Jemal+&#x00026;publication_year=2017&#x00026;title=Cancer+Statistics,+2017&#x00026;journal=CA+Cancer+J+Clin.&#x00026;volume=67&#x00026;pages=7-30" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B3" id="B3"></a> 3. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. <i>CA Cancer J Clin.</i> (2016) 66:115&#x02013;32. doi: 10.3322/caac.21338</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=26808342" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3322/caac.21338" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=W.+Chen&#x00026;author=R.+Zheng&#x00026;author=PD.+Baade&#x00026;author=S.+Zhang&#x00026;author=H.+Zeng&#x00026;author=F.+Bray+&#x00026;publication_year=2016&#x00026;title=Cancer+statistics+in+China,+2015&#x00026;journal=CA+Cancer+J+Clin.&#x00026;volume=66&#x00026;pages=115-32" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B4" id="B4"></a> 4. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. <i>Nature.</i> (2009) 458:719&#x02013;24. doi: 10.1038/nature07943</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=19360079" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/nature07943" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=MR.+Stratton&#x00026;author=PJ.+Campbell&#x00026;author=PA.+Futreal+&#x00026;publication_year=2009&#x00026;title=The+cancer+genome&#x00026;journal=Nature.&#x00026;volume=458&#x00026;pages=719-24" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B5" id="B5"></a> 5. Stratton MR. Exploring the genomes of cancer cells: progress and promise. <i>Science.</i> (2011) 331:1553&#x02013;8. doi: 10.1126/science.1204040</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=21436442" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1126/science.1204040" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=MR.+Stratton+&#x00026;publication_year=2011&#x00026;title=Exploring+the+genomes+of+cancer+cells%3A+progress+and+promise&#x00026;journal=Science.&#x00026;volume=331&#x00026;pages=1553-8" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B6" id="B6"></a> 6. Lu C, Xie M, Wendl MC, Wang J, McLellan MD, Leiserson MD, et al. Patterns and functional implications of rare germline variants across 12 cancer types. <i>Nat Commun.</i> (2015) 6:10086. doi: 10.1038/ncomms10086</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=26689913" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/ncomms10086" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=C.+Lu&#x00026;author=M.+Xie&#x00026;author=MC.+Wendl&#x00026;author=J.+Wang&#x00026;author=MD.+McLellan&#x00026;author=MD.+Leiserson+&#x00026;publication_year=2015&#x00026;title=Patterns+and+functional+implications+of+rare+germline+variants+across+12+cancer+types&#x00026;journal=Nat+Commun.&#x00026;volume=6&#x00026;pages=10086" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B7" id="B7"></a> 7. Russo A, Calo V, Bruno L, Rizzo S, Bazan V, Di Fede G. Hereditary ovarian cancer. <i>Crit Rev Oncol Hematol.</i> (2009) 69:28&#x02013;44. doi: 10.1016/j.critrevonc.2008.06.003</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=18656380" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.critrevonc.2008.06.003" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A.+Russo&#x00026;author=V.+Calo&#x00026;author=L.+Bruno&#x00026;author=S.+Rizzo&#x00026;author=V.+Bazan&#x00026;author=FedeG.+Di+&#x00026;publication_year=2009&#x00026;title=Hereditary+ovarian+cancer&#x00026;journal=Crit+Rev+Oncol+Hematol.&#x00026;volume=69&#x00026;pages=28-44" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B8" id="B8"></a> 8. Narod SA, Madlensky L, Bradley L, Cole D, Tonin P, Rosen B, et al. Hereditary and familial ovarian cancer in southern Ontario. <i>Cancer.</i> (1994) 74:2341&#x02013;6. </p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=7922985" target="_blank">PubMed Abstract</a> | <a href="http://scholar.google.com/scholar_lookup?author=SA.+Narod&#x00026;author=L.+Madlensky&#x00026;author=L.+Bradley&#x00026;author=D.+Cole&#x00026;author=P.+Tonin&#x00026;author=B.+Rosen+&#x00026;publication_year=1994&#x00026;title=Hereditary+and+familial+ovarian+cancer+in+southern+Ontario&#x00026;journal=Cancer.&#x00026;volume=74&#x00026;pages=2341-6" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B9" id="B9"></a> 9. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. <i>Nature.</i> (2011) 474:609&#x02013;15. doi: 10.1038/nature10166</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=21720365" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/nature10166" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?publication_year=2011&#x00026;title=Integrated+genomic+analyses+of+ovarian+carcinoma&#x00026;journal=Nature.&#x00026;volume=474&#x00026;pages=609-15" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B10" id="B10"></a> 10. Kanchi KL, Johnson KJ, Lu C, McLellan MD, Leiserson MD, Wendl MC, et al. Integrated analysis of germline and somatic variants in ovarian cancer. <i>Nat Commun.</i> (2014) 5:3156. doi: 10.1038/ncomms4156</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=24448499" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/ncomms4156" target="_blank">CrossRef Full Text</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B11" id="B11"></a> 11. Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. <i>Am J Hum Genet.</i> (1993) 52:678&#x02013;701. </p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=8460634" target="_blank">PubMed Abstract</a> | <a href="http://scholar.google.com/scholar_lookup?author=DF.+Easton&#x00026;author=DT.+Bishop&#x00026;author=D.+Ford&#x00026;author=GP.+Crockford+&#x00026;publication_year=1993&#x00026;title=Genetic+linkage+analysis+in+familial+breast+and+ovarian+cancer%3A+results+from+214+families.+The+Breast+Cancer+Linkage+Consortium&#x00026;journal=Am+J+Hum+Genet.&#x00026;volume=52&#x00026;pages=678-701" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B12" id="B12"></a> 12. Lynch HT, Albano WA, Lynch JF, Lynch PM, Campbell A. Surveillance and management of patients at high genetic risk for ovarian carcinoma. <i>Obstet Gynecol.</i> (1982) 59:589&#x02013;96. </p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=7070730" target="_blank">PubMed Abstract</a> | <a href="http://scholar.google.com/scholar_lookup?author=HT.+Lynch&#x00026;author=WA.+Albano&#x00026;author=JF.+Lynch&#x00026;author=PM.+Lynch&#x00026;author=A.+Campbell+&#x00026;publication_year=1982&#x00026;title=Surveillance+and+management+of+patients+at+high+genetic+risk+for+ovarian+carcinoma&#x00026;journal=Obstet+Gynecol.&#x00026;volume=59&#x00026;pages=589-96" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B13" id="B13"></a> 13. Ding L, Bailey MH, Porta-Pardo E, Thorsson V, Colaprico A, Bertrand D, et al. Perspective on oncogenic processes at the end of the beginning of cancer genomics. <i>Cell.</i> (2018) 173:305&#x02013;20 e10. doi: 10.1016/j.cell.2018.03.033</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=29625049" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.cell.2018.03.033" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=L.+Ding&#x00026;author=MH.+Bailey&#x00026;author=E.+Porta-Pardo&#x00026;author=V.+Thorsson&#x00026;author=A.+Colaprico&#x00026;author=D.+Bertrand+&#x00026;publication_year=2018&#x00026;title=Perspective+on+oncogenic+processes+at+the+end+of+the+beginning+of+cancer+genomics&#x00026;journal=Cell.&#x00026;volume=173&#x00026;pages=305-20" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B14" id="B14"></a> 14. Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, et al. A comprehensive pan-cancer molecular study of gynecologic and breast cancers. <i>Cancer Cell.</i> (2018) 33:690&#x02013;705 e9. doi: 10.1016/j.ccell.2018.03.014</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=29622464" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.ccell.2018.03.014" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=AC.+Berger&#x00026;author=A.+Korkut&#x00026;author=RS.+Kanchi&#x00026;author=AM.+Hegde&#x00026;author=W.+Lenoir&#x00026;author=W.+Liu+&#x00026;publication_year=2018&#x00026;title=A+comprehensive+pan-cancer+molecular+study+of+gynecologic+and+breast+cancers&#x00026;journal=Cancer+Cell.&#x00026;volume=33&#x00026;pages=690-705" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B15" id="B15"></a> 15. Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, et al. Inherited mutations in women with ovarian carcinoma. <i>JAMA Oncol.</i> (2016) 2:482&#x02013;90. doi: 10.1001/jamaoncol.2015.5495</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=26720728" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1001/jamaoncol.2015.5495" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=BM.+Norquist&#x00026;author=MI.+Harrell&#x00026;author=MF.+Brady&#x00026;author=T.+Walsh&#x00026;author=MK.+Lee&#x00026;author=S.+Gulsuner+&#x00026;publication_year=2016&#x00026;title=Inherited+mutations+in+women+with+ovarian+carcinoma&#x00026;journal=JAMA+Oncol.&#x00026;volume=2&#x00026;pages=482-90" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B16" id="B16"></a> 16. Li A, Xie R, Zhi Q, Deng Y, Wu Y, Li W, et al. BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls. <i>Gynecol Oncol.</i> (2018) 151:145&#x02013;52. doi: 10.1016/j.ygyno.2018.07.024</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=30078507" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.ygyno.2018.07.024" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A.+Li&#x00026;author=R.+Xie&#x00026;author=Q.+Zhi&#x00026;author=Y.+Deng&#x00026;author=Y.+Wu&#x00026;author=W.+Li+&#x00026;publication_year=2018&#x00026;title=BRCA+germline+mutations+in+an+unselected+nationwide+cohort+of+Chinese+patients+with+ovarian+cancer+and+healthy+controls&#x00026;journal=Gynecol+Oncol.&#x00026;volume=151&#x00026;pages=145-52" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B17" id="B17"></a> 17. Boyd J. Molecular genetics of hereditary ovarian cancer. <i>Oncology.</i> (1998) 12:399&#x02013;406; discussion 9&#x02013;10, 13. </p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=9534190" target="_blank">PubMed Abstract</a> | <a href="http://scholar.google.com/scholar_lookup?author=J.+Boyd+&#x00026;publication_year=1998&#x00026;title=Molecular+genetics+of+hereditary+ovarian+cancer&#x00026;journal=Oncology.&#x00026;volume=12&#x00026;pages=399-406" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B18" id="B18"></a> 18. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. <i>Am J Hum Genet.</i> (2001) 68:700&#x02013;10. doi: 10.1086/318787</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=11179017" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1086/318787" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=HA.+Risch&#x00026;author=JR.+McLaughlin&#x00026;author=DE.+Cole&#x00026;author=B.+Rosen&#x00026;author=L.+Bradley&#x00026;author=E.+Kwan+&#x00026;publication_year=2001&#x00026;title=Prevalence+and+penetrance+of+germline+BRCA1+and+BRCA2+mutations+in+a+population+series+of+649+women+with+ovarian+cancer&#x00026;journal=Am+J+Hum+Genet.&#x00026;volume=68&#x00026;pages=700-10" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B19" id="B19"></a> 19. Matloff ET. The breast surgeon&#x00027;s role in BRCA1 and BRCA2 testing. <i>Am J Surg.</i> (2000) 180:294&#x02013;8. doi: 10.1016/s0002-9610(00)00460-8</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=11113439" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/s0002-9610(00)00460-8" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=ET.+Matloff+&#x00026;publication_year=2000&#x00026;title=The+breast+surgeon&#x00027;s+role+in+BRCA1+and+BRCA2+testing&#x00026;journal=Am+J+Surg.&#x00026;volume=180&#x00026;pages=294-8" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B20" id="B20"></a> 20. Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, et al. Tumour lineage shapes BRCA-mediated phenotypes. <i>Nature.</i> (2019) 571:576&#x02013;9. doi: 10.1038/s41586-019-1382-1</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=31292550" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/s41586-019-1382-1" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=P.+Jonsson&#x00026;author=C.+Bandlamudi&#x00026;author=ML.+Cheng&#x00026;author=P.+Srinivasan&#x00026;author=SS.+Chavan&#x00026;author=ND.+Friedman+&#x00026;publication_year=2019&#x00026;title=Tumour+lineage+shapes+BRCA-mediated+phenotypes&#x00026;journal=Nature.&#x00026;volume=571&#x00026;pages=576-9" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B21" id="B21"></a> 21. Hartmann LC, Lindor NM. The role of risk-reducing surgery in hereditary breast and ovarian cancer. <i>N Engl J Med.</i> (2016) 374:454&#x02013;68. doi: 10.1056/NEJMra1503523</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=26840135" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1056/NEJMra1503523" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=LC.+Hartmann&#x00026;author=NM.+Lindor+&#x00026;publication_year=2016&#x00026;title=The+role+of+risk-reducing+surgery+in+hereditary+breast+and+ovarian+cancer&#x00026;journal=N+Engl+J+Med.&#x00026;volume=374&#x00026;pages=454-68" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B22" id="B22"></a> 22. Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. <i>N Engl J Med.</i> (2018) 379:2495&#x02013;505. doi: 10.1056/NEJMoa1810858</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=30345884" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1056/NEJMoa1810858" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=K.+Moore&#x00026;author=N.+Colombo&#x00026;author=G.+Scambia&#x00026;author=BG.+Kim&#x00026;author=A.+Oaknin&#x00026;author=M.+Friedlander+&#x00026;publication_year=2018&#x00026;title=Maintenance+olaparib+in+patients+with+newly+diagnosed+advanced+ovarian+cancer&#x00026;journal=N+Engl+J+Med.&#x00026;volume=379&#x00026;pages=2495-505" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B23" id="B23"></a> 23. Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. <i>N Engl J Med.</i> (2019) 381:2403&#x02013;15. doi: 10.1056/NEJMoa1909707</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=31562800" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1056/NEJMoa1909707" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=RL.+Coleman&#x00026;author=GF.+Fleming&#x00026;author=MF.+Brady&#x00026;author=EM.+Swisher&#x00026;author=KD.+Steffensen&#x00026;author=M.+Friedlander+&#x00026;publication_year=2019&#x00026;title=Veliparib+with+first-line+chemotherapy+and+as+maintenance+therapy+in+ovarian+cancer&#x00026;journal=N+Engl+J+Med.&#x00026;volume=381&#x00026;pages=2403-15" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B24" id="B24"></a> 24. Enomoto T, Aoki D, Hattori K, Jinushi M, Kigawa J, Takeshima N, et al. The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE). <i>Int J Gynecol Cancer.</i> (2019) 29:1043&#x02013;9. doi: 10.1136/ijgc-2019-000384</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=31263023" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1136/ijgc-2019-000384" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=T.+Enomoto&#x00026;author=D.+Aoki&#x00026;author=K.+Hattori&#x00026;author=M.+Jinushi&#x00026;author=J.+Kigawa&#x00026;author=N.+Takeshima+&#x00026;publication_year=2019&#x00026;title=The+first+Japanese+nationwide+multicenter+study+of+BRCA+mutation+testing+in+ovarian+cancer%3A+CHARacterizing+the+cross-sectionaL+approach+to+Ovarian+cancer+geneTic+TEsting+of+BRCA+(CHARLOTTE)&#x00026;journal=Int+J+Gynecol+Cancer.&#x00026;volume=29&#x00026;pages=1043-9" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B25" id="B25"></a> 25. Gonzalez-Martin A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. <i>N Engl J Med.</i> (2019) 381:2391&#x02013;402. doi: 10.1056/NEJMoa1910962</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=31562799" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1056/NEJMoa1910962" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A.+Gonzalez-Martin&#x00026;author=B.+Pothuri&#x00026;author=I.+Vergote&#x00026;author=ChristensenR.+DePont&#x00026;author=W.+Graybill&#x00026;author=MR.+Mirza+&#x00026;publication_year=2019&#x00026;title=Niraparib+in+patients+with+newly+diagnosed+advanced+ovarian+cancer&#x00026;journal=N+Engl+J+Med.&#x00026;volume=381&#x00026;pages=2391-402" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B26" id="B26"></a> 26. Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. <i>JAMA.</i> (2011) 306:1557&#x02013;65. doi: 10.1001/jama.2011.1456</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=21990299" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1001/jama.2011.1456" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=D.+Yang&#x00026;author=S.+Khan&#x00026;author=Y.+Sun&#x00026;author=K.+Hess&#x00026;author=I.+Shmulevich&#x00026;author=AK.+Sood+&#x00026;publication_year=2011&#x00026;title=Association+of+BRCA1+and+BRCA2+mutations+with+survival,+chemotherapy+sensitivity,+and+gene+mutator+phenotype+in+patients+with+ovarian+cancer&#x00026;journal=JAMA.&#x00026;volume=306&#x00026;pages=1557-65" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B27" id="B27"></a> 27. Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. <i>JAMA.</i> (2012) 307:382&#x02013;90. doi: 10.1001/jama.2012.20</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=22274685" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1001/jama.2012.20" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=KL.+Bolton&#x00026;author=G.+Chenevix-Trench&#x00026;author=C.+Goh&#x00026;author=S.+Sadetzki&#x00026;author=SJ.+Ramus&#x00026;author=BY.+Karlan+&#x00026;publication_year=2012&#x00026;title=Association+between+BRCA1+and+BRCA2+mutations+and+survival+in+women+with+invasive+epithelial+ovarian+cancer&#x00026;journal=JAMA.&#x00026;volume=307&#x00026;pages=382-90" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B28" id="B28"></a> 28. Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. <i>Clin Cancer Res.</i> (2014) 20:764&#x02013;75. doi: 10.1158/1078-0432.CCR-13-2287</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=24240112" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1158/1078-0432.CCR-13-2287" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=KP.+Pennington&#x00026;author=T.+Walsh&#x00026;author=MI.+Harrell&#x00026;author=MK.+Lee&#x00026;author=CC.+Pennil&#x00026;author=MH.+Rendi+&#x00026;publication_year=2014&#x00026;title=Germline+and+somatic+mutations+in+homologous+recombination+genes+predict+platinum+response+and+survival+in+ovarian,+fallopian+tube,+and+peritoneal+carcinomas&#x00026;journal=Clin+Cancer+Res.&#x00026;volume=20&#x00026;pages=764-75" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B29" id="B29"></a> 29. Ray-Coquard I, Pautier P, Pignata S, Perol D, Gonzalez-Martin A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. <i>N Engl J Med.</i> (2019) 381:2416&#x02013;28. doi: 10.1056/NEJMoa1911361</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=31851799" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1056/NEJMoa1911361" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=I.+Ray-Coquard&#x00026;author=P.+Pautier&#x00026;author=S.+Pignata&#x00026;author=D.+Perol&#x00026;author=A.+Gonzalez-Martin&#x00026;author=R.+Berger+&#x00026;publication_year=2019&#x00026;title=Olaparib+plus+bevacizumab+as+first-line+maintenance+in+ovarian+cancer&#x00026;journal=N+Engl+J+Med.&#x00026;volume=381&#x00026;pages=2416-28" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B30" id="B30"></a> 30. Lai CH, Vallikad E, Lin H, Yang LY, Jung SM, Liu HE, et al. Maintenance of pegylated liposomal doxorubicin/carboplatin in patients with advanced ovarian cancer: randomized study of an Asian Gynecologic Oncology Group. <i>J Gynecol Oncol.</i> (2020) 31:e5. doi: 10.3802/jgo.2020.31.e5</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=31788995" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3802/jgo.2020.31.e5" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=CH.+Lai&#x00026;author=E.+Vallikad&#x00026;author=H.+Lin&#x00026;author=LY.+Yang&#x00026;author=SM.+Jung&#x00026;author=HE.+Liu+&#x00026;publication_year=2020&#x00026;title=Maintenance+of+pegylated+liposomal+doxorubicin%2Fcarboplatin+in+patients+with+advanced+ovarian+cancer%3A+randomized+study+of+an+Asian+Gynecologic+Oncology+Group&#x00026;journal=J+Gynecol+Oncol.&#x00026;volume=31&#x00026;pages=e5" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B31" id="B31"></a> 31. Lee YJ, Kim D, Shim JE, Bae SJ, Jung YJ, Kim S, et al. Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy. <i>Int J Cancer.</i> (2020) 146:1851&#x02013;61. doi: 10.1002/ijc.32729</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=31603993" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/ijc.32729" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=YJ.+Lee&#x00026;author=D.+Kim&#x00026;author=JE.+Shim&#x00026;author=SJ.+Bae&#x00026;author=YJ.+Jung&#x00026;author=S.+Kim+&#x00026;publication_year=2020&#x00026;title=Genomic+profiling+of+the+residual+disease+of+advanced+high-grade+serous+ovarian+cancer+after+neoadjuvant+chemotherapy&#x00026;journal=Int+J+Cancer.&#x00026;volume=146&#x00026;pages=1851-61" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B32" id="B32"></a> 32. Lu R, Xie S, Wang Y, Zheng H, Zhang H, Deng M, et al. MUS81 Participates in the progression of serous ovarian cancer associated with dysfunctional DNA repair system. <i>Front Oncol.</i> (2019) 9:1189. doi: 10.3389/fonc.2019.01189</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=31803609" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3389/fonc.2019.01189" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=R.+Lu&#x00026;author=S.+Xie&#x00026;author=Y.+Wang&#x00026;author=H.+Zheng&#x00026;author=H.+Zhang&#x00026;author=M.+Deng+&#x00026;publication_year=2019&#x00026;title=MUS81+Participates+in+the+progression+of+serous+ovarian+cancer+associated+with+dysfunctional+DNA+repair+system&#x00026;journal=Front+Oncol.&#x00026;volume=9&#x00026;pages=1189" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B33" id="B33"></a> 33. Takaya H, Nakai H, Sakai K, Nishio K, Murakami K, Mandai M, et al. Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course. <i>Gynecol Oncol.</i> (2020) 156:415&#x02013;22. doi: 10.1016/j.ygyno.2019.11.013</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=31785864" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.ygyno.2019.11.013" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=H.+Takaya&#x00026;author=H.+Nakai&#x00026;author=K.+Sakai&#x00026;author=K.+Nishio&#x00026;author=K.+Murakami&#x00026;author=M.+Mandai+&#x00026;publication_year=2020&#x00026;title=Intratumor+heterogeneity+and+homologous+recombination+deficiency+of+high-grade+serous+ovarian+cancer+are+associated+with+prognosis+and+molecular+subtype+and+change+in+treatment+course&#x00026;journal=Gynecol+Oncol.&#x00026;volume=156&#x00026;pages=415-22" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B34" id="B34"></a> 34. Shi T, Wang P, Xie C, Yin S, Shi D, Wei C, et al. BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer. <i>Int J Cancer.</i> (2017) 140:2051&#x02013;9. doi: 10.1002/ijc.30633</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=28176296" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/ijc.30633" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=T.+Shi&#x00026;author=P.+Wang&#x00026;author=C.+Xie&#x00026;author=S.+Yin&#x00026;author=D.+Shi&#x00026;author=C.+Wei+&#x00026;publication_year=2017&#x00026;title=BRCA1+and+BRCA2+mutations+in+ovarian+cancer+patients+from+China%3A+ethnic-related+mutations+in+BRCA1+associated+with+an+increased+risk+of+ovarian+cancer&#x00026;journal=Int+J+Cancer.&#x00026;volume=140&#x00026;pages=2051-9" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B35" id="B35"></a> 35. Wu X, Wu L, Kong B, Liu J, Yin R, Wen H, et al. The first nationwide multicenter prevalence study of germline BRCA1 and BRCA2 mutations in Chinese ovarian cancer patients. <i>Int J Gynecol Cancer.</i> (2017) 27:1650&#x02013;7. doi: 10.1097/IGC.0000000000001065</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=28692638" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1097/IGC.0000000000001065" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=X.+Wu&#x00026;author=L.+Wu&#x00026;author=B.+Kong&#x00026;author=J.+Liu&#x00026;author=R.+Yin&#x00026;author=H.+Wen+&#x00026;publication_year=2017&#x00026;title=The+first+nationwide+multicenter+prevalence+study+of+germline+BRCA1+and+BRCA2+mutations+in+Chinese+ovarian+cancer+patients&#x00026;journal=Int+J+Gynecol+Cancer.&#x00026;volume=27&#x00026;pages=1650-7" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B36" id="B36"></a> 36. Li W, Shao D, Li L, Wu M, Ma S, Tan X, et al. Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study. <i>J Ovarian Res.</i> (2019) 12:80. doi: 10.1186/s13048-019-0560-y</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=31472684" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s13048-019-0560-y" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=W.+Li&#x00026;author=D.+Shao&#x00026;author=L.+Li&#x00026;author=M.+Wu&#x00026;author=S.+Ma&#x00026;author=X.+Tan+&#x00026;publication_year=2019&#x00026;title=Germline+and+somatic+mutations+of+multi-gene+panel+in+Chinese+patients+with+epithelial+ovarian+cancer%3A+a+prospective+cohort+study&#x00026;journal=J+Ovarian+Res.&#x00026;volume=12&#x00026;pages=80" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B37" id="B37"></a> 37. Mutch DG, Prat J. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. <i>Gynecol Oncol.</i> (2014) 133:401&#x02013;4. doi: 10.1016/j.ygyno.2014.04.013</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=24878391" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.ygyno.2014.04.013" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=DG.+Mutch&#x00026;author=J.+Prat+&#x00026;publication_year=2014&#x00026;title=2014+FIGO+staging+for+ovarian,+fallopian+tube+and+peritoneal+cancer&#x00026;journal=Gynecol+Oncol.&#x00026;volume=133&#x00026;pages=401-4" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B38" id="B38"></a> 38. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>&#x000AE;</sup>). <i>Genetic/Familial High-Risk Assessment: Breast and Ovarian</i>. Version 2.2019 - July 30, 2018. Available online at: <a href="https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf">https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf</a></p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?title=Genetic%2FFamilial+High-Risk+Assessment%3A+Breast+and+Ovarian" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B39" id="B39"></a> 39. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. <i>Genet Med.</i> (2015) 17:405&#x02013;24. doi: 10.1038/gim.2015.30</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=25741868" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/gim.2015.30" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S.+Richards&#x00026;author=N.+Aziz&#x00026;author=S.+Bale&#x00026;author=D.+Bick&#x00026;author=S.+Das&#x00026;author=J.+Gastier-Foster+&#x00026;publication_year=2015&#x00026;title=Standards+and+guidelines+for+the+interpretation+of+sequence+variants%3A+a+joint+consensus+recommendation+of+the+American+College+of+Medical+Genetics+and+Genomics+and+the+Association+for+Molecular+Pathology&#x00026;journal=Genet+Med.&#x00026;volume=17&#x00026;pages=405-24" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B40" id="B40"></a> 40. Alsop K, Fereday S, Meldrum C, Defazio A, Emmanuel C, George J, et al. BRCA Mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. <i>J Clin Oncol.</i> (2012) 30:2654&#x02013;63. doi: 10.1200/JCO.2011.39.8545</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=22711857" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1200/JCO.2011.39.8545" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=K.+Alsop&#x00026;author=S.+Fereday&#x00026;author=C.+Meldrum&#x00026;author=A.+Defazio&#x00026;author=C.+Emmanuel&#x00026;author=J.+George+&#x00026;publication_year=2012&#x00026;title=BRCA+Mutation+frequency+and+patterns+of+treatment+response+in+BRCA+mutation-positive+women+with+ovarian+cancer%3A+a+report+from+the+Australian+Ovarian+Cancer+Study+Group&#x00026;journal=J+Clin+Oncol.&#x00026;volume=30&#x00026;pages=2654-63" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B41" id="B41"></a> 41. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the National Israeli Study of Ovarian Cancer. <i>J Clin Oncol.</i> (2008) 26:20&#x02013;5. doi: 10.1200/jco.2007.11.6905</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=18165636" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1200/jco.2007.11.6905" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A.+Chetrit&#x00026;author=G.+Hirsh-Yechezkel&#x00026;author=Y.+Ben-David&#x00026;author=F.+Lubin&#x00026;author=E.+Friedman&#x00026;author=S.+Sadetzki+&#x00026;publication_year=2008&#x00026;title=Effect+of+BRCA1%2F2+mutations+on+long-term+survival+of+patients+with+invasive+ovarian+cancer%3A+the+National+Israeli+Study+of+Ovarian+Cancer&#x00026;journal=J+Clin+Oncol.&#x00026;volume=26&#x00026;pages=20-5" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B42" id="B42"></a> 42. Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, et al. Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: an NRG Oncology/Gynecologic Oncology Group Study. <i>Clin Cancer Res.</i> (2018) 24:777&#x02013;83. doi: 10.1158/1078-0432.ccr-17-1327</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=29191972" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1158/1078-0432.ccr-17-1327" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=BM.+Norquist&#x00026;author=MF.+Brady&#x00026;author=MI.+Harrell&#x00026;author=T.+Walsh&#x00026;author=MK.+Lee&#x00026;author=S.+Gulsuner+&#x00026;publication_year=2018&#x00026;title=Mutations+in+homologous+recombination+genes+and+outcomes+in+ovarian+carcinoma+patients+in+GOG+218%3A+an+NRG+Oncology%2FGynecologic+Oncology+Group+Study&#x00026;journal=Clin+Cancer+Res.&#x00026;volume=24&#x00026;pages=777-83" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B43" id="B43"></a> 43. Hjortkjaer M, Malik Aagaard Jorgensen M, Waldstrom M, Ornskov D, Sogaard-Andersen E, Jakobsen A, et al. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer. <i>Int J Gynecol Cancer.</i> (2019) 29:166&#x02013;73. doi: 10.1136/ijgc-2018-000017</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=30640700" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1136/ijgc-2018-000017" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M.+Hjortkjaer&#x00026;author=AagaardJorgensenM.+Malik&#x00026;author=M.+Waldstrom&#x00026;author=D.+Ornskov&#x00026;author=E.+Sogaard-Andersen&#x00026;author=A.+Jakobsen+&#x00026;publication_year=2019&#x00026;title=The+clinical+importance+of+BRCAness+in+a+population-based+cohort+of+Danish+epithelial+ovarian+cancer&#x00026;journal=Int+J+Gynecol+Cancer.&#x00026;volume=29&#x00026;pages=166-73" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B44" id="B44"></a> 44. Huang M, Kamath P, Schlumbrecht M, Miao F, Driscoll D, Oldak S, et al. Identifying disparities in germline and somatic testing for ovarian cancer. <i>Gynecol Oncol.</i> (2019) 153:297&#x02013;303. doi: 10.1016/j.ygyno.2019.03.007</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=30890269" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.ygyno.2019.03.007" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M.+Huang&#x00026;author=P.+Kamath&#x00026;author=M.+Schlumbrecht&#x00026;author=F.+Miao&#x00026;author=D.+Driscoll&#x00026;author=S.+Oldak+&#x00026;publication_year=2019&#x00026;title=Identifying+disparities+in+germline+and+somatic+testing+for+ovarian+cancer&#x00026;journal=Gynecol+Oncol.&#x00026;volume=153&#x00026;pages=297-303" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B45" id="B45"></a> 45. Hinchcliff EM, Bednar EM, Lu KH, Rauh-Hain JA. Disparities in gynecologic cancer genetics evaluation. <i>Gynecol Oncol.</i> (2019) 153:184&#x02013;91. doi: 10.1016/j.ygyno.2019.01.024</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=30711300" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.ygyno.2019.01.024" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=EM.+Hinchcliff&#x00026;author=EM.+Bednar&#x00026;author=KH.+Lu&#x00026;author=JA.+Rauh-Hain+&#x00026;publication_year=2019&#x00026;title=Disparities+in+gynecologic+cancer+genetics+evaluation&#x00026;journal=Gynecol+Oncol.&#x00026;volume=153&#x00026;pages=184-91" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B46" id="B46"></a> 46. Wang J, Li W, Shi Y, Huang Y, Sun T, Tang L, et al. Germline mutation landscape of Chinese patients with familial breast/ovarian cancer in a panel of 22 susceptibility genes. <i>Cancer Med.</i> (2019) 8:2074&#x02013;84. doi: 10.1002/cam4.2093</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=30982232" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/cam4.2093" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J.+Wang&#x00026;author=W.+Li&#x00026;author=Y.+Shi&#x00026;author=Y.+Huang&#x00026;author=T.+Sun&#x00026;author=L.+Tang+&#x00026;publication_year=2019&#x00026;title=Germline+mutation+landscape+of+Chinese+patients+with+familial+breast%2Fovarian+cancer+in+a+panel+of+22+susceptibility+genes&#x00026;journal=Cancer+Med.&#x00026;volume=8&#x00026;pages=2074-84" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B47" id="B47"></a> 47. Gao X, Nan X, Liu Y, Liu R, Zang W, Shan G, et al. Comprehensive profiling of BRCA1 and BRCA2 variants in breast and ovarian cancer in Chinese patients. <i>Hum Mutat.</i> (2020) 41:696&#x02013;708. doi: 10.1002/humu.23965</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=31825140" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/humu.23965" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=X.+Gao&#x00026;author=X.+Nan&#x00026;author=Y.+Liu&#x00026;author=R.+Liu&#x00026;author=W.+Zang&#x00026;author=G.+Shan+&#x00026;publication_year=2020&#x00026;title=Comprehensive+profiling+of+BRCA1+and+BRCA2+variants+in+breast+and+ovarian+cancer+in+Chinese+patients&#x00026;journal=Hum+Mutat.&#x00026;volume=41&#x00026;pages=696-708" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B48" id="B48"></a> 48. Zhao Q, Yang J, Li L, Cao D, Yu M, Shen K. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing. <i>J Gynecol Oncol.</i> (2017) 28:e39. doi: 10.3802/jgo.2017.28.e39</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=28541631" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3802/jgo.2017.28.e39" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=Q.+Zhao&#x00026;author=J.+Yang&#x00026;author=L.+Li&#x00026;author=D.+Cao&#x00026;author=M.+Yu&#x00026;author=K.+Shen+&#x00026;publication_year=2017&#x00026;title=Germline+and+somatic+mutations+in+homologous+recombination+genes+among+Chinese+ovarian+cancer+patients+detected+using+next-generation+sequencing&#x00026;journal=J+Gynecol+Oncol.&#x00026;volume=28&#x00026;pages=e39" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B49" id="B49"></a> 49. Li L, Qiu L, Wu M. A survey of willingness about genetic counseling and tests in patients of epithelial ovarian cancer. <i>Zhonghua Yi Xue Za Zhi.</i> (2017) 97:3412&#x02013;5. doi: 10.3760/cma.j.issn.0376-2491.2017.43.011</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=29179283" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3760/cma.j.issn.0376-2491.2017.43.011" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=L.+Li&#x00026;author=L.+Qiu&#x00026;author=M.+Wu+&#x00026;publication_year=2017&#x00026;title=A+survey+of+willingness+about+genetic+counseling+and+tests+in+patients+of+epithelial+ovarian+cancer&#x00026;journal=Zhonghua+Yi+Xue+Za+Zhi.&#x00026;volume=97&#x00026;pages=3412-5" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B50" id="B50"></a> 50. Liu GY, Zhang W. Will Chinese ovarian cancer patients benefit from knowing the BRCA2 mutation status? <i>Chin J Cancer.</i> (2012) 31:1&#x02013;4. doi: 10.5732/cjc.011.10432</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=22176776" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.5732/cjc.011.10432" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=GY.+Liu&#x00026;author=W.+Zhang+&#x00026;publication_year=2012&#x00026;title=Will+Chinese+ovarian+cancer+patients+benefit+from+knowing+the+BRCA2+mutation+status%3F&#x00026;journal=Chin+J+Cancer.&#x00026;volume=31&#x00026;pages=1-4" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B51" id="B51"></a> 51. Shipman H, Flynn S, MacDonald-Smith CF, Brenton J, Crawford R, Tischkowitz M, et al. Universal BRCA1/BRCA2 testing for ovarian cancer patients is welcomed, but with care: how women and staff contextualize experiences of expanded access. <i>J Genet Couns.</i> (2017) 26:1280&#x02013;91. doi: 10.1007/s10897-017-0108-5</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=28540621" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s10897-017-0108-5" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=H.+Shipman&#x00026;author=S.+Flynn&#x00026;author=CF.+MacDonald-Smith&#x00026;author=J.+Brenton&#x00026;author=R.+Crawford&#x00026;author=M.+Tischkowitz+&#x00026;publication_year=2017&#x00026;title=Universal+BRCA1%2FBRCA2+testing+for+ovarian+cancer+patients+is+welcomed,+but+with+care%3A+how+women+and+staff+contextualize+experiences+of+expanded+access&#x00026;journal=J+Genet+Couns.&#x00026;volume=26&#x00026;pages=1280-91" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B52" id="B52"></a> 52. Koczkowska M, Zuk M, Gorczynski A, Ratajska M, Lewandowska M, Biernat W, et al. Detection of somatic BRCA1/2 mutations in ovarian cancer - next-generation sequencing analysis of 100 cases. <i>Cancer Med.</i> (2016) 5:1640&#x02013;6. doi: 10.1002/cam4.748</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=27167707" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/cam4.748" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M.+Koczkowska&#x00026;author=M.+Zuk&#x00026;author=A.+Gorczynski&#x00026;author=M.+Ratajska&#x00026;author=M.+Lewandowska&#x00026;author=W.+Biernat+&#x00026;publication_year=2016&#x00026;title=Detection+of+somatic+BRCA1%2F2+mutations+in+ovarian+cancer+-+next-generation+sequencing+analysis+of+100+cases&#x00026;journal=Cancer+Med.&#x00026;volume=5&#x00026;pages=1640-6" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B53" id="B53"></a> 53. Zakrzewski F, Gieldon L, Rump A, Seifert M, Grutzmann K, Kruger A, et al. Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples. <i>BMC Cancer.</i> (2019) 19:396. doi: 10.1186/s12885-019-5584-6</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=31029168" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s12885-019-5584-6" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=F.+Zakrzewski&#x00026;author=L.+Gieldon&#x00026;author=A.+Rump&#x00026;author=M.+Seifert&#x00026;author=K.+Grutzmann&#x00026;author=A.+Kruger+&#x00026;publication_year=2019&#x00026;title=Targeted+capture-based+NGS+is+superior+to+multiplex+PCR-based+NGS+for+hereditary+BRCA1+and+BRCA2+gene+analysis+in+FFPE+tumor+samples&#x00026;journal=BMC+Cancer.&#x00026;volume=19&#x00026;pages=396" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B54" id="B54"></a> 54. Choi MC, Bae JS, Jung SG, Park H, Joo WD, Song SH, et al. Prevalence of germline BRCA mutations among women with carcinoma of the peritoneum or fallopian tube. <i>J Gynecol Oncol.</i> (2018) 29:e43. doi: 10.3802/jgo.2018.29.e43</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=29770616" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3802/jgo.2018.29.e43" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=MC.+Choi&#x00026;author=JS.+Bae&#x00026;author=SG.+Jung&#x00026;author=H.+Park&#x00026;author=WD.+Joo&#x00026;author=SH.+Song+&#x00026;publication_year=2018&#x00026;title=Prevalence+of+germline+BRCA+mutations+among+women+with+carcinoma+of+the+peritoneum+or+fallopian+tube&#x00026;journal=J+Gynecol+Oncol.&#x00026;volume=29&#x00026;pages=e43" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B55" id="B55"></a> 55. Petrillo M, Marchetti C, De Leo R, Musella A, Capoluongo E, Paris I, et al. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. <i>Am J Obstet Gynecol.</i> (2017) 217:334 e1&#x02013;9. doi: 10.1016/j.ajog.2017.05.036</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=28549976" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.ajog.2017.05.036" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M.+Petrillo&#x00026;author=C.+Marchetti&#x00026;author=R.+De+Leo&#x00026;author=A.+Musella&#x00026;author=E.+Capoluongo&#x00026;author=I.+Paris+&#x00026;publication_year=2017&#x00026;title=BRCA+mutational+status,+initial+disease+presentation,+and+clinical+outcome+in+high-grade+serous+advanced+ovarian+cancer%3A+a+multicenter+study&#x00026;journal=Am+J+Obstet+Gynecol.&#x00026;volume=217&#x00026;pages=334" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B56" id="B56"></a> 56. Naumann RW, Morris JC, Tait DL, Higgins RV, Crane EK, Drury LK, et al. Patients with BRCA mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected high grade ovarian cancer. <i>Gynecol Oncol.</i> (2018) 151:477&#x02013;80. doi: 10.1016/j.ygyno.2018.10.003</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=30309722" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.ygyno.2018.10.003" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=RW.+Naumann&#x00026;author=JC.+Morris&#x00026;author=DL.+Tait&#x00026;author=RV.+Higgins&#x00026;author=EK.+Crane&#x00026;author=LK.+Drury+&#x00026;publication_year=2018&#x00026;title=Patients+with+BRCA+mutations+have+superior+outcomes+after+intraperitoneal+chemotherapy+in+optimally+resected+high+grade+ovarian+cancer&#x00026;journal=Gynecol+Oncol.&#x00026;volume=151&#x00026;pages=477-80" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B57" id="B57"></a> 57. Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD, 2nd, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. <i>J Clin Oncol.</i> (2010) 28:3570&#x02013;6. doi: 10.1200/jco.2009.27.2997</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=20606085" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1200/jco.2009.27.2997" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=BT.+Hennessy&#x00026;author=KM.+Timms&#x00026;author=MS.+Carey&#x00026;author=A.+Gutin&#x00026;author=LA.+Meyer&#x00026;author=DD.+Flake+&#x00026;publication_year=2010&#x00026;title=Somatic+mutations+in+BRCA1+and+BRCA2+could+expand+the+number+of+patients+that+benefit+from+poly+(ADP+ribose)+polymerase+inhibitors+in+ovarian+cancer&#x00026;journal=J+Clin+Oncol.&#x00026;volume=28&#x00026;pages=3570-6" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B58" id="B58"></a> 58. Minion LE, Dolinsky JS, Chase DM, Dunlop CL, Chao EC, Monk BJ. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2. <i>Gynecol Oncol.</i> (2015) 137:86&#x02013;92. doi: 10.1016/j.ygyno.2015.01.537</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=25622547" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.ygyno.2015.01.537" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=LE.+Minion&#x00026;author=JS.+Dolinsky&#x00026;author=DM.+Chase&#x00026;author=CL.+Dunlop&#x00026;author=EC.+Chao&#x00026;author=BJ.+Monk+&#x00026;publication_year=2015&#x00026;title=Hereditary+predisposition+to+ovarian+cancer,+looking+beyond+BRCA1%2FBRCA2&#x00026;journal=Gynecol+Oncol.&#x00026;volume=137&#x00026;pages=86-92" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B59" id="B59"></a> 59. Singh J, Thota N, Singh S, Padhi S, Mohan P, Deshwal S, et al. Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations. <i>Breast Cancer Res Treat.</i> (2018) 170:189&#x02013;96. doi: 10.1007/s10549-018-4726-x</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=29470806" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s10549-018-4726-x" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J.+Singh&#x00026;author=N.+Thota&#x00026;author=S.+Singh&#x00026;author=S.+Padhi&#x00026;author=P.+Mohan&#x00026;author=S.+Deshwal+&#x00026;publication_year=2018&#x00026;title=Screening+of+over+1000+Indian+patients+with+breast+and%2For+ovarian+cancer+with+a+multi-gene+panel%3A+prevalence+of+BRCA1%2F2+and+non-BRCA+mutations&#x00026;journal=Breast+Cancer+Res+Treat.&#x00026;volume=170&#x00026;pages=189-96" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B60" id="B60"></a> 60. Eoh KJ, Kim JE, Park HS, Lee ST, Park JS, Han JW, et al. Detection of germline mutations in patients with epithelial ovarian cancer using multi-gene panels: beyond BRCA1/2. <i>Cancer Res Treat.</i> (2018) 50:917&#x02013;25. doi: 10.4143/crt.2017.220</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=29020732" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.4143/crt.2017.220" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=KJ.+Eoh&#x00026;author=JE.+Kim&#x00026;author=HS.+Park&#x00026;author=ST.+Lee&#x00026;author=JS.+Park&#x00026;author=JW.+Han+&#x00026;publication_year=2018&#x00026;title=Detection+of+germline+mutations+in+patients+with+epithelial+ovarian+cancer+using+multi-gene+panels%3A+beyond+BRCA1%2F2&#x00026;journal=Cancer+Res+Treat.&#x00026;volume=50&#x00026;pages=917-25" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B61" id="B61"></a> 61. Graffeo R, Livraghi L, Pagani O, Goldhirsch A, Partridge AH, Garber JE. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care. <i>Breast Cancer Res Treat.</i> (2016) 160:393&#x02013;410. doi: 10.1007/s10549-016-4003-9</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=27734215" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s10549-016-4003-9" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=R.+Graffeo&#x00026;author=L.+Livraghi&#x00026;author=O.+Pagani&#x00026;author=A.+Goldhirsch&#x00026;author=AH.+Partridge&#x00026;author=JE.+Garber+&#x00026;publication_year=2016&#x00026;title=Time+to+incorporate+germline+multigene+panel+testing+into+breast+and+ovarian+cancer+patient+care&#x00026;journal=Breast+Cancer+Res+Treat.&#x00026;volume=160&#x00026;pages=393-410" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B62" id="B62"></a> 62. Feliubadalo L, Lopez-Fernandez A, Pineda M, Diez O, Del Valle J, Gutierrez-Enriquez S, et al. Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels. <i>Int J Cancer.</i> (2019) 145:2682&#x02013;91. doi: 10.1002/ijc.32304</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=30927264" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/ijc.32304" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=L.+Feliubadalo&#x00026;author=A.+Lopez-Fernandez&#x00026;author=M.+Pineda&#x00026;author=O.+Diez&#x00026;author=ValleJ.+Del&#x00026;author=S.+Gutierrez-Enriquez+&#x00026;publication_year=2019&#x00026;title=Opportunistic+testing+of+BRCA1,+BRCA2+and+mismatch+repair+genes+improves+the+yield+of+phenotype+driven+hereditary+cancer+gene+panels&#x00026;journal=Int+J+Cancer.&#x00026;volume=145&#x00026;pages=2682-91" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B63" id="B63"></a> 63. Frey MK, Kim SH, Bassett RY, Martineau J, Dalton E, Chern JY, et al. Rescreening for genetic mutations using multi-gene panel testing in patients who previously underwent non-informative genetic screening. <i>Gynecol Oncol.</i> (2015) 139:211&#x02013;5. doi: 10.1016/j.ygyno.2015.08.006</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=26296696" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.ygyno.2015.08.006" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=MK.+Frey&#x00026;author=SH.+Kim&#x00026;author=RY.+Bassett&#x00026;author=J.+Martineau&#x00026;author=E.+Dalton&#x00026;author=JY.+Chern+&#x00026;publication_year=2015&#x00026;title=Rescreening+for+genetic+mutations+using+multi-gene+panel+testing+in+patients+who+previously+underwent+non-informative+genetic+screening&#x00026;journal=Gynecol+Oncol.&#x00026;volume=139&#x00026;pages=211-5" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B64" id="B64"></a> 64. Moschetta M, George A, Kaye SB, Banerjee S. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. <i>Ann Oncol.</i> (2016) 27:1449&#x02013;55. doi: 10.1093/annonc/mdw142</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=27037296" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/annonc/mdw142" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M.+Moschetta&#x00026;author=A.+George&#x00026;author=SB.+Kaye&#x00026;author=S.+Banerjee+&#x00026;publication_year=2016&#x00026;title=BRCA+somatic+mutations+and+epigenetic+BRCA+modifications+in+serous+ovarian+cancer&#x00026;journal=Ann+Oncol.&#x00026;volume=27&#x00026;pages=1449-55" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B65" id="B65"></a> 65. Weren RD, Mensenkamp AR, Simons M, Eijkelenboom A, Sie AS, Ouchene H, et al. Novel BRCA1 and BRCA2 tumor test as basis for treatment decisions and referral for genetic counselling of patients with ovarian carcinomas. <i>Hum Mutat.</i> (2017) 38:226&#x02013;35. doi: 10.1002/humu.23137</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=27767231" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/humu.23137" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=RD.+Weren&#x00026;author=AR.+Mensenkamp&#x00026;author=M.+Simons&#x00026;author=A.+Eijkelenboom&#x00026;author=AS.+Sie&#x00026;author=H.+Ouchene+&#x00026;publication_year=2017&#x00026;title=Novel+BRCA1+and+BRCA2+tumor+test+as+basis+for+treatment+decisions+and+referral+for+genetic+counselling+of+patients+with+ovarian+carcinomas&#x00026;journal=Hum+Mutat.&#x00026;volume=38&#x00026;pages=226-35" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B66" id="B66"></a> 66. Riahi A, Chabouni-Bouhamed H, Kharrat M. Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: implications for genetic testing. <i>Cancer Genet.</i> (2017) 210:22&#x02013;7. doi: 10.1016/j.cancergen.2016.11.002</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=28212807" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.cancergen.2016.11.002" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A.+Riahi&#x00026;author=H.+Chabouni-Bouhamed&#x00026;author=M.+Kharrat+&#x00026;publication_year=2017&#x00026;title=Prevalence+of+BRCA1+and+BRCA2+large+genomic+rearrangements+in+Tunisian+high+risk+breast%2Fovarian+cancer+families%3A+implications+for+genetic+testing&#x00026;journal=Cancer+Genet.&#x00026;volume=210&#x00026;pages=22-7" target="_blank">Google Scholar</a></p>
</div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.7em;"><a name="B67" id="B67"></a> 67. Bernards SS, Pennington KP, Harrell MI, Agnew KJ, Garcia RL, Norquist BM, et al. Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma. <i>Gynecol Oncol.</i> (2018) 148:281&#x02013;5. doi: 10.1016/j.ygyno.2017.12.004</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=29233532" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.ygyno.2017.12.004" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=SS.+Bernards&#x00026;author=KP.+Pennington&#x00026;author=MI.+Harrell&#x00026;author=KJ.+Agnew&#x00026;author=RL.+Garcia&#x00026;author=BM.+Norquist+&#x00026;publication_year=2018&#x00026;title=Clinical+characteristics+and+outcomes+of+patients+with+BRCA1+or+RAD51C+methylated+versus+mutated+ovarian+carcinoma&#x00026;journal=Gynecol+Oncol.&#x00026;volume=148&#x00026;pages=281-5" target="_blank">Google Scholar</a></p>
</div>
</div>
<div class="thinLineM20"></div>
<div class="AbstractSummary">
<p><span>Keywords:</span> epithelial ovarian cancer, <i>BRCA</i> mutations, germline mutations, somatic mutations, progression-free survival, overall survival</p>
<p><span>Citation:</span> You Y, Li L, Lu J, Wu H, Wang J, Gao J, Wu M and Liang Z (2020) Germline and Somatic <i>BRCA1/2</i> Mutations in 172 Chinese Women With Epithelial Ovarian Cancer. <i>Front. Oncol.</i> 10:295. doi: 10.3389/fonc.2020.00295</p>
<p id="timestamps"><span>Received:</span> 13 January 2020; <span>Accepted:</span> 20 February 2020;<br> <span>Published:</span> 10 March 2020.</p>
<div><p>Edited by:</p> <a href="http://loop.frontiersin.org/people/754893/overview">Giuseppe Vizzielli</a>, Agostino Gemelli University Polyclinic, Italy</div>
<div><p>Reviewed by:</p> <a href="http://loop.frontiersin.org/people/304800/overview">Michael Dean</a>, National Cancer Institute at Frederick, United States<br> <a href="http://loop.frontiersin.org/people/786233/overview">Martina Arcieri</a>, University of Eastern Piedmont, Italy</div>
<p><span>Copyright</span> &#x000A9; 2020 You, Li, Lu, Wu, Wang, Gao, Wu and Liang. This is an open-access article distributed under the terms of the <a rel="license" href="http://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License (CC BY)</a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
<p><span>&#x0002A;Correspondence:</span> Ming Wu, <a id="encmail">d3VtaW5nQHB1bWNoLmNu</a>; Zhiyong Liang, <a id="encmail">bGlhbmd6aGl5b25nMTIyMEB5YWhvby5jb20=</a></p>
<p><span><sup>&#x02020;</sup></span>These authors have contributed equally to this work</p>
<div class="clear"></div>
</div></div></div><p class="AbstractSummary__disclaimer"><span>Disclaimer: </span> All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher. </p></div></div><!----></main><aside class="Layout__aside"><div class="ArticleDetails__wrapper"><div class="ArticleDetails__aside"><div class="ArticleDetails__aside__responsiveButtons"><div class="ActionsDropDown" id="FloatingButtonsEl"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--icon ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00295/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fonc.2020.00295" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00295/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00295/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="ArticleDetails__aside__responsiveButtons__items"><span></span><div class="ArticleDetailsShare__responsive"><button class="ArticleDetailsShare__trigger" aria-label="Open share options"></button><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00295/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00295/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00295/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div></div><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeIconButton ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><!----></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Export citation</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00295/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00295/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00295/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00295/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div></div></div><div class="TotalViews"><div class="TotalViews__data"><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">9,4K</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Total views</div></div></div><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">2,3K</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Downloads</div></div></div><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">23</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Citations</div></div></div><div class="ImpactMetricsInfoPopover"><button aria-label="Open impact metrics info" class="ImpactMetricsInfoPopover__button"></button><div class="ImpactMetricsInfoPopover__tooltip"><button aria-label="Close impact metrics info" class="ImpactMetricsInfoPopover__tooltip__closeButton"></button><div class="ImpactMetricsInfoPopover__tooltip__text"> Citation numbers are available from Dimensions </div></div></div></div><div class="TotalViews__viewImpactLink"><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View article impact" href="http://loop-impact.frontiersin.org/impact/article/526265#totalviews/views" target="_blank" data-event="customLink-link-a_viewArticleImpact"><span>View article impact</span></a></span></div><div class="TotalViews__altmetric"><div data-badge-popover="bottom" data-badge-type="donut" data-doi="10.3389/fonc.2020.00295" data-condensed="true" data-link-target="new" class="altmetric-embed"></div><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View altmetric score" href="https://www.altmetric.com/details/doi/10.3389/fonc.2020.00295" target="_blank" data-event="customLink-link-a_viewAltmetricScore"><span>View altmetric score</span></a></span></div></div><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00295/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00295/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00295/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Edited by</div><!--[--><a href="https://loop.frontiersin.org/people/754893/overview" data-event="editorInfo-a-giuseppeVizzielli" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">G</span><span class="notranslate">V</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Giuseppe  Vizzielli</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">University of Udine, Italy</div></div></a><!--]--></div></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Reviewed by</div><!--[--><a href="https://loop.frontiersin.org/people/786233/overview" data-event="editorInfo-a-martinaArcieri" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">M</span><span class="notranslate">A</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Martina  Arcieri</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Ospedale Santa Maria della Misericordia di Udine, Italy</div></div></a><a href="https://loop.frontiersin.org/people/304800/overview" data-event="editorInfo-a-michaelDean" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">M</span><span class="notranslate">D</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Michael  Dean</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">National Cancer Institute at Frederick (NIH), United States</div></div></a><!--]--></div></div><div class="ArticleDetailsGlossary ArticleDetailsGlossary--open"><button class="ArticleDetailsGlossary__header"><div class="ArticleDetailsGlossary__header__title">Table of contents</div><div class="ArticleDetailsGlossary__header__arrow"></div></button><div class="ArticleDetailsGlossary__content"><ul class="flyoutJournal">
<li><a href="#h1">Abstract</a></li>
<li><a href="#h2">Introduction</a></li>
<li><a href="#h3">Materials and Methods</a></li>
<li><a href="#h4">Results</a></li>
<li><a href="#h5">Discussion</a></li>
<li><a href="#h6">Conclusions</a></li>
<li><a href="#h7">Data Availability Statement</a></li>
<li><a href="#h8">Ethics Statement</a></li>
<li><a href="#h9">Author Contributions</a></li>
<li><a href="#h10">Funding</a></li>
<li><a href="#h11">Conflict of Interest</a></li>
<li><a href="#h12">Supplementary Material</a></li>
<li><a href="#h13">References</a></li>
</ul>
</div></div><span></span><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeOutline ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Export citation</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00295/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00295/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00295/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00295/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="CheckForUpdates"><button data-target="crossmark" class="CheckForUpdates__link" data-event="checkForUpdates-btn-openModal"><img class="CheckForUpdates__link__img" src="/ap-2024/images/crossmark.svg" alt="Crossmark icon"><div class="CheckForUpdates__link__text">Check for updates</div></button></div><div class="AnnouncementCard"><p class="AnnouncementCard__title">Frontiers&#39; impact</p><article class="CardA"><div class="CardA__wrapper CardA__wrapper--vertical"><figure class="FrontiersImage CardA__img"><picture class="FrontiersImage"><!--[--><source srcset="https://images-provider.frontiersin.org/api/ipx/w=440&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 563px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=320x400&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1024px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=268x280&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1441px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><!--]--><img src="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" class="is-inside-mask" alt loading="eager"></picture><!----></figure><div class="CardA__info"><!--[--><h2 class="CardA__title">Articles published with Frontiers have received 12 million total citations</h2><p class="CardA__text">Your research is the real superpower - learn how we maximise its impact through our leading community journals</p><br><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--small Link--icon Link--chevronRight Link--right" aria-label="Explore our impact metrics" href="https://www.frontiersin.org/about/impact" target="_self" data-event="customLink-linkType-a_exploreOurImpactMe"><span>Explore our impact metrics</span></a></span><!--]--></div></div></article></div><!----><!----></div><div><div class="Modal Modal--noFooter"><button aria-label="Close modal" class="Modal__overlay" data-event="modal-overlay-close"></button><div class="Modal__container"><div class="Modal__header"><p class="Modal__title">Supplementary Material</p><button aria-label="Close modal" class="Modal__close" data-event="modal-button-close"></button></div><div class="Modal__body"><!--[--><div class="SupplementalData"><ul class="SupplementalData__list"><!--[--><!--]--></ul></div><!--]--><!----></div><!----><!----></div></div></div><div><div class="FloatingButtons"><!----><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--iconDownload ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Download</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00295/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fonc.2020.00295" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00295/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00295/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><!----></div></div></div></aside></div><div class=""><!----></div><!--]--></div><!----><footer class="Footer"><div class="Footer__wrapper"><div class="Footer__sections"><ul class="Accordion"><!--[--><!--[--><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Guidelines</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/guidelines/author-guidelines" target="_self" data-event="footer-block_0-a_authorGuidelines">Author guidelines</a></li><li><a href="https://www.frontiersin.org/for-authors/author-services" target="_self" data-event="footer-block_0-a_servicesForAuthors">Services for authors</a></li><li><a href="https://www.frontiersin.org/guidelines/policies-and-publication-ethics" target="_self" data-event="footer-block_0-a_policiesAndPublicationE">Policies and publication ethics</a></li><li><a href="https://www.frontiersin.org/guidelines/editor-guidelines" target="_self" data-event="footer-block_0-a_editorGuidelines">Editor guidelines</a></li><li><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="footer-block_0-a_feePolicy">Fee policy</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Explore</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/articles" target="_self" data-event="footer-block_1-a_articles">Articles</a></li><li><a href="https://www.frontiersin.org/research-topics" target="_self" data-event="footer-block_1-a_researchTopics">Research Topics </a></li><li><a href="https://www.frontiersin.org/journals" target="_self" data-event="footer-block_1-a_journals">Journals</a></li><li><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="footer-block_1-a_howWePublish">How we publish</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Outreach</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://forum.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForum">Frontiers Forum </a></li><li><a href="https://policylabs.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersPolicyLabs">Frontiers Policy Labs </a></li><li><a href="https://kids.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForYoungMinds">Frontiers for Young Minds</a></li><li><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="footer-block_2-a_frontiersPlanetPrize">Frontiers Planet Prize</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Connect</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://helpcenter.frontiersin.org" target="_blank" data-event="footer-block_3-a_helpCenter">Help center</a></li><li><a href="https://subscription-management.frontiersin.org/emails/preferences#block0" target="_blank" data-event="footer-block_3-a_emailsAndAlerts">Emails and alerts </a></li><li><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="footer-block_3-a_contactUs">Contact us </a></li><li><a href="https://www.frontiersin.org/submission/submit" target="_self" data-event="footer-block_3-a_submit">Submit</a></li><li><a href="https://careers.frontiersin.org/" target="_blank" data-event="footer-block_3-a_careerOpportunities">Career opportunities</a></li><!--]--></ul><!--]--></div></li><!--]--><!--]--></ul><div class="Footer__socialLinks"><div class="Footer__socialLinks__title">Follow us</div><!--[--><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--facebook Link--right" aria-label="Frontiers Facebook" href="https://www.facebook.com/Frontiersin" target="_blank" data-event="footer-facebook-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--twitter Link--right" aria-label="Frontiers Twitter" href="https://twitter.com/frontiersin" target="_blank" data-event="footer-twitter-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--linkedin Link--right" aria-label="Frontiers LinkedIn" href="https://www.linkedin.com/company/frontiers" target="_blank" data-event="footer-linkedIn-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--instagram Link--right" aria-label="Frontiers Instagram" href="https://www.instagram.com/frontiersin_" target="_blank" data-event="footer-instagram-a_true"><span></span></a></span><!--]--></div></div><div class="Footer__copyright"><div><span> 2025 Frontiers Media SA. All rights reserved.</span></div><div><a href="https://www.frontiersin.org/legal/privacy-policy" target="_blank">Privacy policy</a><span>|</span><a href="https://www.frontiersin.org/legal/terms-and-conditions" target="_blank">Terms and conditions</a></div></div></div></footer><div class="SnackbarWrapper"><div class="SnackbarManager"><!--[--><!--]--></div></div></div><noscript><iframe
            src="https://tag-manager.frontiersin.org/ns.html?id=GTM-M322FV2&gtm_auth=owVbWxfaJr21yQv1fe1cAQ&gtm_preview=env-1&gtm_cookies_win=x"
            height="0"
            width="0"
            style="display: none; visibility: hidden">
          </iframe></noscript><!--]--></div><div id="teleports"></div><script type="application/json" id="__NUXT_DATA__" data-ssr="true">[["ShallowReactive",1],{"data":2,"state":4,"once":10,"_errors":11,"serverRendered":13,"path":14,"pinia":15},["ShallowReactive",3],{},["Reactive",5],{"$ssite-config":6},{"env":7,"name":8,"url":9},"production","Frontiers articles","https://article-pages-2024.frontiersin.org/",["Set"],["ShallowReactive",12],{},true,"/journals/oncology/articles/10.3389/fonc.2020.00295/full",["Reactive",16],{"main":17,"user":532,"article":533,"articleHub":826,"mainHeader":830},{"ibar":18,"footer":284,"newsletterComponent":-1,"snackbarItem":366,"toggleShowSnackbar":367,"contentfulJournal":368,"graphJournal":433,"settingsFeaturesSwitchers":437,"templateToggleBanner":438,"tenantConfig":497},{"tenantLogo":19,"journalLogo":19,"aboutUs":20,"submitUrl":113,"showSubmitButton":13,"journal":114,"sectionTerm":215,"aboutJournal":216,"mainLinks":265,"journalLinks":272,"helpCenterLink":281},"",[21,38,47,71,87],{"title":22,"links":23},"Who we are",[24,29,32,35],{"text":25,"url":26,"target":27,"ariaLabel":28},"Mission and values","https://www.frontiersin.org/about/mission","_self",null,{"text":30,"url":31,"target":27,"ariaLabel":28},"History","https://www.frontiersin.org/about/history",{"text":33,"url":34,"target":27,"ariaLabel":28},"Leadership","https://www.frontiersin.org/about/leadership",{"text":36,"url":37,"target":27,"ariaLabel":28},"Awards","https://www.frontiersin.org/about/awards",{"title":39,"links":40},"Impact and progress",[41,44],{"text":42,"url":43,"target":27,"ariaLabel":28},"Frontiers' impact","https://www.frontiersin.org/about/impact",{"text":45,"url":46,"target":27,"ariaLabel":28},"Our annual reports","https://www.frontiersin.org/about/annual-reports",{"title":48,"links":49},"Publishing model",[50,53,56,59,62,65,68],{"text":51,"url":52,"target":27,"ariaLabel":28},"How we publish","https://www.frontiersin.org/about/how-we-publish",{"text":54,"url":55,"target":27,"ariaLabel":28},"Open access","https://www.frontiersin.org/about/open-access",{"text":57,"url":58,"target":27,"ariaLabel":28},"Peer review","https://www.frontiersin.org/about/peer-review",{"text":60,"url":61,"target":27,"ariaLabel":28},"Research integrity","https://www.frontiersin.org/about/research-integrity",{"text":63,"url":64,"target":27,"ariaLabel":28},"Research Topics","https://www.frontiersin.org/about/research-topics",{"text":66,"url":67,"target":27,"ariaLabel":28},"FAIR Data Management","https://www.frontiersin.org/about/fair-data-management",{"text":69,"url":70,"target":27,"ariaLabel":28},"Fee policy","https://www.frontiersin.org/about/fee-policy",{"title":72,"links":73},"Services",[74,78,81,84],{"text":75,"url":76,"target":77,"ariaLabel":28},"Societies","https://publishingpartnerships.frontiersin.org/","_blank",{"text":79,"url":80,"target":27,"ariaLabel":28},"National consortia","https://www.frontiersin.org/open-access-agreements/consortia",{"text":82,"url":83,"target":27,"ariaLabel":28},"Institutional partnerships","https://www.frontiersin.org/about/open-access-agreements",{"text":85,"url":86,"target":27,"ariaLabel":28},"Collaborators","https://www.frontiersin.org/about/collaborators",{"title":88,"links":89},"More from Frontiers",[90,94,97,101,105,109],{"text":91,"url":92,"target":77,"ariaLabel":93},"Frontiers Forum","https://forum.frontiersin.org/","this link will take you to the Frontiers Forum website",{"text":95,"url":96,"target":27,"ariaLabel":28},"Frontiers Planet Prize","https://www.frontiersin.org/about/frontiers-planet-prize",{"text":98,"url":99,"target":77,"ariaLabel":100},"Press office","https://pressoffice.frontiersin.org/","this link will take you to the Frontiers press office website",{"text":102,"url":103,"target":27,"ariaLabel":104},"Sustainability","https://www.frontiersin.org/about/sustainability","link to information about Frontiers' sustainability",{"text":106,"url":107,"target":77,"ariaLabel":108},"Career opportunities","https://careers.frontiersin.org/","this link will take you to the Frontiers careers website",{"text":110,"url":111,"target":27,"ariaLabel":112},"Contact us","https://www.frontiersin.org/about/contact","this link will take you to the help pages to contact our support team","https://www.frontiersin.org/submission/submit?domainid=2&fieldid=57&specialtyid=0&entitytype=2&entityid=451",{"id":115,"name":116,"slug":117,"sections":118},451,"Frontiers in Oncology","oncology",[119,123,127,131,135,139,143,147,151,155,159,163,167,171,175,179,183,187,191,195,199,203,207,211],{"id":120,"name":121,"slug":122},500,"Breast Cancer","breast-cancer",{"id":124,"name":125,"slug":126},2606,"Cancer Cell Signaling","cancer-cell-signaling",{"id":128,"name":129,"slug":130},513,"Cancer Epidemiology and Prevention","cancer-epidemiology-and-prevention",{"id":132,"name":133,"slug":134},506,"Cancer Genetics","cancer-genetics",{"id":136,"name":137,"slug":138},515,"Cancer Imaging and Image-directed Interventions","cancer-imaging-and-image-directed-interventions",{"id":140,"name":141,"slug":142},527,"Cancer Immunity and Immunotherapy","cancer-immunity-and-immunotherapy",{"id":144,"name":145,"slug":146},1510,"Cancer Metabolism","cancer-metabolism",{"id":148,"name":149,"slug":150},507,"Cancer Molecular Targets and Therapeutics","cancer-molecular-targets-and-therapeutics",{"id":152,"name":153,"slug":154},1513,"Cardio-Oncology","cardio-oncology",{"id":156,"name":157,"slug":158},2413,"Gastrointestinal Cancers: Colorectal Cancer","gastrointestinal-cancers-colorectal-cancer",{"id":160,"name":161,"slug":162},2415,"Gastrointestinal Cancers: Gastric and Esophageal Cancers","gastrointestinal-cancers-gastric-and-esophageal-cancers",{"id":164,"name":165,"slug":166},2414,"Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers","gastrointestinal-cancers-hepato-pancreatic-biliary-cancers",{"id":168,"name":169,"slug":170},503,"Genitourinary Oncology","genitourinary-oncology",{"id":172,"name":173,"slug":174},2079,"Gynecological Oncology","gynecological-oncology",{"id":176,"name":177,"slug":178},517,"Head and Neck Cancer","head-and-neck-cancer",{"id":180,"name":181,"slug":182},505,"Hematologic Malignancies","hematologic-malignancies",{"id":184,"name":185,"slug":186},508,"Molecular and Cellular Oncology","molecular-and-cellular-oncology",{"id":188,"name":189,"slug":190},150,"Neuro-Oncology and Neurosurgical Oncology","neuro-oncology-and-neurosurgical-oncology",{"id":192,"name":193,"slug":194},509,"Pediatric Oncology","pediatric-oncology",{"id":196,"name":197,"slug":198},192,"Pharmacology of Anti-Cancer Drugs","pharmacology-of-anti-cancer-drugs",{"id":200,"name":201,"slug":202},511,"Radiation Oncology","radiation-oncology",{"id":204,"name":205,"slug":206},1630,"Skin Cancer","skin-cancer",{"id":208,"name":209,"slug":210},512,"Surgical Oncology","surgical-oncology",{"id":212,"name":213,"slug":214},502,"Thoracic Oncology","thoracic-oncology","Sections",[217,241],{"title":218,"links":219},"Scope",[220,223,226,229,232,235,238],{"text":221,"url":222,"target":27,"ariaLabel":28},"Field chief editors","https://www.frontiersin.org/journals/oncology/about#about-editors",{"text":224,"url":225,"target":27,"ariaLabel":28},"Mission & scope","https://www.frontiersin.org/journals/oncology/about#about-scope",{"text":227,"url":228,"target":27,"ariaLabel":28},"Facts","https://www.frontiersin.org/journals/oncology/about#about-facts",{"text":230,"url":231,"target":27,"ariaLabel":28},"Journal sections","https://www.frontiersin.org/journals/oncology/about#about-submission",{"text":233,"url":234,"target":27,"ariaLabel":28},"Open access statement","https://www.frontiersin.org/journals/oncology/about#about-open",{"text":236,"url":237,"target":27,"ariaLabel":28},"Copyright statement","https://www.frontiersin.org/journals/oncology/about#copyright-statement",{"text":239,"url":240,"target":27,"ariaLabel":28},"Quality","https://www.frontiersin.org/journals/oncology/about#about-quality",{"title":242,"links":243},"For authors",[244,247,250,253,256,259,262],{"text":245,"url":246,"target":27,"ariaLabel":28},"Why submit?","https://www.frontiersin.org/journals/oncology/for-authors/why-submit",{"text":248,"url":249,"target":27,"ariaLabel":28},"Article types","https://www.frontiersin.org/journals/oncology/for-authors/article-types",{"text":251,"url":252,"target":27,"ariaLabel":28},"Author guidelines","https://www.frontiersin.org/journals/oncology/for-authors/author-guidelines",{"text":254,"url":255,"target":27,"ariaLabel":28},"Editor guidelines","https://www.frontiersin.org/journals/oncology/for-authors/editor-guidelines",{"text":257,"url":258,"target":27,"ariaLabel":28},"Publishing fees","https://www.frontiersin.org/journals/oncology/for-authors/publishing-fees",{"text":260,"url":261,"target":27,"ariaLabel":28},"Submission checklist","https://www.frontiersin.org/journals/oncology/for-authors/submission-checklist",{"text":263,"url":264,"target":27,"ariaLabel":28},"Contact editorial office","https://www.frontiersin.org/journals/oncology/for-authors/contact-editorial-office",[266,269],{"text":267,"url":268,"target":27,"ariaLabel":28},"All journals","https://www.frontiersin.org/journals",{"text":270,"url":271,"target":27,"ariaLabel":28},"All articles","https://www.frontiersin.org/articles",[273,276,278],{"text":274,"url":275,"target":27,"ariaLabel":28},"Articles","articles",{"text":63,"url":277,"target":27,"ariaLabel":28},"research-topics",{"text":279,"url":280,"target":27,"ariaLabel":28},"Editorial board","editors",{"text":282,"url":283,"target":77,"ariaLabel":282},"Help center","https://helpcenter.frontiersin.org",{"blocks":285,"socialLinks":339,"copyright":363,"termsAndConditionsUrl":364,"privacyPolicyUrl":365},[286,300,310,324],{"title":287,"links":288},"Guidelines",[289,291,294,297,299],{"text":251,"url":290,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/author-guidelines",{"text":292,"url":293,"target":27,"ariaLabel":28},"Services for authors","https://www.frontiersin.org/for-authors/author-services",{"text":295,"url":296,"target":27,"ariaLabel":28},"Policies and publication ethics","https://www.frontiersin.org/guidelines/policies-and-publication-ethics",{"text":254,"url":298,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/editor-guidelines",{"text":69,"url":70,"target":27,"ariaLabel":28},{"title":301,"links":302},"Explore",[303,304,307,309],{"text":274,"url":271,"target":27,"ariaLabel":28},{"text":305,"url":306,"target":27,"ariaLabel":28},"Research Topics ","https://www.frontiersin.org/research-topics",{"text":308,"url":268,"target":27,"ariaLabel":28},"Journals",{"text":51,"url":52,"target":27,"ariaLabel":28},{"title":311,"links":312},"Outreach",[313,316,319,323],{"text":314,"url":92,"target":77,"ariaLabel":315},"Frontiers Forum ","Frontiers Forum website",{"text":317,"url":318,"target":77,"ariaLabel":28},"Frontiers Policy Labs ","https://policylabs.frontiersin.org/",{"text":320,"url":321,"target":77,"ariaLabel":322},"Frontiers for Young Minds","https://kids.frontiersin.org/","Frontiers for Young Minds journal",{"text":95,"url":96,"target":27,"ariaLabel":28},{"title":325,"links":326},"Connect",[327,328,332,335,338],{"text":282,"url":283,"target":77,"ariaLabel":282},{"text":329,"url":330,"target":77,"ariaLabel":331},"Emails and alerts ","https://subscription-management.frontiersin.org/emails/preferences#block0","Subscribe to Frontiers emails",{"text":333,"url":111,"target":27,"ariaLabel":334},"Contact us ","Subscribe to newsletter",{"text":336,"url":337,"target":27,"ariaLabel":28},"Submit","https://www.frontiersin.org/submission/submit",{"text":106,"url":107,"target":77,"ariaLabel":28},[340,348,353,358],{"link":341,"type":344,"color":345,"icon":346,"size":347,"hiddenText":13},{"text":342,"url":343,"target":77,"ariaLabel":342},"Frontiers Facebook","https://www.facebook.com/Frontiersin","Link","Grey","Facebook","Medium",{"link":349,"type":344,"color":345,"icon":352,"size":347,"hiddenText":13},{"text":350,"url":351,"target":77,"ariaLabel":28},"Frontiers Twitter","https://twitter.com/frontiersin","Twitter",{"link":354,"type":344,"color":345,"icon":357,"size":347,"hiddenText":13},{"text":355,"url":356,"target":77,"ariaLabel":28},"Frontiers LinkedIn","https://www.linkedin.com/company/frontiers","LinkedIn",{"link":359,"type":344,"color":345,"icon":362,"size":347,"hiddenText":13},{"text":360,"url":361,"target":77,"ariaLabel":28},"Frontiers Instagram","https://www.instagram.com/frontiersin_","Instagram","Frontiers Media SA. All rights reserved.","https://www.frontiersin.org/legal/terms-and-conditions","https://www.frontiersin.org/legal/privacy-policy",{},false,{"__typename":369,"identifier":115,"name":116,"slug":117,"banner":370,"description":426,"mission":427,"palette":428,"impactFactor":429,"citeScore":430,"citations":431,"showTagline":28,"twitter":432},"Journal",[371],{"id":372,"src":373,"name":374,"tags":375,"type":384,"width":385,"height":386,"idHash":387,"archive":388,"brandId":389,"limited":388,"fileSize":390,"isPublic":391,"original":392,"copyright":393,"extension":394,"thumbnails":396,"dateCreated":404,"description":405,"orientation":406,"userCreated":407,"watermarked":388,"dateModified":404,"datePublished":408,"ecsArchiveFiles":409,"propertyOptions":410,"property_Channel":415,"property_Sub-Type":417,"property_Asset_Type":419,"activeOriginalFocusPoint":421,"property_Office_Department":424},"A08FCA58-05EE-4283-A13E51F93BB73C97","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/webimage-6A59331A-8816-4B2C-BC3F6EF168F6183E.jpg","FONC_Main Visual_Purple_Website",[376,377,378,379,380,381,382,383],"body part","dead","anatomy","defending","protection","skin","treatment","cell","image",7200,4050,"7f2922f165e2e1ba",0,"22C10171-81B3-4DA6-99342F272A32E8BB",9449881,1,"https://brand.frontiersin.org/m/7f2922f165e2e1ba/original/FONC_Main-Visual_Purple_Website.jpeg","Copyright (c) 2021 Design_Cells/Shutterstock.  No use without permission.",[395],"jpeg",{"mini":397,"thul":398,"webimage":373,"Guidelines":399,"WebsiteJpg_XL":400,"WebsiteWebP_L":401,"WebsiteWebP_M":402,"WebsiteWebP_XL":403},"https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/mini-5795EAF1-94A7-4623-B52EAC7FC8A5098F.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/thul-301BCB38-FCF6-4517-9359D5382707B640.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/352DFCCB-44FF-4821-962507007B815780/Guidelines-FONC_Main Visual_Purple_Website.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/352DFCCB-44FF-4821-962507007B815780/WebsiteJpg_XL-FONC_Main Visual_Purple_Website.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/352DFCCB-44FF-4821-962507007B815780/WebsiteWebP_L-FONC_Main Visual_Purple_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/352DFCCB-44FF-4821-962507007B815780/WebsiteWebP_M-FONC_Main Visual_Purple_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/352DFCCB-44FF-4821-962507007B815780/WebsiteWebP_XL-FONC_Main Visual_Purple_Website.webp","2022-06-27T10:00:39Z","Cancer cell, cell grow out of control and become invasive. 3d illustration","landscape","Caroline Sutter","2022-06-27T09:27:09Z",[],[411,412,413,414],"414FB2D4-2283-43FD-BE14E534ECA67928","6C18119B-14BD-4951-B437696F4357BD33","7C692885-DB25-4858-B1FB4FF47B241E9B","D88C0047-EC30-4506-A7DF28A4D765E1CF",[416],"frontiersin_org",[418],"Main_Visual",[420],"Photography",{"x":422,"y":423},3600,2025,[425],"Publishing","Explore global oncology research advancing cancer diagnosis, treatment, and management across diverse populations and healthcare systems.","\u003Cp>Frontiers in Oncology is a broad-scope, multidisciplinary journal covering all areas of cancer research to advance our knowledge of cancer epidemiology to improve diagnosis, therapeutics, and management strategies.\u003C/p>\n\n\u003Cp>The journal is led by Field Chief Editor Prof Giuseppe Giaccone (Cornell University and Amgen, USA), and Assistant Field Chief Editor Prof Sharon Pine (University of Colorado, USA). Indexed in PubMed Central (PMC), Scopus, Web of Science (SCIE), and the DOAJ, Frontiers in Oncology welcomes clinical and experimental research contributions in the various domains of cancer research, which bridge the gap between basic research and clinical applications. Topics include, but are not limited to:\u003C/p>\n\u003Cul>\n  \u003Cli>breast cancer\u003C/li>\n  \u003Cli>cancer cell signaling\u003C/li>\n  \u003Cli>cancer epidemiology and prevention\u003C/li>\n  \u003Cli>cancer genetics\u003C/li>\n  \u003Cli>cancer imaging and image-directed interventions\u003C/li>\n  \u003Cli>cancer immunity and immunotherapy\u003C/li>\n  \u003Cli>cancer metabolism\u003C/li>\n  \u003Cli>cancer molecular targets and therapeutics\u003C/li>\n  \u003Cli>cardio-oncology\u003C/li>\n  \u003Cli>gastrointestinal cancers\u003C/li>\n  \u003Cli>genitourinary oncology\u003C/li>\n  \u003Cli>gynecological oncology\u003C/li>\n  \u003Cli>head and neck cancer\u003C/li>\n  \u003Cli>hematologic malignancies\u003C/li>\n  \u003Cli>molecular and cellular oncology\u003C/li>\n  \u003Cli>neuro-oncology and neurosurgical oncology\u003C/li>\n  \u003Cli>pediatric oncology\u003C/li>\n  \u003Cli>pharmacology of anti-cancer drugs\u003C/li>\n  \u003Cli>radiation oncology\u003C/li>\n  \u003Cli>skin cancer\u003C/li>\n  \u003Cli>surgical oncology\u003C/li>\n  \u003Cli>thoracic oncology.\u003C/li>\n\u003C/ul>\n\n\u003Cp>In particular, the journal welcomes submissions which support and advance the UNs Sustainable Development Goals (SDGs), notable SDG 3: ensure healthy lives and promote well-being for all at all ages.\u003C/p>\n\n\u003Cp>Frontiers' journals require that manuscripts primarily comprising solely of bioinformatics analyses, computational studies of public data, or findings from Mendelian Randomisation studies must include appropriate validation. Acceptable forms of validation include:\u003Cp>\n\u003Cul>\n  \u003Cli>independent clinical or patient cohorts that are not publicly available\u003C/li>\n  \u003Cli>biological validation of the main conclusions, either \u003Cem>in vitro\u003C/em> or \u003Cem>in vivo\u003C/em>\u003C/li>\n  \u003Cli>multi-database queries (bibliometric studies only)\u003C/li>\n\u003C/ul>\n\n\u003Cp>Manuscripts lacking robust validation will be considered unsuitable for publication, as they do not meet the required evidence standards necessary for scientific conclusions. Please refer to the \u003Ca href=\"https://www.frontiersin.org/guidelines/policies-and-publication-ethics#standards-for-research-methodology\">Frontiers Standards for research methodology policy\u003C/a>, for more information.\u003C/p>\n\n\u003Cp>Frontiers in Oncology is committed to advancing developments in the field of cancer research by allowing unrestricted access to articles, and communicating scientific knowledge to researchers and the public alike, to enable the scientific breakthroughs of the future.\u003C/p>","purple","4.7","5.2","464146","@FrontOncology",{"id":115,"name":116,"slug":117,"abbreviation":434,"isOnline":13,"isOpenForSubmissions":13,"citeScore":435,"impactFactor":436},"fonc",6.9,3.3,{"displayTitlePillLabels":13,"displayRelatedArticlesBox":13,"showEditors":13,"showReviewers":13,"showLoopImpactLink":13,"enableFigshare":367},{"isPublic":13,"allowCompanyUsers":367,"whiteListEmails":439,"enableAllJournals":13,"whiteListJournals":461},[440,441,442,443,444,445,446,447,448,445,449,450,451,452,453,454,455,456,457,458,459,460],"Y2FybG9zLmxvcmNhQGZyb250aWVyc2luLm9yZw==","ZGFuaWVsLmx1ekBmcm9udGllcnNpbi5vcmc=","bGF1cmEudGVuYUBmcm9udGllcnNpbi5vcmc=","cmFmYWVsLnJpYW5jaG9AZnJvbnRpZXJzaW4ub3Jn","amFtZXMuc21hbGxib25lQGZyb250aWVyc2luLm9yZw==","ZnJhbi5tb3Jlbm9AZnJvbnRpZXJzaW4ub3Jn","c2FtdWVsLmZlcm5hbmRlekBmcm9udGllcnNpbi5vcmc=","YmFyYmFyYS5jYXJjYW5naXVAZnJvbnRpZXJzaW4ub3Jn","aXZhbi5zYW50YW1hcmlhQGZyb250aWVyc2luLm9yZw==","aHVlLnRyYW5AZnJvbnRpZXJzaW4ub3Jn","Z29uY2Fsby52YXJnYXNAZnJvbnRpZXJzaW4ub3Jn","bHVjaWUuc2VubkBmcm9udGllcnNpbi5vcmc=","bG9ybi5mcmFzZXJAZnJvbnRpZXJzaW4ub3Jn","ZWxzYS5jYXJyb25AZnJvbnRpZXJzaW4ub3Jn","bWFhcnRlbi52YW5kaWpja0Bmcm9udGllcnNpbi5vcmc=","YmluZGh1LmtyaXNobmFuQGZyb250aWVyc2luLm9yZw==","bWF0dGhldy5hdHR3YXRlcnNAZnJvbnRpZXJzaW4ub3Jn","Z2l1bGlhLnZhbHNlY2NoaUBmcm9udGllcnNpbi5vcmc=","ZmFiaWFuLmRlbGxhbW9ydGVAZnJvbnRpZXJzaW4ub3Jn","dmlqYXlhbi5wcEBwaXRzb2x1dGlvbnMuY29t","Z3VpbGxhdW1lLnNldXJhdEBmcm9udGllcnNpbi5vcmc=",[462,463,464,465,466,467,391,468,469,470,471,472,473,474,475,476,477,478,479,480,481,115,482,483,484,485,486,487,488,489,490,491,492,493,494,495,496],2232,1729,2357,2456,2176,2333,1843,602,106,616,310,657,3123,1468,2137,628,1566,2726,2086,1490,141,1335,2655,1238,604,698,1547,176,1440,403,1239,755,2136,609,1534,{"spaceId":391,"name":391,"availableJournalPages":498,"announcement":502},[275,280,277,499,500,501],"volumes","about","community-reviewers",{"__typename":503,"sys":504,"preHeader":42,"title":506,"description":507,"image":508,"link":530},"Announcement",{"id":505},"5ITtnTtQgAzPPGH6rX0AlM","Articles published with Frontiers have received 12 million total citations","Your research is the real superpower - learn how we maximise its impact through our leading community journals",[509],{"archive":388,"brandId":389,"copyright":28,"dateCreated":510,"dateModified":511,"datePublished":512,"description":28,"extension":513,"fileSize":515,"height":516,"id":517,"isPublic":388,"limited":388,"name":518,"orientation":406,"original":28,"thumbnails":519,"type":384,"watermarked":388,"width":526,"videoPreviewURLs":527,"tags":528,"textMetaproperties":529,"src":520},"2025-06-18T12:58:01Z","2025-06-18T14:15:34Z","2025-06-18T12:57:32Z",[514],"png",1365026,920,"7C5269C4-3C83-4591-951A74D15B95DAEA","Impact metrics banner for article pages",{"webimage":520,"thul":521,"mini":522,"WebsiteWebP_L":523,"WebsiteWebP_M":524,"Guidelines":525},"https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/thul-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/mini-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_L/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_M/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/Guidelines/Impact-metrics-banner-for-article-pages.png",1600,[],[],[],{"text":531,"url":43,"target":27,"ariaLabel":28},"Explore our impact metrics",{"loggedUserInfo":-1},{"currentArticle":534,"isPreviewPage":367,"hasSupplementalData":367,"showCrossmarkWidget":13,"articleTemplate":687,"currentArticlePageMetaInfo":688,"xmlParsedArticleContent":-1,"xmlParsingError":-1},{"id":535,"doi":536,"title":537,"acceptanceDate":538,"receptionDate":539,"publicationDate":540,"lastModifiedDate":541,"isPublished":13,"abstract":542,"researchTopic":28,"articleType":543,"stage":546,"keywords":548,"authors":555,"editors":610,"reviewers":620,"journal":638,"section":646,"impactMetrics":651,"volume":655,"articleVolume":656,"relatedArticles":657,"isPublishedV2":367,"contents":658,"files":662},526265,"10.3389/fonc.2020.00295","Germline and Somatic BRCA1/2 Mutations in 172 Chinese Women With Epithelial Ovarian Cancer",["Date","2020-02-20T08:54:38.000Z"],["Date","2020-01-13T02:49:13.000Z"],["Date","2020-03-10T00:00:00.000Z"],["Date","2025-11-25T13:20:35.644Z"],"Objective\nDespite several nationwide cohort studies on germline BRCA1/2 mutations and several small cohort studies on somatic BRCA1/2 mutations in Chinese epithelial ovarian cancer (EOC) patients, little is known about the impact of these findings on survival outcomes in this population. In this study of 172 retrospectively recruited Chinese EOC patients, germline and somatic BRCA1/2 mutations and their value for predicting survival outcomes were evaluated.\nMethods\nUnselected patients who visited the study center from January 1, 2011, to January 1, 2015, were recruited and asked to provide peripheral blood samples for this study if they were pathologically confirmed to have primary EOC. All patients received staging surgeries or debulking surgeries systemic platinum-based chemotherapy, and the patients were then followed up to December 1, 2017. DNA was extracted from formalin-fixed, paraffin-embedded (FFPE) sections and peripheral blood and sequenced for somatic and germline testing, respectively. The demographic and clinicopathological characteristics of the patients were collected to analyze the distribution of BRCA mutations in subgroups. Survival outcomes were compared among various BRCA mutation statuses using univariate and multivariate models.\nResults\nIn 59 (34.1%) patients, 64 variants were identified, including variants of unknown signicance (VUS) in 19 patients (11.0%) and pathogenic or likely pathogenic variants in a partially overlapping set of 41 patients (23.8%). Germline BRCA mutations, somatic BRCA mutations, BRCA1 mutations in general, and BRCA2 mutations in general were found in 35 (20.3%), 7 (4.1%), 28 (16.3%) and 13 (7.6%) patients, respectively. Five recurrent mutations were identified. Personal and family cancer history as well as hereditary breast and ovarian cancer (HBOC) criteria were associated with deleterious BRCA mutations both overall and in the germline specifically, whereas only age at diagnosis of EOC was associated with somatic BRCA mutations. In univariate and Cox regression analyses, patients with BRCA1/2 mutations in general had significant improvements in progression-free survival (PFS) and overall survival (OS).\nConclusions\nIn Chinese EOC patients, the distributions and risk factors associated with germline and somatic BRCA1/2 were similar to those previously reported in international studies. Deleterious BRCA mutations in general were associated with improved survival outcomes in this cohort.",{"id":544,"name":545},24,"Original Research",{"id":547,"name":19},18,[549,550,551,552,553,554],"epithelial ovarian cancer","BRCA mutations","germline mutations","somatic mutations","Progression-free survival","overall survival",[556,565,573,580,586,592,598,604],{"id":557,"firstName":558,"middleName":19,"lastName":559,"givenNames":560,"isCorresponding":367,"isProfilePublic":13,"userId":557,"email":-1,"affiliations":561},708236,"Yan","You","Yan ",[562],{"organizationName":563,"countryName":564,"cityName":19,"stateName":19,"zipCode":19},"Department of Pathology, Molecular Pathology Research Center, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science","China",{"id":566,"firstName":567,"middleName":19,"lastName":568,"givenNames":569,"isCorresponding":367,"isProfilePublic":13,"userId":566,"email":-1,"affiliations":570},802691,"Lei","Li","Lei ",[571],{"organizationName":572,"countryName":564,"cityName":19,"stateName":19,"zipCode":19},"Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science",{"id":574,"firstName":575,"middleName":19,"lastName":576,"givenNames":577,"isCorresponding":367,"isProfilePublic":13,"userId":574,"email":-1,"affiliations":578},881070,"Junliang","Lu","Junliang ",[579],{"organizationName":563,"countryName":564,"cityName":19,"stateName":19,"zipCode":19},{"id":388,"firstName":581,"middleName":19,"lastName":582,"givenNames":583,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":584},"Huanwen","Wu","Huanwen ",[585],{"organizationName":563,"countryName":564,"cityName":19,"stateName":19,"zipCode":19},{"id":388,"firstName":587,"middleName":19,"lastName":588,"givenNames":589,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":590},"Jing","Wang","Jing ",[591],{"organizationName":563,"countryName":564,"cityName":19,"stateName":19,"zipCode":19},{"id":388,"firstName":593,"middleName":19,"lastName":594,"givenNames":595,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":596},"Jie","Gao","Jie ",[597],{"organizationName":563,"countryName":564,"cityName":19,"stateName":19,"zipCode":19},{"id":599,"firstName":600,"middleName":19,"lastName":582,"givenNames":601,"isCorresponding":367,"isProfilePublic":13,"userId":599,"email":-1,"affiliations":602},920530,"Ming","Ming ",[603],{"organizationName":572,"countryName":564,"cityName":19,"stateName":19,"zipCode":19},{"id":388,"firstName":605,"middleName":19,"lastName":606,"givenNames":607,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":608},"Zhiyong","Liang","Zhiyong ",[609],{"organizationName":563,"countryName":564,"cityName":19,"stateName":19,"zipCode":19},[611],{"id":612,"firstName":613,"middleName":19,"lastName":614,"givenNames":615,"isCorresponding":367,"isProfilePublic":13,"userId":612,"email":-1,"affiliations":616},754893,"Giuseppe","Vizzielli","Giuseppe ",[617],{"organizationName":618,"countryName":619,"cityName":19,"stateName":19,"zipCode":19},"University of Udine","Italy",[621,629],{"id":622,"firstName":623,"middleName":19,"lastName":624,"givenNames":625,"isCorresponding":367,"isProfilePublic":13,"userId":622,"email":-1,"affiliations":626},786233,"Martina","Arcieri","Martina ",[627],{"organizationName":628,"countryName":619,"cityName":19,"stateName":19,"zipCode":19},"Ospedale Santa Maria della Misericordia di Udine",{"id":630,"firstName":631,"middleName":19,"lastName":632,"givenNames":633,"isCorresponding":367,"isProfilePublic":13,"userId":630,"email":-1,"affiliations":634},304800,"Michael","Dean","Michael ",[635],{"organizationName":636,"countryName":637,"cityName":19,"stateName":19,"zipCode":19},"National Cancer Institute at Frederick (NIH)","United States",{"id":115,"slug":117,"name":116,"shortName":639,"electronicISSN":640,"field":641,"specialtyId":28,"journalSectionPaths":644},"Front. Oncol.","2234-943X",{"id":642,"domainId":643},57,2,[645],{"section":646},{"id":647,"name":648,"slug":649,"specialtyId":650},597,"Women's Cancer","womens-cancer",1301,{"views":652,"downloads":653,"citations":654},9382,2326,23,10,"Volume 10 - 2020",[],{"titleHtml":659,"fullTextHtml":660,"menuHtml":661},"Germline and Somatic \u003Ci>BRCA1/2\u003C/i> Mutations in 172 Chinese Women With Epithelial Ovarian Cancer","\u003Cdiv class=\"JournalAbstract\">\n\u003Ca id=\"h1\" name=\"h1\">\u003C/a>\n\u003Cdiv class=\"authors\">\u003Cspan class=\"author-wrapper notranslate\">\n\u003Ca href=\"https://loop.frontiersin.org/people/708236\" class=\"user-id-708236\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/708236/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"\nYan You&#x;\">Yan You\u003C/a>\u003Csup>1\u003C/sup>\u003Csup>&#x02020;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/802691\" class=\"user-id-802691\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/802691/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Lei Li&#x;\">Lei Li\u003C/a>\u003Csup>2\u003C/sup>\u003Csup>&#x02020;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/881070\" class=\"user-id-881070\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/881070/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Junliang Lu&#x;\">Junliang Lu\u003C/a>\u003Csup>1\u003C/sup>\u003Csup>&#x02020;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Huanwen Wu\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Huanwen Wu\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Jing Wang\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Jing Wang\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Jie Gao\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Jie Gao\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/920530\" class=\"user-id-920530\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/920530/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Ming Wu&#xA;\">Ming Wu\u003C/a>\u003Csup>2\u003C/sup>\u003Csup>&#x0002A;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Zhiyong Liang&#xA;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Zhiyong Liang\u003Csup>1\u003C/sup>\u003Csup>&#x0002A;\u003C/sup>\u003C/span>\u003C/div>\n\u003Cul class=\"notes\">\n\u003Cli>\u003Cspan>\u003Csup>1\u003C/sup>\u003C/span>Department of Pathology, Molecular Pathology Research Center, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, Beijing, China\u003C/li>\n\u003Cli>\u003Cspan>\u003Csup>2\u003C/sup>\u003C/span>Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, Beijing, China\u003C/li>\n\u003C/ul>\n\u003Cp class=\"mb15\">\u003Cstrong>Objective:\u003C/strong> Despite several nationwide cohort studies of germline \u003Ci>BRCA1/2\u003C/i> mutations and several small cohort studies of somatic \u003Ci>BRCA1/2\u003C/i> mutations in Chinese epithelial ovarian cancer (EOC) patients, little is known about the impact of these findings on survival outcomes in this population. In this study of 172 retrospectively recruited Chinese EOC patients, germline and somatic \u003Ci>BRCA1/2\u003C/i> mutations and their value for predicting survival outcomes were evaluated.\u003C/p>\n\u003Cp class=\"mb15\">\u003Cstrong>Methods:\u003C/strong> Unselected patients who visited the study center from January 1, 2011, to January 1, 2015, were recruited and asked to provide peripheral blood samples for this study if they were pathologically confirmed to have primary EOC. All patients received staging surgeries or debulking surgeries involving systemic platinum-based chemotherapy, and the patients were then followed up to December 1, 2017. DNA was extracted from formalin-fixed, paraffin-embedded (FFPE) sections and peripheral blood and sequenced for somatic and germline testing, respectively. The demographic and clinicopathological characteristics of the patients were collected to analyze the distribution of \u003Ci>BRCA\u003C/i> mutations in subgroups. Survival outcomes were compared among various \u003Ci>BRCA\u003C/i> mutation statuses using univariate and multivariate models.\u003C/p>\n\u003Cp class=\"mb15\">\u003Cstrong>Results:\u003C/strong> In 58 (33.7%) patients, 63 variants were identified, including variants of unknown significance (VUS) in 18 patients (10.5%) and pathogenic or likely pathogenic variants in a partially overlapping set of 41 patients (23.8%). Germline \u003Ci>BRCA\u003C/i> mutations, somatic \u003Ci>BRCA\u003C/i> mutations, \u003Ci>BRCA1\u003C/i> mutations in general, and \u003Ci>BRCA2\u003C/i> mutations in general were found in 35 (20.3%), 7 (4.1%), 28 (16.3%), and 13 (7.6%) patients, respectively. Five recurrent mutations were identified. Personal and family cancer histories as well as hereditary breast and ovarian cancer (HBOC) criteria were associated with deleterious \u003Ci>BRCA\u003C/i> mutations both overall and in the germline specifically, whereas only age at diagnosis of EOC was associated with somatic \u003Ci>BRCA\u003C/i> mutations. In univariate and Cox regression analyses, patients with \u003Ci>BRCA1/2\u003C/i> mutations in general had significant improvements in progression-free survival (PFS) and overall survival (OS).\u003C/p>\n\u003Cp class=\"mb0\">\u003Cstrong>Conclusions:\u003C/strong> In Chinese EOC patients, the distributions and risk factors associated with germline and somatic \u003Ci>BRCA1/2\u003C/i> mutations were similar to those previously reported in international studies. Deleterious \u003Ci>BRCA\u003C/i> mutations in general were associated with improved survival outcomes in this cohort.\u003C/p>\n\u003Cdiv class=\"clear\">\u003C/div>\n\u003C/div>\n\u003Cdiv class=\"JournalFullText\">\n\u003Ca id=\"h2\" name=\"h2\">\u003C/a>\u003Ch2>Introduction\u003C/h2>\n\u003Cp class=\"mb15\">Ovarian cancer is the third most common gynecological malignancy and the leading cause of mortality in female cancers (\u003Ca href=\"#B1\">1\u003C/a>), representing 1.3% of all new cancer cases in the United States in 2018 (\u003Ca href=\"#B2\">2\u003C/a>). In China, the prevalence of ovarian cancer has increased in the past decade, with 52,100 new cases and 22,500 related deaths in 2015 (\u003Ca href=\"#B3\">3\u003C/a>). Ovarian cancers are a heterogeneous group of malignancies varying in etiology and molecular biology. Approximately 90% of cases belong to the epithelial type [epithelial ovarian cancer (EOC)], with the most common being high-grade serous carcinoma (HGSC). A majority of EOC patients are diagnosed at advanced stages and have a poor prognosis. As with other malignancies, the tumorigenesis of EOC is a process that drives normal cells toward a malignant state and can involve both somatic (acquired) and germline (inherited) mutations (\u003Ca href=\"#B4\">4\u003C/a>, \u003Ca href=\"#B5\">5\u003C/a>). Large-scale cancer sequencing data from cases in The Cancer Genome Atlas (TCGA) revealed that ovarian cancer has the highest prevalence of susceptibility-associated genes (\u003Ca href=\"#B6\">6\u003C/a>). In previous reports, &#x0007E;5 to 10% of invasive EOC cases were hereditary (\u003Ca href=\"#B7\">7\u003C/a>&#x02013;\u003Ca href=\"#B10\">10\u003C/a>). In addition, inherited ovarian cancer may present as hereditary breast and ovarian cancer (HBOC) (\u003Ca href=\"#B11\">11\u003C/a>, \u003Ca href=\"#B12\">12\u003C/a>). However, in recent reports, &#x0007E;20% or more of all EOCs have been identified to be associated with germline mutations (\u003Ca href=\"#B13\">13\u003C/a>&#x02013;\u003Ca href=\"#B16\">16\u003C/a>). Most cases of inherited susceptibility to EOC are primarily related to germline mutations of \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i>, which account for about 80% of hereditary ovarian cancers (\u003Ca href=\"#B17\">17\u003C/a>&#x02013;\u003Ca href=\"#B19\">19\u003C/a>). Mutant \u003Ci>BRCA\u003C/i> is an indispensable founding mutation in EOC (\u003Ca href=\"#B20\">20\u003C/a>). Knowledge of the pathogenic molecular mechanism and genetic mutations involved in EOC has promoted genetic counseling and testing as well as potential intervention (\u003Ca href=\"#B21\">21\u003C/a>). The emergence of poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors (PARPis) has necessitated genetic testing (\u003Ca href=\"#B22\">22\u003C/a>). However, there is controversy regarding the optimum testing strategy (\u003Ca href=\"#B23\">23\u003C/a>&#x02013;\u003Ca href=\"#B25\">25\u003C/a>). Information on \u003Ci>BRCA1/2\u003C/i> germline mutations has predictive value for the platinum sensitivity of tumors and the survival outcomes of patients (\u003Ca href=\"#B26\">26\u003C/a>&#x02013;\u003Ca href=\"#B28\">28\u003C/a>). In a study by Pennington et al. (\u003Ca href=\"#B28\">28\u003C/a>) compared to germline \u003Ci>BRCA1/2\u003C/i> mutations, somatic \u003Ci>BRCA1/2\u003C/i> mutations had a similar positive impact on overall survival (OS) and platinum responsiveness. On the other hand, in recent reports, homologous recombination deficiency has gained in importance, in addition to the BRCA mutations, on the targeted treatment (\u003Ca href=\"#B23\">23\u003C/a>, \u003Ca href=\"#B29\">29\u003C/a>), chemotherapy (\u003Ca href=\"#B30\">30\u003C/a>, \u003Ca href=\"#B31\">31\u003C/a>), and prognosis (\u003Ca href=\"#B32\">32\u003C/a>, \u003Ca href=\"#B33\">33\u003C/a>) in EOC patients.\u003C/p>\n\u003Cp class=\"mb15\">Despite several national cohort studies of \u003Ci>BRCA\u003C/i> germline mutations in China (\u003Ca href=\"#B16\">16\u003C/a>, \u003Ca href=\"#B34\">34\u003C/a>, \u003Ca href=\"#B35\">35\u003C/a>) and in Japan (\u003Ca href=\"#B24\">24\u003C/a>), no study has attempted to reveal the association between mutations and treatment effects or survival outcomes in Chinese EOC patients. The specific impact of somatic mutations on EOC cohorts is also not well-explored. In our previous report (\u003Ca href=\"#B36\">36\u003C/a>), no significant outcomes were discovered due to the limited sample size and short follow-up period.\u003C/p>\n\u003Cp class=\"mb0\">In the present report, we aimed to determine the frequencies of germline and somatic \u003Ci>BRCA1/2\u003C/i> mutations in a single study center based on pathological findings from primary samples or surgical tissues. The mutation status was analyzed in the context of various demographic and clinicopathological characteristics, such as personal and family cancer history as well as histological subtypes. The impact of mutation status on sensitivity to platinum-based chemotherapy and on patient survival outcomes was also described in univariate and multivariate models.\u003C/p>\n\u003Ca id=\"h3\" name=\"h3\">\u003C/a>\u003Ch2>Materials and Methods\u003C/h2>\n\u003Ch3 class=\"pt0\">Study Subjects\u003C/h3>\n\u003Cp class=\"mb0\">Unselected patients who visited the study center from January 1, 2011, to January 1, 2015, and were diagnosed with EOC were recruited for this study. Once the pathological examination confirmed EOC, the patients were asked to provide samples of peripheral blood for germline testing if they met the following inclusion criteria: (1) age 18 years or older; (2) pathologically confirmed EOC (including EOC, carcinoma of the fallopian tube and primary peritoneal carcinoma); (3) receipt of comprehensive staging surgery or debulking surgery and systemic platinum-based chemotherapy; (4) sufficient formalin-fixed, paraffin-embedded (FFPE) sections for somatic testing, which could be performed between any two systematic chemotherapy treatments; these tissues could be collected by core biopsy or by laparoscopy for patients prepared for neoadjuvant chemotherapy or by laparotomic sampling for patients of primary staging or cytoreductive surgeries; (5) willingness to provide signed consent in advance of the trial; and (6) provision of peripheral blood for germline testing. Patients not meeting all of these inclusion criteria were excluded. Basic patient information regarding age at diagnosis, neoplasm staging and histopathological type was retrieved from medical records. This study was approved by the Institutional Review Board (IRB) of the study center (Registration No. ZS-1245). The Chinese Human Genetic Resources Management Office of the National Ministry of Science and Technology also approved this study (registration No. [2017]1901, \u003Ca href=\"http://www.most.gov.cn/bszn/new/rlyc/jgcx/index.htm\">http://www.most.gov.cn/bszn/new/rlyc/jgcx/index.htm\u003C/a>). As previously mentioned, all patients gave informed consent before enrollment.\u003C/p>\n\u003Ch3>Treatment and Follow-Up\u003C/h3>\n\u003Cp class=\"mb15\">All patients received staging surgeries or primary or interval debulking surgeries along with systematic chemotherapy, which was initiated with platinum-based chemotherapy. Demographic data and medical history, including the date of diagnosis, were retrieved from the patients&#x00027; medical records. Data regarding histological classification and grading were obtained from the electronic pathology database at the study center. Staging was determined by the International Federation of Gynecology and Obstetrics (FIGO) 2014 staging system (\u003Ca href=\"#B37\">37\u003C/a>). Personal and family cancer histories were addressed, especially personal breast cancer history and the aspects of cancer history specified by the &#x0201C;Criteria for further genetic risk evaluation&#x0201D; from the National Comprehensive Cancer Network (NCCN) HBOC guideline of &#x0201C;Genetic/Familial High-Risk Assessment: Breast and Ovarian&#x0201D; (\u003Ca href=\"#B38\">38\u003C/a>).\u003C/p>\n\u003Cp class=\"mb0\">Tumors were sorted into the following categories depending on their response to platinum-based chemotherapy: (1) platinum sensitive, if the time between administration and first relapse of the disease was more than 6 months; (2) platinum resistant, if the patient had a relapse 4 weeks to 6 months after administration; or (3) refractory, if the disease relapsed within 4 weeks under platinum-based agents. Follow-ups were conducted for all enrolled patients until December 1, 2017, or death. Disease relapse or progression was determined by medical imaging, serology, or histology. Progression-free survival (PFS) was defined as the time span between initial diagnosis and disease relapse or progression, while OS was defined as the time span between initial diagnosis and patient death.\u003C/p>\n\u003Ch3>Analysis of Germline and Somatic \u003Ci>BRCA1/2\u003C/i> Mutational Status\u003C/h3>\n\u003Cp class=\"mb15\">For germline \u003Ci>BRCA1/2\u003C/i> analyses, DNA was extracted from 200 &#x003BC;l of peripheral blood with the QIAamp DNA Blood Mini Kit (QIAGEN, Hilden, Germany). For somatic \u003Ci>BRCA1/2\u003C/i> analysis, 10 FFPE sections measuring five micrometers in thickness and taken from representative blocks were made for each case. The cancerous region was then marked by two experienced pathologists (YY and HW) and macro-dissected following deparaffinization using xylene. DNA was then extracted from the tumor tissue using the QIAamp DNA FFPE Tissue Kit (QIAGEN, Hilden, Germany).\u003C/p>\n\u003Cp class=\"mb15\">Sequencing libraries were prepared using an Oncomine \u003Ci>BRCA\u003C/i> research assay (Thermo Fisher, Waltham, Massachusetts, USA); the libraries were then subjected to emulsion PCR using the Ion OneTouch 2 System and sequenced on an Ion Torrent Personal Genome Machine sequencer to a median of 500X depth for germline mutations and 1000X for somatic mutations according to the manufacturer&#x00027;s instructions. Upon completion, the raw data were sent through a pipeline customized by Life Technologies. The parameters for variation calling are available (in JSON format) upon request. The sequences covered all exons of the \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> genes as well as &#x000B1;20 bp flanking regions to enable the detection of variations affecting potential splice sites. However, due to its high cost, we did not include multiplex ligation-dependent probe amplification (MLPA) in the tests for \u003Ci>BRCA1/2\u003C/i>.\u003C/p>\n\u003Cp class=\"mb0\">The identified \u003Ci>BRCA1/2\u003C/i> variations were classified according to the 2015 American College of Medical Genetics and Genomics (ACMG) guidelines (\u003Ca href=\"#B39\">39\u003C/a>). Pathogenic and likely pathogenic mutations were regarded as deleterious mutations.\u003C/p>\n\u003Ch3>Statistical Analysis\u003C/h3>\n\u003Cp class=\"mb0\">Comparisons of continuous variables were conducted with parametric methods if the assumption of normality was met. Non-normally distributed variables and categorical data were compared between patients with and without specific deleterious mutations by using non-parametric tests. Kaplan&#x02013;Meier survival curves were generated, and proportional hazards models were used to estimate the hazard ratios (HRs) and 95% confidence intervals (95% CIs) for the effects of deleterious mutations on PFS and OS. A multivariable analysis of disease-free survival was performed with adjustment for the important baseline risk factors of major histological subtype (HGSC vs. others), age at diagnosis, and stage (stage I&#x02013;II vs. III&#x02013;IV). Unless otherwise stated, all analyses used a two-sided significance level of 0.05 and were conducted with Statistical Product and Service Solutions (SPSS) Statistics 20.0 software (IBM Corporation, Armonk, NY, USA).\u003C/p>\n\u003Ca id=\"h4\" name=\"h4\">\u003C/a>\u003Ch2>Results\u003C/h2>\n\u003Ch3 class=\"pt0\">Demographic and Clinicopathological Characteristics of Ovarian Cancer Patients\u003C/h3>\n\u003Cp class=\"mb0\">The demographic and clinicopathological characteristics of the patients are listed in \u003Ca href=\"#T1\">Table 1\u003C/a>. In total, 172 patients were recruited and had final genetic testing outcomes. The median age at diagnosis in the cohort was 52.5 years (range 18&#x02013;81). Most cases were ovarian carcinomas (168 cases, 97.7%), stage III-IV (140 cases, 81.4%), and HGSC (138 cases, 80.2%). Based on personal and family cancer history, 31 patients met the HBOC criteria. No patients had ever received PARPi treatment. Progression and mortality occurred in 106 (61.6%) and 50 (29.1%) patients, and the median PFS and OS were 23 months (range 0&#x02013;68) and 39 (12&#x02013;93) months, respectively.\u003C/p>\n\u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cdiv class=\"Imageheaders\">TABLE 1\u003C/div>\n\u003Cdiv class=\"FigureDesc\">\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-t001.jpg\" name=\"Table1\" target=\"_blank\">\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-t001.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-t001.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-t001.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-t001.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-t001.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-t001.jpg\" alt=\"www.frontiersin.org\" id=\"T1\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cstrong>Table 1\u003C/strong>. The clinicopathological characteristics and survival outcomes of the patients.\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"clear\">\u003C/div>\n\u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Ch3>Mutation Analysis\u003C/h3>\n\u003Cp class=\"mb0\">In 58 (33.7%) patients, 63 variants were identified, including variants of unknown significance (VUS) in 18 patients (10.5%) and pathogenic or likely pathogenic variants in a partially overlapping set of 41 patients (23.8%) (\u003Ca href=\"#F1\">Figure 1\u003C/a>). Germline \u003Ci>BRCA\u003C/i> mutations, somatic \u003Ci>BRCA\u003C/i> mutations, BRCA1 mutations in general, and \u003Ci>BRCA2\u003C/i> mutations in general were found in 35 (20.3%), 7 (4.1%), 28 (16.3%), and 13 (7.6%) patients, respectively. The mutation details are listed in \u003Ca href=\"#SM1\">Supplement Table 1\u003C/a>. Likely pathogenic or pathogenic mutations consisted of 19 (46.3%) frameshift deletions, 4 (9.8%) frameshift insertions, 12 (29.3%) non-sense mutations, 4 (9.8%) splice-site mutations, and 2 (4.9%) missense mutations.\u003C/p>\n\u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cdiv class=\"Imageheaders\">FIGURE 1\u003C/div>\n\u003Cdiv class=\"FigureDesc\">\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g001.jpg\" name=\"figure1\" target=\"_blank\">\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g001.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g001.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g001.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g001.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g001.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g001.jpg\" alt=\"www.frontiersin.org\" id=\"F1\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cstrong>Figure 1\u003C/strong>. \u003Ci>BRCA1\u003C/i> \u003Cstrong>(A)\u003C/strong> and \u003Ci>BRCA2\u003C/i> \u003Cstrong>(B)\u003C/strong> pathogenic mutation loci.\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"clear\">\u003C/div>\n\u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cp class=\"mt15 w100pc float_left\">As shown in \u003Ca href=\"#T2\">Table 2\u003C/a> and \u003Ca href=\"#SM1\">Supplement Table 1\u003C/a>, 35 (19.7%) and seven (4.1%) patients had at least one germline and somatic deleterious mutation, respectively; 28 (16.3%) and 13 (7.6%) patients harbored at least one deleterious mutation of \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i>, respectively. Two (1.2%), 5 (2.9%), and 2 (1.2%) patients carried dual germline/somatic mutations; dual germline and dual somatic mutations classified as VUS; and dual likely pathogenic and pathogenic mutations, respectively. In cases No. 063 and No. 068, the distance between the co-occurring mutations exceeded the amplicon length; therefore, we were unable to determine whether these mutations were in cis or in trans. The criteria for reclassification were unmet for these mutations. In case No. 032, the patient harbored one likely pathogenic germline variant and one somatic pathogenic variant (\u003Ca href=\"#SM1\">Supplement Table 1\u003C/a>).\u003C/p>\n\u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cdiv class=\"Imageheaders\">TABLE 2\u003C/div>\n\u003Cdiv class=\"FigureDesc\">\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-t002.jpg\" name=\"Table2\" target=\"_blank\">\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-t002.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-t002.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-t002.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-t002.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-t002.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-t002.jpg\" alt=\"www.frontiersin.org\" id=\"T2\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cstrong>Table 2\u003C/strong>. Distributions of pathogenic or likely pathogenic mutations in the overall and subgroup populations.\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"clear\">\u003C/div>\n\u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cp class=\"mb0 w100pc float_left mt15\">Five recurrent mutations were identified in the cohort. Three pathogenic mutations occurred in two patients (\u003Ci>BRCA1\u003C/i> c.5470_5477delATTGGGCA, \u003Ci>BRCA1\u003C/i> c.66dup, and \u003Ci>BRCA2\u003C/i> c.1963delC). Two VUS missense mutations (\u003Ci>BRCA2\u003C/i> c.1568A&#x0003E;G and \u003Ci>BRCA2\u003C/i> c.6325G&#x0003E;A) appeared in three and four patients, respectively. All recurrent mutations were in the germline except for \u003Ci>BRCA2\u003C/i> c.1964delC.\u003C/p>\n\u003Ch3>Deleterious \u003Ci>BRCA\u003C/i> Mutations and Clinicopathological Characteristics\u003C/h3>\n\u003Cp class=\"mb0\">As shown in \u003Ca href=\"#T2\">Table 2\u003C/a>, FIGO stages had no significant association with deleterious mutations of \u003Ci>BRCA\u003C/i> genes in general or of \u003Ci>BRCA1\u003C/i> or \u003Ci>BRCA2\u003C/i> in particular. Personal and family cancer history and HBOC criteria were associated with overall and germline \u003Ci>BRCA\u003C/i> mutations. HBOC criteria were also associated with overall \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> mutations. For somatic \u003Ci>BRCA\u003C/i> mutations, only age at diagnosis had a significant impact, while for germline \u003Ci>BRCA\u003C/i> mutations, histological subtype also had a significant impact. However, only overall deleterious \u003Ci>BRCA\u003C/i> mutations had a significant impact on sensitivity to platinum-based chemotherapy (\u003Ca href=\"#T2\">Table 2\u003C/a>).\u003C/p>\n\u003Ch3>Survival Analyses\u003C/h3>\n\u003Cp class=\"mb0\">The survival outcomes associated with various deleterious \u003Ci>BRCA\u003C/i> mutations are shown in \u003Ca href=\"#F2\">Figures 2\u003C/a>, \u003Ca href=\"#F3\">3\u003C/a> and \u003Ca href=\"#SM1\">Supplement Table 2\u003C/a>. In univariate and Cox regression analyses, patients with overall \u003Ci>BRCA1/2\u003C/i> mutations had significant improvements in PFS and OS (\u003Ca href=\"#F2\">Figure 2\u003C/a>, \u003Ca href=\"#SM1\">Supplement Table 2\u003C/a>). Overall, germline \u003Ci>BRCA1/2\u003C/i> mutations were associated with significant improvement in OS but not PFS. Overall, \u003Ci>BRCA2\u003C/i> mutations were associated with significantly improved OS in the Cox regression model. Somatic \u003Ci>BRCA1/2\u003C/i> and overall \u003Ci>BRCA1\u003C/i> had no significant impact on survival outcomes. However, in the subgroup analysis of HGSC patients (\u003Ci>n\u003C/i> = 138), various mutation statuses had no significant impact on survival outcomes, except that overall \u003Ci>BRCA\u003C/i> mutations affected PFS (\u003Ca href=\"#SM1\">Supplement Table 2\u003C/a>).\u003C/p>\n\u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cdiv class=\"Imageheaders\">FIGURE 2\u003C/div>\n\u003Cdiv class=\"FigureDesc\">\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g002.jpg\" name=\"figure2\" target=\"_blank\">\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g002.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g002.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g002.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g002.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g002.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g002.jpg\" alt=\"www.frontiersin.org\" id=\"F2\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cstrong>Figure 2\u003C/strong>. Survival outcomes of various \u003Ci>BRCA\u003C/i> aberrations according to Kaplan&#x02013;Meier analysis. \u003Cstrong>(A)\u003C/strong> Progression-free survival (PFS) with and without deleterious \u003Ci>BRCA1/2\u003C/i> mutations. \u003Cstrong>(B)\u003C/strong> PFS with and without deleterious \u003Ci>BRCA1\u003C/i> mutations. \u003Cstrong>(C)\u003C/strong> PFS with and without deleterious \u003Ci>BRCA2\u003C/i> mutations. \u003Cstrong>(D)\u003C/strong> Overall survival (OS) with and without deleterious \u003Ci>BRCA1/2\u003C/i> mutations. \u003Cstrong>(E)\u003C/strong> OS with and without deleterious \u003Ci>BRCA1\u003C/i> mutations. \u003Cstrong>(F)\u003C/strong> OS with and without deleterious \u003Ci>BRCA2\u003C/i> mutations.\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"clear\">\u003C/div>\n\u003Cdiv class=\"DottedLine mb15\">\u003C/div>\n\u003Cdiv class=\"Imageheaders\">FIGURE 3\u003C/div>\n\u003Cdiv class=\"FigureDesc\">\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g003.jpg\" name=\"figure3\" target=\"_blank\">\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g003.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g003.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g003.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g003.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g003.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g003.jpg\" alt=\"www.frontiersin.org\" id=\"F3\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cstrong>Figure 3\u003C/strong>. Survival outcomes of germline and somatic \u003Ci>BRCA\u003C/i> aberrations according to Kaplan&#x02013;Meier analysis. \u003Cstrong>(A)\u003C/strong> Progression-free survival (PFS) with and without deleterious germline \u003Ci>BRCA1/2\u003C/i> mutations. \u003Cstrong>(B)\u003C/strong> Overall survival (OS) with and without deleterious germline \u003Ci>BRCA1/2\u003C/i> mutations. \u003Cstrong>(C)\u003C/strong> PFS with and without deleterious somatic \u003Ci>BRCA1/2\u003C/i> mutations. \u003Cstrong>(D)\u003C/strong> OS with and without deleterious somatic \u003Ci>BRCA1/2\u003C/i> mutations.\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"clear\">\u003C/div>\n\u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Ca id=\"h5\" name=\"h5\">\u003C/a>\u003Ch2>Discussion\u003C/h2>\n\u003Cp class=\"mb15\">To our knowledge, this study is the first to describe the positive impact of \u003Ci>BRCA\u003C/i> mutation status on survival outcomes in a Chinese EOC cohort. In our study, overall \u003Ci>BRCA\u003C/i> mutations, germline \u003Ci>BRCA\u003C/i> mutations, and overall \u003Ci>BRCA2\u003C/i> mutations were all associated with improved survival outcomes, as in previous reports (\u003Ca href=\"#B27\">27\u003C/a>, \u003Ca href=\"#B28\">28\u003C/a>, \u003Ca href=\"#B40\">40\u003C/a>&#x02013;\u003Ca href=\"#B42\">42\u003C/a>). We did not find a significant impact of germline mutations on PFS or a significant impact of somatic mutations on PFS or OS. The limited sample size was probably the main reason. As shown in \u003Ca href=\"#T2\">Table 2\u003C/a>, HGSC patients harbored more deleterious \u003Ci>BRCA1/2\u003C/i> and \u003Ci>BRCA1\u003C/i> mutations than patients with other subtypes, and the BRCAness phenotype was independently associated with improved OS in HGSC patients (\u003Ca href=\"#B43\">43\u003C/a>). However, in our study, the effects of sample size were so obvious that HGSC patients, the majority of the cohort, had no significant associations between mutation status and survival outcome (\u003Ca href=\"#SM1\">Supplement Table 2\u003C/a>). A larger cohort of Chinese EOC patients (NCT03015376) would provide more details and profound perspectives on such issues. The improved survival outcomes were likely caused by a higher sensitivity to platinum in patients with deleterious mutations than in those without such mutations, as revealed in the Pennington et al. (\u003Ca href=\"#B28\">28\u003C/a>) study.\u003C/p>\n\u003Cp class=\"mb15\">Overall, we found that germline and somatic \u003Ci>BRCA1/2\u003C/i> mutations had prevalence rates of 20.3 and 4.1%, respectively. Disparities in both germline and somatic testing exist (\u003Ca href=\"#B44\">44\u003C/a>, \u003Ca href=\"#B45\">45\u003C/a>). Regarding other Chinese studies, our germline mutation prevalence approximated the values reported by Li et al. (1331 cases, 22.4%) (\u003Ca href=\"#B16\">16\u003C/a>). Wang et al. (481 cases, 19.6%) (\u003Ca href=\"#B46\">46\u003C/a>), Shi et al. (916 cases, 17.0%), and a meta-analysis (21.8%) (\u003Ca href=\"#B47\">47\u003C/a>), but it was significantly lower than the value reported by Wu et al. (826 cases, 28.4%) (\u003Ca href=\"#B35\">35\u003C/a>). Our somatic \u003Ci>BRCA1/2\u003C/i> mutation prevalence was similar to those in two small cohort studies, which reported prevalence values of 4.0% (2/50) (\u003Ca href=\"#B48\">48\u003C/a>) and 6.4% (4/62) (\u003Ca href=\"#B36\">36\u003C/a>). These differences may originate from the selection of subjects and the database used for analysis. As addressed in a recently published meta-analysis (\u003Ca href=\"#B47\">47\u003C/a>), the variant profile in ethnically Chinese people was distinctive from those in other ethnic groups with no distinct founder pathogenic variants. However, this conclusion should be treated cautiously. China needs a uniform platform such as TCGA to further promote genomic testing. Chinese healthcare providers, including gynecologists, still have greatly divergent opinions and suggestions about genetic testing for gynecologic oncology, and these positions are also significantly different from the requirements and recommendations in the guidelines and consensus statements (\u003Ca href=\"#B49\">49\u003C/a>&#x02013;\u003Ca href=\"#B51\">51\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">There are several issues worth considering in relation to the selection bias in this report. In our study, HGSC had a significantly higher frequency of overall \u003Ci>BRCA1/2\u003C/i> and \u003Ci>BRCA1\u003C/i> mutations than other subtypes. These tumors displayed defective homologous recombination due to germline and somatic \u003Ci>BRCA\u003C/i> mutations, epigenetic inactivation of \u003Ci>BRCA\u003C/i> and abnormalities in DNA repair genes (\u003Ca href=\"#B9\">9\u003C/a>, \u003Ca href=\"#B13\">13\u003C/a>, \u003Ca href=\"#B14\">14\u003C/a>). The quality of the data that can be obtained from FFPE tissues as opposed to fresh tissues needs clarification. The fact that the distribution of somatic mutations was consistent with other Chinese studies (\u003Ca href=\"#B36\">36\u003C/a>, \u003Ca href=\"#B48\">48\u003C/a>) and with a Polish study using FFPE tissues from HGSC patients (\u003Ca href=\"#B52\">52\u003C/a>) could guarantee the quality of our sample preparation. It was suggested that an adjusted targeted capture-based enrichment protocol was superior to commonly applied multiplex PCR-based protocols for reliable \u003Ci>BRCA1/2\u003C/i> variant detection, including CNV detection, using FFPE tumor samples (\u003Ca href=\"#B53\">53\u003C/a>). As previously reported, the prevalence of \u003Ci>BRCA1/2\u003C/i> mutations in patients with peritoneal carcinoma or fallopian tube carcinoma is comparable to that in EOC patients (\u003Ca href=\"#B54\">54\u003C/a>). Therefore, we did not perform a subgroup analysis of these three site-specific cancers. We also did not evaluate the impact of neoadjuvant therapy on prognosis by \u003Ci>BRCA\u003C/i> status since primary debulking surgery seems to ensure a longer PFS than neoadjuvant chemotherapy alone in women with the \u003Ci>BRCA\u003C/i> wild-type genotype (\u003Ca href=\"#B55\">55\u003C/a>). However, patients with pathogenic mutations in \u003Ci>BRCA\u003C/i> may benefit from intraperitoneal therapy (\u003Ca href=\"#B56\">56\u003C/a>). Finally, no patients in our study had ever utilized PARPis. The high cost of genetic testing is an important barrier to universal performance. However, somatic and germline mutations and expression loss of \u003Ci>BRCA1/2\u003C/i> are sufficiently common in ovarian cancer to warrant assessment for the prediction of treatment benefit in clinical trials of PARPis (\u003Ca href=\"#B57\">57\u003C/a>).\u003C/p>\n\u003Cp class=\"mb0\">We reported the previously unknown association between \u003Ci>BRCA\u003C/i> mutation and survival outcomes in Chinese EOC patients, which was the most important strength of our study. However, the present study has several limitations. We did not exploit all mechanisms of \u003Ci>BRCA1/2\u003C/i> regulation, such as large gene rearrangements and epigenetic modifications. Second, the present study population did not include a sufficient sample of histological subtypes other than HGSC; this limitation impairs the ability to capture the mutational landscape of these tumors. Third, as reported previously (\u003Ca href=\"#B58\">58\u003C/a>&#x02013;\u003Ca href=\"#B61\">61\u003C/a>). a multigene panel for germline and/or somatic testing would probably be cost effective, providing a substantial rate of clinically actionable pathogenic variants (\u003Ca href=\"#B62\">62\u003C/a>). There is a potential benefit to be gained from rescreening with a multigene panel in patients who previously underwent non-informative genetic screening (\u003Ca href=\"#B63\">63\u003C/a>). On the other hand, up to 50% of ovarian HGSC patients may exhibit homologous recombination defects (\u003Ca href=\"#B64\">64\u003C/a>), which are associated with the indication of PARPis as maintenance therapy, even in newly diagnosed EOC patients (\u003Ca href=\"#B23\">23\u003C/a>, \u003Ca href=\"#B25\">25\u003C/a>, \u003Ca href=\"#B29\">29\u003C/a>). These advancements in genetic and genomic testing in EOC will promote further exploration in the future. Importantly, we did not include the MLPA analysis in our study, which is also very important for the evaluation of BRCAness (\u003Ca href=\"#B43\">43\u003C/a>, \u003Ca href=\"#B65\">65\u003C/a>). The lack of MLPA obviously decreases the deleterious mutation frequency in patients with EOC or breast cancer and causes bias regarding the association between BRCAness and survival prognosis (\u003Ca href=\"#B66\">66\u003C/a>). We did not include \u003Ci>BRCA\u003C/i> methylation in the study. However, unlike \u003Ci>BRCA\u003C/i> mutation, \u003Ci>BRCA1\u003C/i> methylation was not associated with improved survival or greater sensitivity to platinum chemotherapy (\u003Ca href=\"#B67\">67\u003C/a>). Last but not least, a discussion of cosegregation analysis and potential interventions (such as NCT03294343 and NCT04190667) should be provided to all patients with deleterious mutations.\u003C/p>\n\u003Ca id=\"h6\" name=\"h6\">\u003C/a>\u003Ch2>Conclusions\u003C/h2>\n\u003Cp class=\"mb0\">In conclusion, we reported the prevalence of germline and somatic \u003Ci>BRCA1/2\u003C/i> mutations in an unselected Chinese EOC cohort comprising 172 patients. Germline mutations were associated with cancer history, especially the aspects relevant to the HBOC criteria. Somatic mutations were associated only with age at diagnosis of EOC. In our study, overall deleterious \u003Ci>BRCA\u003C/i> mutations predicted increased sensitivity to platinum-based chemotherapy and significantly improved survival outcomes. A larger cohort must be examined with multigene panel testing and even the homologous recombination deficiency model to clarify the indications for PARPis.\u003C/p>\n\u003Ca id=\"h7\" name=\"h7\">\u003C/a>\u003Ch2>Data Availability Statement\u003C/h2>\n\u003Cp class=\"mb0\">All datasets generated for this study are included in the article/\u003Ca href=\"#h12\">Supplementary Material\u003C/a>.\u003C/p>\n\u003Ca id=\"h8\" name=\"h8\">\u003C/a>\u003Ch2>Ethics Statement\u003C/h2>\n\u003Cp class=\"mb0\">The Institutional Review Board of Peking Union Medical College Hospital approved this study (No. HS-1245). In addition, the Chinese Human Genetic Resources Management Office of the National Ministry of Science and Technology approved this study (registration no. [2017]1901, \u003Ca href=\"http://www.most.gov.cn/bszn/new/rlyc/jgcx/index.htm\">http://www.most.gov.cn/bszn/new/rlyc/jgcx/index.htm\u003C/a>).\u003C/p>\n\u003Ca id=\"h9\" name=\"h9\">\u003C/a>\u003Ch2>Author Contributions\u003C/h2>\n\u003Cp class=\"mb0\">MW and ZL conceived of the original idea for the study, interpreted the results, carried out the statistical analysis, edited the paper, and acted as overall guarantors. YY, LL, and JL obtained ethical approval, contributed to the preparation of the data set, interpreted the results, and contributed to drafts of the paper. HW, JW, and JG contributed to the study design and interpretation of the results and commented on drafts of the paper. Specifically, colleagues from the Department of Obstetrics and Gynecology were in charge of the diagnosis, treatment, and follow-up of the patients, while colleagues from the Department of Pathology were in charge of the pathological evaluation and molecular diagnosis.\u003C/p>\n\u003Ca id=\"h10\" name=\"h10\">\u003C/a>\u003Ch2>Funding\u003C/h2>\n\u003Cp class=\"mb0\">This study was supported by the Chinese Academy of Medical Sciences Initiative for Innovative Medicine (CAMS-2017-I2M-1-002 and CAMS-2016-I2M-1-002), by the National Science-Technology Support Plan Projects (2015BAI13B04), and by the National Natural Science Foundation of China (81602162). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.\u003C/p>\n\u003Ca id=\"h11\" name=\"h11\">\u003C/a>\u003Ch2>Conflict of Interest\u003C/h2>\n\u003Cp class=\"mb0\">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\u003C/p>\n\u003Ca id=\"h12\" name=\"h12\">\u003C/a>\u003Ch2>Supplementary Material\u003C/h2>\n\u003Cp class=\"mb0\" id=\"SM1\">The Supplementary Material for this article can be found online at: \u003Ca href=\"https://www.frontiersin.org/articles/10.3389/fonc.2020.00295/full#supplementary-material\">https://www.frontiersin.org/articles/10.3389/fonc.2020.00295/full#supplementary-material\u003C/a>\u003C/p>\n\u003Ca id=\"h13\" name=\"h13\">\u003C/a>\u003Ch2>References\u003C/h2>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B1\" id=\"B1\">\u003C/a> 1. Tangjitgamol S, Manusirivithaya S, Laopaiboon M, Lumbiganon P. Interval debulking surgery for advanced epithelial ovarian cancer: a Cochrane systematic review. \u003Ci>Gynecol Oncol.\u003C/i> (2009) 112:257&#x02013;64. doi: 10.1016/j.ygyno.2008.09.041\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=19017548\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.ygyno.2008.09.041\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S.+Tangjitgamol&#x00026;author=S.+Manusirivithaya&#x00026;author=M.+Laopaiboon&#x00026;author=P.+Lumbiganon+&#x00026;publication_year=2009&#x00026;title=Interval+debulking+surgery+for+advanced+epithelial+ovarian+cancer%3A+a+Cochrane+systematic+review&#x00026;journal=Gynecol+Oncol.&#x00026;volume=112&#x00026;pages=257-64\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B2\" id=\"B2\">\u003C/a> 2. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. \u003Ci>CA Cancer J Clin.\u003C/i> (2017) 67:7&#x02013;30. doi: 10.3322/caac.21387\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=28055103\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3322/caac.21387\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=RL.+Siegel&#x00026;author=KD.+Miller&#x00026;author=A.+Jemal+&#x00026;publication_year=2017&#x00026;title=Cancer+Statistics,+2017&#x00026;journal=CA+Cancer+J+Clin.&#x00026;volume=67&#x00026;pages=7-30\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B3\" id=\"B3\">\u003C/a> 3. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. \u003Ci>CA Cancer J Clin.\u003C/i> (2016) 66:115&#x02013;32. doi: 10.3322/caac.21338\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=26808342\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3322/caac.21338\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=W.+Chen&#x00026;author=R.+Zheng&#x00026;author=PD.+Baade&#x00026;author=S.+Zhang&#x00026;author=H.+Zeng&#x00026;author=F.+Bray+&#x00026;publication_year=2016&#x00026;title=Cancer+statistics+in+China,+2015&#x00026;journal=CA+Cancer+J+Clin.&#x00026;volume=66&#x00026;pages=115-32\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B4\" id=\"B4\">\u003C/a> 4. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. \u003Ci>Nature.\u003C/i> (2009) 458:719&#x02013;24. doi: 10.1038/nature07943\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=19360079\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/nature07943\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=MR.+Stratton&#x00026;author=PJ.+Campbell&#x00026;author=PA.+Futreal+&#x00026;publication_year=2009&#x00026;title=The+cancer+genome&#x00026;journal=Nature.&#x00026;volume=458&#x00026;pages=719-24\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B5\" id=\"B5\">\u003C/a> 5. Stratton MR. Exploring the genomes of cancer cells: progress and promise. \u003Ci>Science.\u003C/i> (2011) 331:1553&#x02013;8. doi: 10.1126/science.1204040\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=21436442\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1126/science.1204040\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=MR.+Stratton+&#x00026;publication_year=2011&#x00026;title=Exploring+the+genomes+of+cancer+cells%3A+progress+and+promise&#x00026;journal=Science.&#x00026;volume=331&#x00026;pages=1553-8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B6\" id=\"B6\">\u003C/a> 6. Lu C, Xie M, Wendl MC, Wang J, McLellan MD, Leiserson MD, et al. Patterns and functional implications of rare germline variants across 12 cancer types. \u003Ci>Nat Commun.\u003C/i> (2015) 6:10086. doi: 10.1038/ncomms10086\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=26689913\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/ncomms10086\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=C.+Lu&#x00026;author=M.+Xie&#x00026;author=MC.+Wendl&#x00026;author=J.+Wang&#x00026;author=MD.+McLellan&#x00026;author=MD.+Leiserson+&#x00026;publication_year=2015&#x00026;title=Patterns+and+functional+implications+of+rare+germline+variants+across+12+cancer+types&#x00026;journal=Nat+Commun.&#x00026;volume=6&#x00026;pages=10086\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B7\" id=\"B7\">\u003C/a> 7. Russo A, Calo V, Bruno L, Rizzo S, Bazan V, Di Fede G. Hereditary ovarian cancer. \u003Ci>Crit Rev Oncol Hematol.\u003C/i> (2009) 69:28&#x02013;44. doi: 10.1016/j.critrevonc.2008.06.003\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=18656380\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.critrevonc.2008.06.003\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A.+Russo&#x00026;author=V.+Calo&#x00026;author=L.+Bruno&#x00026;author=S.+Rizzo&#x00026;author=V.+Bazan&#x00026;author=FedeG.+Di+&#x00026;publication_year=2009&#x00026;title=Hereditary+ovarian+cancer&#x00026;journal=Crit+Rev+Oncol+Hematol.&#x00026;volume=69&#x00026;pages=28-44\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B8\" id=\"B8\">\u003C/a> 8. Narod SA, Madlensky L, Bradley L, Cole D, Tonin P, Rosen B, et al. Hereditary and familial ovarian cancer in southern Ontario. \u003Ci>Cancer.\u003C/i> (1994) 74:2341&#x02013;6. \u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=7922985\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=SA.+Narod&#x00026;author=L.+Madlensky&#x00026;author=L.+Bradley&#x00026;author=D.+Cole&#x00026;author=P.+Tonin&#x00026;author=B.+Rosen+&#x00026;publication_year=1994&#x00026;title=Hereditary+and+familial+ovarian+cancer+in+southern+Ontario&#x00026;journal=Cancer.&#x00026;volume=74&#x00026;pages=2341-6\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B9\" id=\"B9\">\u003C/a> 9. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. \u003Ci>Nature.\u003C/i> (2011) 474:609&#x02013;15. doi: 10.1038/nature10166\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=21720365\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/nature10166\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?publication_year=2011&#x00026;title=Integrated+genomic+analyses+of+ovarian+carcinoma&#x00026;journal=Nature.&#x00026;volume=474&#x00026;pages=609-15\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B10\" id=\"B10\">\u003C/a> 10. Kanchi KL, Johnson KJ, Lu C, McLellan MD, Leiserson MD, Wendl MC, et al. Integrated analysis of germline and somatic variants in ovarian cancer. \u003Ci>Nat Commun.\u003C/i> (2014) 5:3156. doi: 10.1038/ncomms4156\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=24448499\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/ncomms4156\" target=\"_blank\">CrossRef Full Text\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B11\" id=\"B11\">\u003C/a> 11. Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. \u003Ci>Am J Hum Genet.\u003C/i> (1993) 52:678&#x02013;701. \u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=8460634\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=DF.+Easton&#x00026;author=DT.+Bishop&#x00026;author=D.+Ford&#x00026;author=GP.+Crockford+&#x00026;publication_year=1993&#x00026;title=Genetic+linkage+analysis+in+familial+breast+and+ovarian+cancer%3A+results+from+214+families.+The+Breast+Cancer+Linkage+Consortium&#x00026;journal=Am+J+Hum+Genet.&#x00026;volume=52&#x00026;pages=678-701\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B12\" id=\"B12\">\u003C/a> 12. Lynch HT, Albano WA, Lynch JF, Lynch PM, Campbell A. Surveillance and management of patients at high genetic risk for ovarian carcinoma. \u003Ci>Obstet Gynecol.\u003C/i> (1982) 59:589&#x02013;96. \u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=7070730\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=HT.+Lynch&#x00026;author=WA.+Albano&#x00026;author=JF.+Lynch&#x00026;author=PM.+Lynch&#x00026;author=A.+Campbell+&#x00026;publication_year=1982&#x00026;title=Surveillance+and+management+of+patients+at+high+genetic+risk+for+ovarian+carcinoma&#x00026;journal=Obstet+Gynecol.&#x00026;volume=59&#x00026;pages=589-96\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B13\" id=\"B13\">\u003C/a> 13. Ding L, Bailey MH, Porta-Pardo E, Thorsson V, Colaprico A, Bertrand D, et al. Perspective on oncogenic processes at the end of the beginning of cancer genomics. \u003Ci>Cell.\u003C/i> (2018) 173:305&#x02013;20 e10. doi: 10.1016/j.cell.2018.03.033\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=29625049\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.cell.2018.03.033\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=L.+Ding&#x00026;author=MH.+Bailey&#x00026;author=E.+Porta-Pardo&#x00026;author=V.+Thorsson&#x00026;author=A.+Colaprico&#x00026;author=D.+Bertrand+&#x00026;publication_year=2018&#x00026;title=Perspective+on+oncogenic+processes+at+the+end+of+the+beginning+of+cancer+genomics&#x00026;journal=Cell.&#x00026;volume=173&#x00026;pages=305-20\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B14\" id=\"B14\">\u003C/a> 14. Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, et al. A comprehensive pan-cancer molecular study of gynecologic and breast cancers. \u003Ci>Cancer Cell.\u003C/i> (2018) 33:690&#x02013;705 e9. doi: 10.1016/j.ccell.2018.03.014\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=29622464\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.ccell.2018.03.014\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=AC.+Berger&#x00026;author=A.+Korkut&#x00026;author=RS.+Kanchi&#x00026;author=AM.+Hegde&#x00026;author=W.+Lenoir&#x00026;author=W.+Liu+&#x00026;publication_year=2018&#x00026;title=A+comprehensive+pan-cancer+molecular+study+of+gynecologic+and+breast+cancers&#x00026;journal=Cancer+Cell.&#x00026;volume=33&#x00026;pages=690-705\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B15\" id=\"B15\">\u003C/a> 15. Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, et al. Inherited mutations in women with ovarian carcinoma. \u003Ci>JAMA Oncol.\u003C/i> (2016) 2:482&#x02013;90. doi: 10.1001/jamaoncol.2015.5495\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=26720728\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1001/jamaoncol.2015.5495\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=BM.+Norquist&#x00026;author=MI.+Harrell&#x00026;author=MF.+Brady&#x00026;author=T.+Walsh&#x00026;author=MK.+Lee&#x00026;author=S.+Gulsuner+&#x00026;publication_year=2016&#x00026;title=Inherited+mutations+in+women+with+ovarian+carcinoma&#x00026;journal=JAMA+Oncol.&#x00026;volume=2&#x00026;pages=482-90\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B16\" id=\"B16\">\u003C/a> 16. Li A, Xie R, Zhi Q, Deng Y, Wu Y, Li W, et al. BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls. \u003Ci>Gynecol Oncol.\u003C/i> (2018) 151:145&#x02013;52. doi: 10.1016/j.ygyno.2018.07.024\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=30078507\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.ygyno.2018.07.024\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A.+Li&#x00026;author=R.+Xie&#x00026;author=Q.+Zhi&#x00026;author=Y.+Deng&#x00026;author=Y.+Wu&#x00026;author=W.+Li+&#x00026;publication_year=2018&#x00026;title=BRCA+germline+mutations+in+an+unselected+nationwide+cohort+of+Chinese+patients+with+ovarian+cancer+and+healthy+controls&#x00026;journal=Gynecol+Oncol.&#x00026;volume=151&#x00026;pages=145-52\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B17\" id=\"B17\">\u003C/a> 17. Boyd J. Molecular genetics of hereditary ovarian cancer. \u003Ci>Oncology.\u003C/i> (1998) 12:399&#x02013;406; discussion 9&#x02013;10, 13. \u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=9534190\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J.+Boyd+&#x00026;publication_year=1998&#x00026;title=Molecular+genetics+of+hereditary+ovarian+cancer&#x00026;journal=Oncology.&#x00026;volume=12&#x00026;pages=399-406\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B18\" id=\"B18\">\u003C/a> 18. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. \u003Ci>Am J Hum Genet.\u003C/i> (2001) 68:700&#x02013;10. doi: 10.1086/318787\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=11179017\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1086/318787\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=HA.+Risch&#x00026;author=JR.+McLaughlin&#x00026;author=DE.+Cole&#x00026;author=B.+Rosen&#x00026;author=L.+Bradley&#x00026;author=E.+Kwan+&#x00026;publication_year=2001&#x00026;title=Prevalence+and+penetrance+of+germline+BRCA1+and+BRCA2+mutations+in+a+population+series+of+649+women+with+ovarian+cancer&#x00026;journal=Am+J+Hum+Genet.&#x00026;volume=68&#x00026;pages=700-10\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B19\" id=\"B19\">\u003C/a> 19. Matloff ET. The breast surgeon&#x00027;s role in BRCA1 and BRCA2 testing. \u003Ci>Am J Surg.\u003C/i> (2000) 180:294&#x02013;8. doi: 10.1016/s0002-9610(00)00460-8\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=11113439\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/s0002-9610(00)00460-8\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=ET.+Matloff+&#x00026;publication_year=2000&#x00026;title=The+breast+surgeon&#x00027;s+role+in+BRCA1+and+BRCA2+testing&#x00026;journal=Am+J+Surg.&#x00026;volume=180&#x00026;pages=294-8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B20\" id=\"B20\">\u003C/a> 20. Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, et al. Tumour lineage shapes BRCA-mediated phenotypes. \u003Ci>Nature.\u003C/i> (2019) 571:576&#x02013;9. doi: 10.1038/s41586-019-1382-1\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=31292550\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/s41586-019-1382-1\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=P.+Jonsson&#x00026;author=C.+Bandlamudi&#x00026;author=ML.+Cheng&#x00026;author=P.+Srinivasan&#x00026;author=SS.+Chavan&#x00026;author=ND.+Friedman+&#x00026;publication_year=2019&#x00026;title=Tumour+lineage+shapes+BRCA-mediated+phenotypes&#x00026;journal=Nature.&#x00026;volume=571&#x00026;pages=576-9\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B21\" id=\"B21\">\u003C/a> 21. Hartmann LC, Lindor NM. The role of risk-reducing surgery in hereditary breast and ovarian cancer. \u003Ci>N Engl J Med.\u003C/i> (2016) 374:454&#x02013;68. doi: 10.1056/NEJMra1503523\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=26840135\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1056/NEJMra1503523\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=LC.+Hartmann&#x00026;author=NM.+Lindor+&#x00026;publication_year=2016&#x00026;title=The+role+of+risk-reducing+surgery+in+hereditary+breast+and+ovarian+cancer&#x00026;journal=N+Engl+J+Med.&#x00026;volume=374&#x00026;pages=454-68\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B22\" id=\"B22\">\u003C/a> 22. Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. \u003Ci>N Engl J Med.\u003C/i> (2018) 379:2495&#x02013;505. doi: 10.1056/NEJMoa1810858\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=30345884\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1056/NEJMoa1810858\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=K.+Moore&#x00026;author=N.+Colombo&#x00026;author=G.+Scambia&#x00026;author=BG.+Kim&#x00026;author=A.+Oaknin&#x00026;author=M.+Friedlander+&#x00026;publication_year=2018&#x00026;title=Maintenance+olaparib+in+patients+with+newly+diagnosed+advanced+ovarian+cancer&#x00026;journal=N+Engl+J+Med.&#x00026;volume=379&#x00026;pages=2495-505\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B23\" id=\"B23\">\u003C/a> 23. Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. \u003Ci>N Engl J Med.\u003C/i> (2019) 381:2403&#x02013;15. doi: 10.1056/NEJMoa1909707\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=31562800\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1056/NEJMoa1909707\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=RL.+Coleman&#x00026;author=GF.+Fleming&#x00026;author=MF.+Brady&#x00026;author=EM.+Swisher&#x00026;author=KD.+Steffensen&#x00026;author=M.+Friedlander+&#x00026;publication_year=2019&#x00026;title=Veliparib+with+first-line+chemotherapy+and+as+maintenance+therapy+in+ovarian+cancer&#x00026;journal=N+Engl+J+Med.&#x00026;volume=381&#x00026;pages=2403-15\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B24\" id=\"B24\">\u003C/a> 24. Enomoto T, Aoki D, Hattori K, Jinushi M, Kigawa J, Takeshima N, et al. The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE). \u003Ci>Int J Gynecol Cancer.\u003C/i> (2019) 29:1043&#x02013;9. doi: 10.1136/ijgc-2019-000384\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=31263023\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1136/ijgc-2019-000384\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=T.+Enomoto&#x00026;author=D.+Aoki&#x00026;author=K.+Hattori&#x00026;author=M.+Jinushi&#x00026;author=J.+Kigawa&#x00026;author=N.+Takeshima+&#x00026;publication_year=2019&#x00026;title=The+first+Japanese+nationwide+multicenter+study+of+BRCA+mutation+testing+in+ovarian+cancer%3A+CHARacterizing+the+cross-sectionaL+approach+to+Ovarian+cancer+geneTic+TEsting+of+BRCA+(CHARLOTTE)&#x00026;journal=Int+J+Gynecol+Cancer.&#x00026;volume=29&#x00026;pages=1043-9\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B25\" id=\"B25\">\u003C/a> 25. Gonzalez-Martin A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. \u003Ci>N Engl J Med.\u003C/i> (2019) 381:2391&#x02013;402. doi: 10.1056/NEJMoa1910962\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=31562799\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1056/NEJMoa1910962\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A.+Gonzalez-Martin&#x00026;author=B.+Pothuri&#x00026;author=I.+Vergote&#x00026;author=ChristensenR.+DePont&#x00026;author=W.+Graybill&#x00026;author=MR.+Mirza+&#x00026;publication_year=2019&#x00026;title=Niraparib+in+patients+with+newly+diagnosed+advanced+ovarian+cancer&#x00026;journal=N+Engl+J+Med.&#x00026;volume=381&#x00026;pages=2391-402\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B26\" id=\"B26\">\u003C/a> 26. Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. \u003Ci>JAMA.\u003C/i> (2011) 306:1557&#x02013;65. doi: 10.1001/jama.2011.1456\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=21990299\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1001/jama.2011.1456\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=D.+Yang&#x00026;author=S.+Khan&#x00026;author=Y.+Sun&#x00026;author=K.+Hess&#x00026;author=I.+Shmulevich&#x00026;author=AK.+Sood+&#x00026;publication_year=2011&#x00026;title=Association+of+BRCA1+and+BRCA2+mutations+with+survival,+chemotherapy+sensitivity,+and+gene+mutator+phenotype+in+patients+with+ovarian+cancer&#x00026;journal=JAMA.&#x00026;volume=306&#x00026;pages=1557-65\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B27\" id=\"B27\">\u003C/a> 27. Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. \u003Ci>JAMA.\u003C/i> (2012) 307:382&#x02013;90. doi: 10.1001/jama.2012.20\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=22274685\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1001/jama.2012.20\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=KL.+Bolton&#x00026;author=G.+Chenevix-Trench&#x00026;author=C.+Goh&#x00026;author=S.+Sadetzki&#x00026;author=SJ.+Ramus&#x00026;author=BY.+Karlan+&#x00026;publication_year=2012&#x00026;title=Association+between+BRCA1+and+BRCA2+mutations+and+survival+in+women+with+invasive+epithelial+ovarian+cancer&#x00026;journal=JAMA.&#x00026;volume=307&#x00026;pages=382-90\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B28\" id=\"B28\">\u003C/a> 28. Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. \u003Ci>Clin Cancer Res.\u003C/i> (2014) 20:764&#x02013;75. doi: 10.1158/1078-0432.CCR-13-2287\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=24240112\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1158/1078-0432.CCR-13-2287\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=KP.+Pennington&#x00026;author=T.+Walsh&#x00026;author=MI.+Harrell&#x00026;author=MK.+Lee&#x00026;author=CC.+Pennil&#x00026;author=MH.+Rendi+&#x00026;publication_year=2014&#x00026;title=Germline+and+somatic+mutations+in+homologous+recombination+genes+predict+platinum+response+and+survival+in+ovarian,+fallopian+tube,+and+peritoneal+carcinomas&#x00026;journal=Clin+Cancer+Res.&#x00026;volume=20&#x00026;pages=764-75\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B29\" id=\"B29\">\u003C/a> 29. Ray-Coquard I, Pautier P, Pignata S, Perol D, Gonzalez-Martin A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. \u003Ci>N Engl J Med.\u003C/i> (2019) 381:2416&#x02013;28. doi: 10.1056/NEJMoa1911361\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=31851799\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1056/NEJMoa1911361\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=I.+Ray-Coquard&#x00026;author=P.+Pautier&#x00026;author=S.+Pignata&#x00026;author=D.+Perol&#x00026;author=A.+Gonzalez-Martin&#x00026;author=R.+Berger+&#x00026;publication_year=2019&#x00026;title=Olaparib+plus+bevacizumab+as+first-line+maintenance+in+ovarian+cancer&#x00026;journal=N+Engl+J+Med.&#x00026;volume=381&#x00026;pages=2416-28\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B30\" id=\"B30\">\u003C/a> 30. Lai CH, Vallikad E, Lin H, Yang LY, Jung SM, Liu HE, et al. Maintenance of pegylated liposomal doxorubicin/carboplatin in patients with advanced ovarian cancer: randomized study of an Asian Gynecologic Oncology Group. \u003Ci>J Gynecol Oncol.\u003C/i> (2020) 31:e5. doi: 10.3802/jgo.2020.31.e5\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=31788995\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3802/jgo.2020.31.e5\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=CH.+Lai&#x00026;author=E.+Vallikad&#x00026;author=H.+Lin&#x00026;author=LY.+Yang&#x00026;author=SM.+Jung&#x00026;author=HE.+Liu+&#x00026;publication_year=2020&#x00026;title=Maintenance+of+pegylated+liposomal+doxorubicin%2Fcarboplatin+in+patients+with+advanced+ovarian+cancer%3A+randomized+study+of+an+Asian+Gynecologic+Oncology+Group&#x00026;journal=J+Gynecol+Oncol.&#x00026;volume=31&#x00026;pages=e5\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B31\" id=\"B31\">\u003C/a> 31. Lee YJ, Kim D, Shim JE, Bae SJ, Jung YJ, Kim S, et al. Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy. \u003Ci>Int J Cancer.\u003C/i> (2020) 146:1851&#x02013;61. doi: 10.1002/ijc.32729\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=31603993\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/ijc.32729\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=YJ.+Lee&#x00026;author=D.+Kim&#x00026;author=JE.+Shim&#x00026;author=SJ.+Bae&#x00026;author=YJ.+Jung&#x00026;author=S.+Kim+&#x00026;publication_year=2020&#x00026;title=Genomic+profiling+of+the+residual+disease+of+advanced+high-grade+serous+ovarian+cancer+after+neoadjuvant+chemotherapy&#x00026;journal=Int+J+Cancer.&#x00026;volume=146&#x00026;pages=1851-61\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B32\" id=\"B32\">\u003C/a> 32. Lu R, Xie S, Wang Y, Zheng H, Zhang H, Deng M, et al. MUS81 Participates in the progression of serous ovarian cancer associated with dysfunctional DNA repair system. \u003Ci>Front Oncol.\u003C/i> (2019) 9:1189. doi: 10.3389/fonc.2019.01189\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=31803609\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3389/fonc.2019.01189\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=R.+Lu&#x00026;author=S.+Xie&#x00026;author=Y.+Wang&#x00026;author=H.+Zheng&#x00026;author=H.+Zhang&#x00026;author=M.+Deng+&#x00026;publication_year=2019&#x00026;title=MUS81+Participates+in+the+progression+of+serous+ovarian+cancer+associated+with+dysfunctional+DNA+repair+system&#x00026;journal=Front+Oncol.&#x00026;volume=9&#x00026;pages=1189\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B33\" id=\"B33\">\u003C/a> 33. Takaya H, Nakai H, Sakai K, Nishio K, Murakami K, Mandai M, et al. Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course. \u003Ci>Gynecol Oncol.\u003C/i> (2020) 156:415&#x02013;22. doi: 10.1016/j.ygyno.2019.11.013\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=31785864\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.ygyno.2019.11.013\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=H.+Takaya&#x00026;author=H.+Nakai&#x00026;author=K.+Sakai&#x00026;author=K.+Nishio&#x00026;author=K.+Murakami&#x00026;author=M.+Mandai+&#x00026;publication_year=2020&#x00026;title=Intratumor+heterogeneity+and+homologous+recombination+deficiency+of+high-grade+serous+ovarian+cancer+are+associated+with+prognosis+and+molecular+subtype+and+change+in+treatment+course&#x00026;journal=Gynecol+Oncol.&#x00026;volume=156&#x00026;pages=415-22\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B34\" id=\"B34\">\u003C/a> 34. Shi T, Wang P, Xie C, Yin S, Shi D, Wei C, et al. BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer. \u003Ci>Int J Cancer.\u003C/i> (2017) 140:2051&#x02013;9. doi: 10.1002/ijc.30633\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=28176296\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/ijc.30633\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=T.+Shi&#x00026;author=P.+Wang&#x00026;author=C.+Xie&#x00026;author=S.+Yin&#x00026;author=D.+Shi&#x00026;author=C.+Wei+&#x00026;publication_year=2017&#x00026;title=BRCA1+and+BRCA2+mutations+in+ovarian+cancer+patients+from+China%3A+ethnic-related+mutations+in+BRCA1+associated+with+an+increased+risk+of+ovarian+cancer&#x00026;journal=Int+J+Cancer.&#x00026;volume=140&#x00026;pages=2051-9\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B35\" id=\"B35\">\u003C/a> 35. Wu X, Wu L, Kong B, Liu J, Yin R, Wen H, et al. The first nationwide multicenter prevalence study of germline BRCA1 and BRCA2 mutations in Chinese ovarian cancer patients. \u003Ci>Int J Gynecol Cancer.\u003C/i> (2017) 27:1650&#x02013;7. doi: 10.1097/IGC.0000000000001065\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=28692638\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1097/IGC.0000000000001065\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=X.+Wu&#x00026;author=L.+Wu&#x00026;author=B.+Kong&#x00026;author=J.+Liu&#x00026;author=R.+Yin&#x00026;author=H.+Wen+&#x00026;publication_year=2017&#x00026;title=The+first+nationwide+multicenter+prevalence+study+of+germline+BRCA1+and+BRCA2+mutations+in+Chinese+ovarian+cancer+patients&#x00026;journal=Int+J+Gynecol+Cancer.&#x00026;volume=27&#x00026;pages=1650-7\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B36\" id=\"B36\">\u003C/a> 36. Li W, Shao D, Li L, Wu M, Ma S, Tan X, et al. Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study. \u003Ci>J Ovarian Res.\u003C/i> (2019) 12:80. doi: 10.1186/s13048-019-0560-y\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=31472684\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/s13048-019-0560-y\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=W.+Li&#x00026;author=D.+Shao&#x00026;author=L.+Li&#x00026;author=M.+Wu&#x00026;author=S.+Ma&#x00026;author=X.+Tan+&#x00026;publication_year=2019&#x00026;title=Germline+and+somatic+mutations+of+multi-gene+panel+in+Chinese+patients+with+epithelial+ovarian+cancer%3A+a+prospective+cohort+study&#x00026;journal=J+Ovarian+Res.&#x00026;volume=12&#x00026;pages=80\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B37\" id=\"B37\">\u003C/a> 37. Mutch DG, Prat J. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. \u003Ci>Gynecol Oncol.\u003C/i> (2014) 133:401&#x02013;4. doi: 10.1016/j.ygyno.2014.04.013\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=24878391\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.ygyno.2014.04.013\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=DG.+Mutch&#x00026;author=J.+Prat+&#x00026;publication_year=2014&#x00026;title=2014+FIGO+staging+for+ovarian,+fallopian+tube+and+peritoneal+cancer&#x00026;journal=Gynecol+Oncol.&#x00026;volume=133&#x00026;pages=401-4\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B38\" id=\"B38\">\u003C/a> 38. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u003Csup>&#x000AE;\u003C/sup>). \u003Ci>Genetic/Familial High-Risk Assessment: Breast and Ovarian\u003C/i>. Version 2.2019 - July 30, 2018. Available online at: \u003Ca href=\"https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf\">https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf\u003C/a>\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Genetic%2FFamilial+High-Risk+Assessment%3A+Breast+and+Ovarian\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B39\" id=\"B39\">\u003C/a> 39. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. \u003Ci>Genet Med.\u003C/i> (2015) 17:405&#x02013;24. doi: 10.1038/gim.2015.30\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=25741868\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/gim.2015.30\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S.+Richards&#x00026;author=N.+Aziz&#x00026;author=S.+Bale&#x00026;author=D.+Bick&#x00026;author=S.+Das&#x00026;author=J.+Gastier-Foster+&#x00026;publication_year=2015&#x00026;title=Standards+and+guidelines+for+the+interpretation+of+sequence+variants%3A+a+joint+consensus+recommendation+of+the+American+College+of+Medical+Genetics+and+Genomics+and+the+Association+for+Molecular+Pathology&#x00026;journal=Genet+Med.&#x00026;volume=17&#x00026;pages=405-24\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B40\" id=\"B40\">\u003C/a> 40. Alsop K, Fereday S, Meldrum C, Defazio A, Emmanuel C, George J, et al. BRCA Mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. \u003Ci>J Clin Oncol.\u003C/i> (2012) 30:2654&#x02013;63. doi: 10.1200/JCO.2011.39.8545\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=22711857\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1200/JCO.2011.39.8545\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=K.+Alsop&#x00026;author=S.+Fereday&#x00026;author=C.+Meldrum&#x00026;author=A.+Defazio&#x00026;author=C.+Emmanuel&#x00026;author=J.+George+&#x00026;publication_year=2012&#x00026;title=BRCA+Mutation+frequency+and+patterns+of+treatment+response+in+BRCA+mutation-positive+women+with+ovarian+cancer%3A+a+report+from+the+Australian+Ovarian+Cancer+Study+Group&#x00026;journal=J+Clin+Oncol.&#x00026;volume=30&#x00026;pages=2654-63\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B41\" id=\"B41\">\u003C/a> 41. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the National Israeli Study of Ovarian Cancer. \u003Ci>J Clin Oncol.\u003C/i> (2008) 26:20&#x02013;5. doi: 10.1200/jco.2007.11.6905\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=18165636\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1200/jco.2007.11.6905\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A.+Chetrit&#x00026;author=G.+Hirsh-Yechezkel&#x00026;author=Y.+Ben-David&#x00026;author=F.+Lubin&#x00026;author=E.+Friedman&#x00026;author=S.+Sadetzki+&#x00026;publication_year=2008&#x00026;title=Effect+of+BRCA1%2F2+mutations+on+long-term+survival+of+patients+with+invasive+ovarian+cancer%3A+the+National+Israeli+Study+of+Ovarian+Cancer&#x00026;journal=J+Clin+Oncol.&#x00026;volume=26&#x00026;pages=20-5\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B42\" id=\"B42\">\u003C/a> 42. Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, et al. Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: an NRG Oncology/Gynecologic Oncology Group Study. \u003Ci>Clin Cancer Res.\u003C/i> (2018) 24:777&#x02013;83. doi: 10.1158/1078-0432.ccr-17-1327\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=29191972\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1158/1078-0432.ccr-17-1327\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=BM.+Norquist&#x00026;author=MF.+Brady&#x00026;author=MI.+Harrell&#x00026;author=T.+Walsh&#x00026;author=MK.+Lee&#x00026;author=S.+Gulsuner+&#x00026;publication_year=2018&#x00026;title=Mutations+in+homologous+recombination+genes+and+outcomes+in+ovarian+carcinoma+patients+in+GOG+218%3A+an+NRG+Oncology%2FGynecologic+Oncology+Group+Study&#x00026;journal=Clin+Cancer+Res.&#x00026;volume=24&#x00026;pages=777-83\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B43\" id=\"B43\">\u003C/a> 43. Hjortkjaer M, Malik Aagaard Jorgensen M, Waldstrom M, Ornskov D, Sogaard-Andersen E, Jakobsen A, et al. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer. \u003Ci>Int J Gynecol Cancer.\u003C/i> (2019) 29:166&#x02013;73. doi: 10.1136/ijgc-2018-000017\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=30640700\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1136/ijgc-2018-000017\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M.+Hjortkjaer&#x00026;author=AagaardJorgensenM.+Malik&#x00026;author=M.+Waldstrom&#x00026;author=D.+Ornskov&#x00026;author=E.+Sogaard-Andersen&#x00026;author=A.+Jakobsen+&#x00026;publication_year=2019&#x00026;title=The+clinical+importance+of+BRCAness+in+a+population-based+cohort+of+Danish+epithelial+ovarian+cancer&#x00026;journal=Int+J+Gynecol+Cancer.&#x00026;volume=29&#x00026;pages=166-73\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B44\" id=\"B44\">\u003C/a> 44. Huang M, Kamath P, Schlumbrecht M, Miao F, Driscoll D, Oldak S, et al. Identifying disparities in germline and somatic testing for ovarian cancer. \u003Ci>Gynecol Oncol.\u003C/i> (2019) 153:297&#x02013;303. doi: 10.1016/j.ygyno.2019.03.007\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=30890269\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.ygyno.2019.03.007\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M.+Huang&#x00026;author=P.+Kamath&#x00026;author=M.+Schlumbrecht&#x00026;author=F.+Miao&#x00026;author=D.+Driscoll&#x00026;author=S.+Oldak+&#x00026;publication_year=2019&#x00026;title=Identifying+disparities+in+germline+and+somatic+testing+for+ovarian+cancer&#x00026;journal=Gynecol+Oncol.&#x00026;volume=153&#x00026;pages=297-303\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B45\" id=\"B45\">\u003C/a> 45. Hinchcliff EM, Bednar EM, Lu KH, Rauh-Hain JA. Disparities in gynecologic cancer genetics evaluation. \u003Ci>Gynecol Oncol.\u003C/i> (2019) 153:184&#x02013;91. doi: 10.1016/j.ygyno.2019.01.024\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=30711300\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.ygyno.2019.01.024\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=EM.+Hinchcliff&#x00026;author=EM.+Bednar&#x00026;author=KH.+Lu&#x00026;author=JA.+Rauh-Hain+&#x00026;publication_year=2019&#x00026;title=Disparities+in+gynecologic+cancer+genetics+evaluation&#x00026;journal=Gynecol+Oncol.&#x00026;volume=153&#x00026;pages=184-91\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B46\" id=\"B46\">\u003C/a> 46. Wang J, Li W, Shi Y, Huang Y, Sun T, Tang L, et al. Germline mutation landscape of Chinese patients with familial breast/ovarian cancer in a panel of 22 susceptibility genes. \u003Ci>Cancer Med.\u003C/i> (2019) 8:2074&#x02013;84. doi: 10.1002/cam4.2093\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=30982232\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/cam4.2093\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J.+Wang&#x00026;author=W.+Li&#x00026;author=Y.+Shi&#x00026;author=Y.+Huang&#x00026;author=T.+Sun&#x00026;author=L.+Tang+&#x00026;publication_year=2019&#x00026;title=Germline+mutation+landscape+of+Chinese+patients+with+familial+breast%2Fovarian+cancer+in+a+panel+of+22+susceptibility+genes&#x00026;journal=Cancer+Med.&#x00026;volume=8&#x00026;pages=2074-84\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B47\" id=\"B47\">\u003C/a> 47. Gao X, Nan X, Liu Y, Liu R, Zang W, Shan G, et al. Comprehensive profiling of BRCA1 and BRCA2 variants in breast and ovarian cancer in Chinese patients. \u003Ci>Hum Mutat.\u003C/i> (2020) 41:696&#x02013;708. doi: 10.1002/humu.23965\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=31825140\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/humu.23965\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=X.+Gao&#x00026;author=X.+Nan&#x00026;author=Y.+Liu&#x00026;author=R.+Liu&#x00026;author=W.+Zang&#x00026;author=G.+Shan+&#x00026;publication_year=2020&#x00026;title=Comprehensive+profiling+of+BRCA1+and+BRCA2+variants+in+breast+and+ovarian+cancer+in+Chinese+patients&#x00026;journal=Hum+Mutat.&#x00026;volume=41&#x00026;pages=696-708\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B48\" id=\"B48\">\u003C/a> 48. Zhao Q, Yang J, Li L, Cao D, Yu M, Shen K. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing. \u003Ci>J Gynecol Oncol.\u003C/i> (2017) 28:e39. doi: 10.3802/jgo.2017.28.e39\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=28541631\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3802/jgo.2017.28.e39\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=Q.+Zhao&#x00026;author=J.+Yang&#x00026;author=L.+Li&#x00026;author=D.+Cao&#x00026;author=M.+Yu&#x00026;author=K.+Shen+&#x00026;publication_year=2017&#x00026;title=Germline+and+somatic+mutations+in+homologous+recombination+genes+among+Chinese+ovarian+cancer+patients+detected+using+next-generation+sequencing&#x00026;journal=J+Gynecol+Oncol.&#x00026;volume=28&#x00026;pages=e39\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B49\" id=\"B49\">\u003C/a> 49. Li L, Qiu L, Wu M. A survey of willingness about genetic counseling and tests in patients of epithelial ovarian cancer. \u003Ci>Zhonghua Yi Xue Za Zhi.\u003C/i> (2017) 97:3412&#x02013;5. doi: 10.3760/cma.j.issn.0376-2491.2017.43.011\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=29179283\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3760/cma.j.issn.0376-2491.2017.43.011\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=L.+Li&#x00026;author=L.+Qiu&#x00026;author=M.+Wu+&#x00026;publication_year=2017&#x00026;title=A+survey+of+willingness+about+genetic+counseling+and+tests+in+patients+of+epithelial+ovarian+cancer&#x00026;journal=Zhonghua+Yi+Xue+Za+Zhi.&#x00026;volume=97&#x00026;pages=3412-5\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B50\" id=\"B50\">\u003C/a> 50. Liu GY, Zhang W. Will Chinese ovarian cancer patients benefit from knowing the BRCA2 mutation status? \u003Ci>Chin J Cancer.\u003C/i> (2012) 31:1&#x02013;4. doi: 10.5732/cjc.011.10432\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=22176776\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.5732/cjc.011.10432\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=GY.+Liu&#x00026;author=W.+Zhang+&#x00026;publication_year=2012&#x00026;title=Will+Chinese+ovarian+cancer+patients+benefit+from+knowing+the+BRCA2+mutation+status%3F&#x00026;journal=Chin+J+Cancer.&#x00026;volume=31&#x00026;pages=1-4\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B51\" id=\"B51\">\u003C/a> 51. Shipman H, Flynn S, MacDonald-Smith CF, Brenton J, Crawford R, Tischkowitz M, et al. Universal BRCA1/BRCA2 testing for ovarian cancer patients is welcomed, but with care: how women and staff contextualize experiences of expanded access. \u003Ci>J Genet Couns.\u003C/i> (2017) 26:1280&#x02013;91. doi: 10.1007/s10897-017-0108-5\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=28540621\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s10897-017-0108-5\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=H.+Shipman&#x00026;author=S.+Flynn&#x00026;author=CF.+MacDonald-Smith&#x00026;author=J.+Brenton&#x00026;author=R.+Crawford&#x00026;author=M.+Tischkowitz+&#x00026;publication_year=2017&#x00026;title=Universal+BRCA1%2FBRCA2+testing+for+ovarian+cancer+patients+is+welcomed,+but+with+care%3A+how+women+and+staff+contextualize+experiences+of+expanded+access&#x00026;journal=J+Genet+Couns.&#x00026;volume=26&#x00026;pages=1280-91\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B52\" id=\"B52\">\u003C/a> 52. Koczkowska M, Zuk M, Gorczynski A, Ratajska M, Lewandowska M, Biernat W, et al. Detection of somatic BRCA1/2 mutations in ovarian cancer - next-generation sequencing analysis of 100 cases. \u003Ci>Cancer Med.\u003C/i> (2016) 5:1640&#x02013;6. doi: 10.1002/cam4.748\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=27167707\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/cam4.748\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M.+Koczkowska&#x00026;author=M.+Zuk&#x00026;author=A.+Gorczynski&#x00026;author=M.+Ratajska&#x00026;author=M.+Lewandowska&#x00026;author=W.+Biernat+&#x00026;publication_year=2016&#x00026;title=Detection+of+somatic+BRCA1%2F2+mutations+in+ovarian+cancer+-+next-generation+sequencing+analysis+of+100+cases&#x00026;journal=Cancer+Med.&#x00026;volume=5&#x00026;pages=1640-6\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B53\" id=\"B53\">\u003C/a> 53. Zakrzewski F, Gieldon L, Rump A, Seifert M, Grutzmann K, Kruger A, et al. Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples. \u003Ci>BMC Cancer.\u003C/i> (2019) 19:396. doi: 10.1186/s12885-019-5584-6\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=31029168\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/s12885-019-5584-6\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=F.+Zakrzewski&#x00026;author=L.+Gieldon&#x00026;author=A.+Rump&#x00026;author=M.+Seifert&#x00026;author=K.+Grutzmann&#x00026;author=A.+Kruger+&#x00026;publication_year=2019&#x00026;title=Targeted+capture-based+NGS+is+superior+to+multiplex+PCR-based+NGS+for+hereditary+BRCA1+and+BRCA2+gene+analysis+in+FFPE+tumor+samples&#x00026;journal=BMC+Cancer.&#x00026;volume=19&#x00026;pages=396\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B54\" id=\"B54\">\u003C/a> 54. Choi MC, Bae JS, Jung SG, Park H, Joo WD, Song SH, et al. Prevalence of germline BRCA mutations among women with carcinoma of the peritoneum or fallopian tube. \u003Ci>J Gynecol Oncol.\u003C/i> (2018) 29:e43. doi: 10.3802/jgo.2018.29.e43\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=29770616\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3802/jgo.2018.29.e43\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=MC.+Choi&#x00026;author=JS.+Bae&#x00026;author=SG.+Jung&#x00026;author=H.+Park&#x00026;author=WD.+Joo&#x00026;author=SH.+Song+&#x00026;publication_year=2018&#x00026;title=Prevalence+of+germline+BRCA+mutations+among+women+with+carcinoma+of+the+peritoneum+or+fallopian+tube&#x00026;journal=J+Gynecol+Oncol.&#x00026;volume=29&#x00026;pages=e43\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B55\" id=\"B55\">\u003C/a> 55. Petrillo M, Marchetti C, De Leo R, Musella A, Capoluongo E, Paris I, et al. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. \u003Ci>Am J Obstet Gynecol.\u003C/i> (2017) 217:334 e1&#x02013;9. doi: 10.1016/j.ajog.2017.05.036\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=28549976\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.ajog.2017.05.036\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M.+Petrillo&#x00026;author=C.+Marchetti&#x00026;author=R.+De+Leo&#x00026;author=A.+Musella&#x00026;author=E.+Capoluongo&#x00026;author=I.+Paris+&#x00026;publication_year=2017&#x00026;title=BRCA+mutational+status,+initial+disease+presentation,+and+clinical+outcome+in+high-grade+serous+advanced+ovarian+cancer%3A+a+multicenter+study&#x00026;journal=Am+J+Obstet+Gynecol.&#x00026;volume=217&#x00026;pages=334\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B56\" id=\"B56\">\u003C/a> 56. Naumann RW, Morris JC, Tait DL, Higgins RV, Crane EK, Drury LK, et al. Patients with BRCA mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected high grade ovarian cancer. \u003Ci>Gynecol Oncol.\u003C/i> (2018) 151:477&#x02013;80. doi: 10.1016/j.ygyno.2018.10.003\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=30309722\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.ygyno.2018.10.003\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=RW.+Naumann&#x00026;author=JC.+Morris&#x00026;author=DL.+Tait&#x00026;author=RV.+Higgins&#x00026;author=EK.+Crane&#x00026;author=LK.+Drury+&#x00026;publication_year=2018&#x00026;title=Patients+with+BRCA+mutations+have+superior+outcomes+after+intraperitoneal+chemotherapy+in+optimally+resected+high+grade+ovarian+cancer&#x00026;journal=Gynecol+Oncol.&#x00026;volume=151&#x00026;pages=477-80\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B57\" id=\"B57\">\u003C/a> 57. Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD, 2nd, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. \u003Ci>J Clin Oncol.\u003C/i> (2010) 28:3570&#x02013;6. doi: 10.1200/jco.2009.27.2997\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=20606085\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1200/jco.2009.27.2997\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=BT.+Hennessy&#x00026;author=KM.+Timms&#x00026;author=MS.+Carey&#x00026;author=A.+Gutin&#x00026;author=LA.+Meyer&#x00026;author=DD.+Flake+&#x00026;publication_year=2010&#x00026;title=Somatic+mutations+in+BRCA1+and+BRCA2+could+expand+the+number+of+patients+that+benefit+from+poly+(ADP+ribose)+polymerase+inhibitors+in+ovarian+cancer&#x00026;journal=J+Clin+Oncol.&#x00026;volume=28&#x00026;pages=3570-6\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B58\" id=\"B58\">\u003C/a> 58. Minion LE, Dolinsky JS, Chase DM, Dunlop CL, Chao EC, Monk BJ. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2. \u003Ci>Gynecol Oncol.\u003C/i> (2015) 137:86&#x02013;92. doi: 10.1016/j.ygyno.2015.01.537\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=25622547\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.ygyno.2015.01.537\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=LE.+Minion&#x00026;author=JS.+Dolinsky&#x00026;author=DM.+Chase&#x00026;author=CL.+Dunlop&#x00026;author=EC.+Chao&#x00026;author=BJ.+Monk+&#x00026;publication_year=2015&#x00026;title=Hereditary+predisposition+to+ovarian+cancer,+looking+beyond+BRCA1%2FBRCA2&#x00026;journal=Gynecol+Oncol.&#x00026;volume=137&#x00026;pages=86-92\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B59\" id=\"B59\">\u003C/a> 59. Singh J, Thota N, Singh S, Padhi S, Mohan P, Deshwal S, et al. Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations. \u003Ci>Breast Cancer Res Treat.\u003C/i> (2018) 170:189&#x02013;96. doi: 10.1007/s10549-018-4726-x\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=29470806\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s10549-018-4726-x\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J.+Singh&#x00026;author=N.+Thota&#x00026;author=S.+Singh&#x00026;author=S.+Padhi&#x00026;author=P.+Mohan&#x00026;author=S.+Deshwal+&#x00026;publication_year=2018&#x00026;title=Screening+of+over+1000+Indian+patients+with+breast+and%2For+ovarian+cancer+with+a+multi-gene+panel%3A+prevalence+of+BRCA1%2F2+and+non-BRCA+mutations&#x00026;journal=Breast+Cancer+Res+Treat.&#x00026;volume=170&#x00026;pages=189-96\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B60\" id=\"B60\">\u003C/a> 60. Eoh KJ, Kim JE, Park HS, Lee ST, Park JS, Han JW, et al. Detection of germline mutations in patients with epithelial ovarian cancer using multi-gene panels: beyond BRCA1/2. \u003Ci>Cancer Res Treat.\u003C/i> (2018) 50:917&#x02013;25. doi: 10.4143/crt.2017.220\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=29020732\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.4143/crt.2017.220\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=KJ.+Eoh&#x00026;author=JE.+Kim&#x00026;author=HS.+Park&#x00026;author=ST.+Lee&#x00026;author=JS.+Park&#x00026;author=JW.+Han+&#x00026;publication_year=2018&#x00026;title=Detection+of+germline+mutations+in+patients+with+epithelial+ovarian+cancer+using+multi-gene+panels%3A+beyond+BRCA1%2F2&#x00026;journal=Cancer+Res+Treat.&#x00026;volume=50&#x00026;pages=917-25\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B61\" id=\"B61\">\u003C/a> 61. Graffeo R, Livraghi L, Pagani O, Goldhirsch A, Partridge AH, Garber JE. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care. \u003Ci>Breast Cancer Res Treat.\u003C/i> (2016) 160:393&#x02013;410. doi: 10.1007/s10549-016-4003-9\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=27734215\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s10549-016-4003-9\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=R.+Graffeo&#x00026;author=L.+Livraghi&#x00026;author=O.+Pagani&#x00026;author=A.+Goldhirsch&#x00026;author=AH.+Partridge&#x00026;author=JE.+Garber+&#x00026;publication_year=2016&#x00026;title=Time+to+incorporate+germline+multigene+panel+testing+into+breast+and+ovarian+cancer+patient+care&#x00026;journal=Breast+Cancer+Res+Treat.&#x00026;volume=160&#x00026;pages=393-410\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B62\" id=\"B62\">\u003C/a> 62. Feliubadalo L, Lopez-Fernandez A, Pineda M, Diez O, Del Valle J, Gutierrez-Enriquez S, et al. Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels. \u003Ci>Int J Cancer.\u003C/i> (2019) 145:2682&#x02013;91. doi: 10.1002/ijc.32304\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=30927264\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/ijc.32304\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=L.+Feliubadalo&#x00026;author=A.+Lopez-Fernandez&#x00026;author=M.+Pineda&#x00026;author=O.+Diez&#x00026;author=ValleJ.+Del&#x00026;author=S.+Gutierrez-Enriquez+&#x00026;publication_year=2019&#x00026;title=Opportunistic+testing+of+BRCA1,+BRCA2+and+mismatch+repair+genes+improves+the+yield+of+phenotype+driven+hereditary+cancer+gene+panels&#x00026;journal=Int+J+Cancer.&#x00026;volume=145&#x00026;pages=2682-91\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B63\" id=\"B63\">\u003C/a> 63. Frey MK, Kim SH, Bassett RY, Martineau J, Dalton E, Chern JY, et al. Rescreening for genetic mutations using multi-gene panel testing in patients who previously underwent non-informative genetic screening. \u003Ci>Gynecol Oncol.\u003C/i> (2015) 139:211&#x02013;5. doi: 10.1016/j.ygyno.2015.08.006\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=26296696\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.ygyno.2015.08.006\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=MK.+Frey&#x00026;author=SH.+Kim&#x00026;author=RY.+Bassett&#x00026;author=J.+Martineau&#x00026;author=E.+Dalton&#x00026;author=JY.+Chern+&#x00026;publication_year=2015&#x00026;title=Rescreening+for+genetic+mutations+using+multi-gene+panel+testing+in+patients+who+previously+underwent+non-informative+genetic+screening&#x00026;journal=Gynecol+Oncol.&#x00026;volume=139&#x00026;pages=211-5\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B64\" id=\"B64\">\u003C/a> 64. Moschetta M, George A, Kaye SB, Banerjee S. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. \u003Ci>Ann Oncol.\u003C/i> (2016) 27:1449&#x02013;55. doi: 10.1093/annonc/mdw142\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=27037296\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/annonc/mdw142\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M.+Moschetta&#x00026;author=A.+George&#x00026;author=SB.+Kaye&#x00026;author=S.+Banerjee+&#x00026;publication_year=2016&#x00026;title=BRCA+somatic+mutations+and+epigenetic+BRCA+modifications+in+serous+ovarian+cancer&#x00026;journal=Ann+Oncol.&#x00026;volume=27&#x00026;pages=1449-55\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B65\" id=\"B65\">\u003C/a> 65. Weren RD, Mensenkamp AR, Simons M, Eijkelenboom A, Sie AS, Ouchene H, et al. Novel BRCA1 and BRCA2 tumor test as basis for treatment decisions and referral for genetic counselling of patients with ovarian carcinomas. \u003Ci>Hum Mutat.\u003C/i> (2017) 38:226&#x02013;35. doi: 10.1002/humu.23137\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=27767231\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/humu.23137\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=RD.+Weren&#x00026;author=AR.+Mensenkamp&#x00026;author=M.+Simons&#x00026;author=A.+Eijkelenboom&#x00026;author=AS.+Sie&#x00026;author=H.+Ouchene+&#x00026;publication_year=2017&#x00026;title=Novel+BRCA1+and+BRCA2+tumor+test+as+basis+for+treatment+decisions+and+referral+for+genetic+counselling+of+patients+with+ovarian+carcinomas&#x00026;journal=Hum+Mutat.&#x00026;volume=38&#x00026;pages=226-35\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B66\" id=\"B66\">\u003C/a> 66. Riahi A, Chabouni-Bouhamed H, Kharrat M. Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: implications for genetic testing. \u003Ci>Cancer Genet.\u003C/i> (2017) 210:22&#x02013;7. doi: 10.1016/j.cancergen.2016.11.002\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=28212807\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.cancergen.2016.11.002\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A.+Riahi&#x00026;author=H.+Chabouni-Bouhamed&#x00026;author=M.+Kharrat+&#x00026;publication_year=2017&#x00026;title=Prevalence+of+BRCA1+and+BRCA2+large+genomic+rearrangements+in+Tunisian+high+risk+breast%2Fovarian+cancer+families%3A+implications+for+genetic+testing&#x00026;journal=Cancer+Genet.&#x00026;volume=210&#x00026;pages=22-7\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\n\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.7em;\">\u003Ca name=\"B67\" id=\"B67\">\u003C/a> 67. Bernards SS, Pennington KP, Harrell MI, Agnew KJ, Garcia RL, Norquist BM, et al. Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma. \u003Ci>Gynecol Oncol.\u003C/i> (2018) 148:281&#x02013;5. doi: 10.1016/j.ygyno.2017.12.004\u003C/p>\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=29233532\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.ygyno.2017.12.004\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=SS.+Bernards&#x00026;author=KP.+Pennington&#x00026;author=MI.+Harrell&#x00026;author=KJ.+Agnew&#x00026;author=RL.+Garcia&#x00026;author=BM.+Norquist+&#x00026;publication_year=2018&#x00026;title=Clinical+characteristics+and+outcomes+of+patients+with+BRCA1+or+RAD51C+methylated+versus+mutated+ovarian+carcinoma&#x00026;journal=Gynecol+Oncol.&#x00026;volume=148&#x00026;pages=281-5\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003C/div>\n\u003Cdiv class=\"thinLineM20\">\u003C/div>\n\u003Cdiv class=\"AbstractSummary\">\n\u003Cp>\u003Cspan>Keywords:\u003C/span> epithelial ovarian cancer, \u003Ci>BRCA\u003C/i> mutations, germline mutations, somatic mutations, progression-free survival, overall survival\u003C/p>\n\u003Cp>\u003Cspan>Citation:\u003C/span> You Y, Li L, Lu J, Wu H, Wang J, Gao J, Wu M and Liang Z (2020) Germline and Somatic \u003Ci>BRCA1/2\u003C/i> Mutations in 172 Chinese Women With Epithelial Ovarian Cancer. \u003Ci>Front. Oncol.\u003C/i> 10:295. doi: 10.3389/fonc.2020.00295\u003C/p>\n\u003Cp id=\"timestamps\">\u003Cspan>Received:\u003C/span> 13 January 2020; \u003Cspan>Accepted:\u003C/span> 20 February 2020;\u003Cbr> \u003Cspan>Published:\u003C/span> 10 March 2020.\u003C/p>\n\u003Cdiv>\u003Cp>Edited by:\u003C/p> \u003Ca href=\"http://loop.frontiersin.org/people/754893/overview\">Giuseppe Vizzielli\u003C/a>, Agostino Gemelli University Polyclinic, Italy\u003C/div>\n\u003Cdiv>\u003Cp>Reviewed by:\u003C/p> \u003Ca href=\"http://loop.frontiersin.org/people/304800/overview\">Michael Dean\u003C/a>, National Cancer Institute at Frederick, United States\u003Cbr> \u003Ca href=\"http://loop.frontiersin.org/people/786233/overview\">Martina Arcieri\u003C/a>, University of Eastern Piedmont, Italy\u003C/div>\n\u003Cp>\u003Cspan>Copyright\u003C/span> &#x000A9; 2020 You, Li, Lu, Wu, Wang, Gao, Wu and Liang. This is an open-access article distributed under the terms of the \u003Ca rel=\"license\" href=\"http://creativecommons.org/licenses/by/4.0/\" target=\"_blank\">Creative Commons Attribution License (CC BY)\u003C/a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.\u003C/p>\n\u003Cp>\u003Cspan>&#x0002A;Correspondence:\u003C/span> Ming Wu, \u003Ca id=\"encmail\">d3VtaW5nQHB1bWNoLmNu\u003C/a>; Zhiyong Liang, \u003Ca id=\"encmail\">bGlhbmd6aGl5b25nMTIyMEB5YWhvby5jb20=\u003C/a>\u003C/p>\n\u003Cp>\u003Cspan>\u003Csup>&#x02020;\u003C/sup>\u003C/span>These authors have contributed equally to this work\u003C/p>\n\u003Cdiv class=\"clear\">\u003C/div>\n\u003C/div>","\u003Cul class=\"flyoutJournal\">\r\n\u003Cli>\u003Ca href=\"#h1\">Abstract\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h2\">Introduction\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h3\">Materials and Methods\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h4\">Results\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h5\">Discussion\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h6\">Conclusions\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h7\">Data Availability Statement\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h8\">Ethics Statement\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h9\">Author Contributions\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h10\">Funding\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h11\">Conflict of Interest\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h12\">Supplementary Material\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h13\">References\u003C/a>\u003C/li>\r\n\u003C/ul>\r\n",[663,668,674,677,683],{"name":664,"fileServerPackageEntryId":19,"fileServerId":665,"fileServerVersionNumber":643,"type":666},"EPUB.epub","526265/epub",{"code":667,"name":667},"EPUB",{"name":669,"fileServerPackageEntryId":670,"fileServerId":671,"fileServerVersionNumber":643,"type":672},"fonc-10-00295.pdf","fonc-10-00295-r1/fonc-10-00295.pdf","526265/pubmed-zip",{"code":673,"name":673},"PDF",{"name":669,"fileServerPackageEntryId":19,"fileServerId":675,"fileServerVersionNumber":643,"type":676},"526265/publishers-proof/pdf",{"code":673,"name":673},{"name":678,"fileServerPackageEntryId":679,"fileServerId":671,"fileServerVersionNumber":643,"type":680},"fonc-10-00295.xml","fonc-10-00295-r1/fonc-10-00295.xml",{"code":681,"name":682},"NLM_XML","XML",{"name":684,"fileServerPackageEntryId":19,"fileServerId":685,"fileServerVersionNumber":391,"type":686},"Provisional PDF.pdf","526265/provisional-pdf",{"code":673,"name":673},"v3",{"title":689,"link":690,"meta":694,"script":814},"Frontiers | Germline and Somatic BRCA1/2 Mutations in 172 Chinese Women With Epithelial Ovarian Cancer",[691],{"rel":692,"href":693},"canonical","https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00295/full",[695,698,701,703,706,710,713,717,720,723,726,728,730,732,734,736,739,742,744,747,750,752,755,758,761,764,767,771,775,778,781,784,786,789,791,794,796,799,801,804,806,809,811],{"hid":696,"property":696,"name":696,"content":697},"description","ObjectiveDespite several nationwide cohort studies on germline BRCA1/2 mutations and several small cohort studies on somatic BRCA1/2 mutations in Chinese epi...",{"hid":699,"property":699,"name":700,"content":689},"og:title","title",{"hid":702,"property":702,"name":696,"content":697},"og:description",{"hid":704,"name":704,"content":705},"keywords","epithelial ovarian cancer,BRCA mutations,germline mutations,somatic mutations,Progression-free survival,overall survival",{"hid":707,"property":707,"name":708,"content":709},"og:site_name","site_name","Frontiers",{"hid":711,"property":711,"name":384,"content":712},"og:image","https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/526265/fonc-10-00295-HTML-r1/image_m/fonc-10-00295-g001.jpg",{"hid":714,"property":714,"name":715,"content":716},"og:type","type","article",{"hid":718,"property":718,"name":719,"content":693},"og:url","url",{"hid":721,"name":721,"content":722},"twitter:card","summary_large_image",{"hid":724,"name":724,"content":725},"citation_volume","10",{"hid":727,"name":727,"content":116},"citation_journal_title",{"hid":729,"name":729,"content":709},"citation_publisher",{"hid":731,"name":731,"content":639},"citation_journal_abbrev",{"hid":733,"name":733,"content":640},"citation_issn",{"hid":735,"name":735,"content":536},"citation_doi",{"hid":737,"name":737,"content":738},"citation_firstpage","526265",{"hid":740,"name":740,"content":741},"citation_language","English",{"hid":743,"name":743,"content":537},"citation_title",{"hid":745,"name":745,"content":746},"citation_keywords","epithelial ovarian cancer; BRCA mutations; germline mutations; somatic mutations; Progression-free survival; overall survival",{"hid":748,"name":748,"content":749},"citation_abstract","ObjectiveDespite several nationwide cohort studies on germline BRCA1/2 mutations and several small cohort studies on somatic BRCA1/2 mutations in Chinese epithelial ovarian cancer (EOC) patients, little is known about the impact of these findings on survival outcomes in this population. In this study of 172 retrospectively recruited Chinese EOC patients, germline and somatic BRCA1/2 mutations and their value for predicting survival outcomes were evaluated.MethodsUnselected patients who visited the study center from January 1, 2011, to January 1, 2015, were recruited and asked to provide peripheral blood samples for this study if they were pathologically confirmed to have primary EOC. All patients received staging surgeries or debulking surgeries systemic platinum-based chemotherapy, and the patients were then followed up to December 1, 2017. DNA was extracted from formalin-fixed, paraffin-embedded (FFPE) sections and peripheral blood and sequenced for somatic and germline testing, respectively. The demographic and clinicopathological characteristics of the patients were collected to analyze the distribution of BRCA mutations in subgroups. Survival outcomes were compared among various BRCA mutation statuses using univariate and multivariate models.ResultsIn 59 (34.1%) patients, 64 variants were identified, including variants of unknown signicance (VUS) in 19 patients (11.0%) and pathogenic or likely pathogenic variants in a partially overlapping set of 41 patients (23.8%). Germline BRCA mutations, somatic BRCA mutations, BRCA1 mutations in general, and BRCA2 mutations in general were found in 35 (20.3%), 7 (4.1%), 28 (16.3%) and 13 (7.6%) patients, respectively. Five recurrent mutations were identified. Personal and family cancer history as well as hereditary breast and ovarian cancer (HBOC) criteria were associated with deleterious BRCA mutations both overall and in the germline specifically, whereas only age at diagnosis of EOC was associated with somatic BRCA mutations. In univariate and Cox regression analyses, patients with BRCA1/2 mutations in general had significant improvements in progression-free survival (PFS) and overall survival (OS).ConclusionsIn Chinese EOC patients, the distributions and risk factors associated with germline and somatic BRCA1/2 were similar to those previously reported in international studies. Deleterious BRCA mutations in general were associated with improved survival outcomes in this cohort.",{"hid":751,"name":751,"content":545},"citation_article_type",{"hid":753,"name":753,"content":754},"citation_pdf_url","https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00295/pdf",{"hid":756,"name":756,"content":757},"citation_xml_url","https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.00295/xml",{"hid":759,"name":759,"content":760},"citation_fulltext_world_readable","yes",{"hid":762,"name":762,"content":763},"citation_online_date","2020/02/20",{"hid":765,"name":765,"content":766},"citation_publication_date","2020/03/10",{"hid":768,"name":769,"content":770},"citation_author_0","citation_author","You, Yan ",{"hid":772,"name":773,"content":774},"citation_author_institution_0","citation_author_institution","Department of Pathology, Molecular Pathology Research Center, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, China",{"hid":776,"name":769,"content":777},"citation_author_1","Li, Lei ",{"hid":779,"name":773,"content":780},"citation_author_institution_1","Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, China",{"hid":782,"name":769,"content":783},"citation_author_2","Lu, Junliang ",{"hid":785,"name":773,"content":774},"citation_author_institution_2",{"hid":787,"name":769,"content":788},"citation_author_3","Wu, Huanwen ",{"hid":790,"name":773,"content":774},"citation_author_institution_3",{"hid":792,"name":769,"content":793},"citation_author_4","Wang, Jing ",{"hid":795,"name":773,"content":774},"citation_author_institution_4",{"hid":797,"name":769,"content":798},"citation_author_5","Gao, Jie ",{"hid":800,"name":773,"content":774},"citation_author_institution_5",{"hid":802,"name":769,"content":803},"citation_author_6","Wu, Ming ",{"hid":805,"name":773,"content":780},"citation_author_institution_6",{"hid":807,"name":769,"content":808},"citation_author_7","Liang, Zhiyong ",{"hid":810,"name":773,"content":774},"citation_author_institution_7",{"hid":812,"name":812,"content":813},"dc.identifier","doi:10.3389/fonc.2020.00295",[815,818,820,822,824],{"src":816,"body":13,"type":817,"async":13},"https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6","text/javascript",{"src":819,"body":13,"type":817,"async":13},"https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML",{"src":821,"body":13,"type":817,"async":13},"https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js",{"src":823,"body":13,"type":817,"async":13},"https://api.altmetric.com/v1/doi/10.3389/fonc.2020.00295?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15",{"src":825,"body":13,"type":817,"async":13},"https://crossmark-cdn.crossref.org/widget/v2.0/widget.js",{"articleHubSlug":19,"articleHubPage":827,"articleHubArticlesList":828,"canJournalHasArticleHub":367,"articleDoiList":829},{},[],[],{"title":19,"image":-1,"breadcrumbs":831,"linksCollection":832,"metricsCollection":834},[],{"total":388,"items":833},[],{"total":388,"items":835},[]]</script>
<script>window.__NUXT__={};window.__NUXT__.config={public:{isDevMode:false,appName:"article-pages-2024",baseUrl:"https://www.frontiersin.org",domain:"frontiersin.org",loopUrl:"https://loop.frontiersin.org",ssMainDomain:"frontiersin.org",contentfulUrl:"https://graphql.contentful.com/content/v1/spaces",spaceId:1,spaceName:"Frontiers",liveSpaceId:1,tenantLogoUrl:"",frontiersGraphUrl:"https://apollo-federation-gateway.frontiersin.org",registrationApiUrl:"https://onboarding-ui.frontiersin.org",emailDigestApiUrl:"https://api-email-digest.frontiersin.org",journalFilesApiUrl:"https://files-journal-api.frontiersin.org",publicPagesFilesUrl:"https://public-pages-files-2025.frontiersin.org",searchApiUrl:"https://search-api.frontiersin.org",productionForumApiUrl:"https://production-forum-api-v2.frontiersin.org",gtmServerUrl:"https://tag-manager.frontiersin.org",gtmId:"GTM-M322FV2",gtmAuth:"owVbWxfaJr21yQv1fe1cAQ",gtmPreview:"env-1",figsharePluginUrl:"https://widgets.figshare.com/static/figshare.js",figshareApiUrl:"https://api.figshare.com/v2/collections/search",figshareTimeout:3000,crossmarkPublishedDate:"2015/08/24",googleRecaptchaSiteKey:"6LdG3i0UAAAAAOC4qUh35ubHgJotEHp_STXHgr_v",googleRecaptchaKeyName:"FrontiersRecaptchaV2",faviconSize16:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png",faviconSize32:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png",faviconSize180:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_180-tenantFavicon-Frontiers.png",faviconSize192:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_192-tenantFavicon-Frontiers.png",faviconSize512:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_512-tenantFavicon-Frontiers.png",socialMediaImg:"https://brand.frontiersin.org/m/1c8bcb536c789e11/Guidelines-Frontiers_Logo_1200x628_1-91to1.png",linkedArticleCopyText:"'{\"articleTypeCopyText\":[{\"articleTypeId\":0,\"originalArticleCopyText\":\"Part of this article's content has been mentioned in:\",\"linkedArticleCopyText\":\"This article mentions parts of:\"},{\"articleTypeId\":122,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an erratum on:\"},{\"articleTypeId\":129,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an addendum to:\"},{\"articleTypeId\":128,\"originalArticleCopyText\":\"A correction has been applied to this article in:\",\"linkedArticleCopyText\":\"This article is a correction to:\"},{\"articleTypeId\":134,\"originalArticleCopyText\":\"A retraction of this article was approved in:\",\"linkedArticleCopyText\":\"This article is a retraction of:\"},{\"articleTypeId\":29,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"},{\"articleTypeId\":30,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"}],\"articleIdCopyText\":[]}'\n",acceptedArticleExcludedJournalIds:"'[2766,979]'\n",articleTypeConfigurableLabel:"\u003C\u003Carticle-type:uppercase>> article",settingsFeaturesSwitchers:"'{\"displayTitlePillLabels\":true,\"displayRelatedArticlesBox\":true,\"showEditors\":true,\"showReviewers\":true,\"showLoopImpactLink\":true,\"enableFigshare\":false}'\n",journalsWithArticleHub:"'{\"strings\":[\"science\"]}'\n",terminologySettings:"'{\"terms\":[{\"sequenceNumber\":1,\"key\":\"frontiers\",\"tenantTerm\":\"Frontiers\",\"frontiersDefaultTerm\":\"Frontiers\",\"category\":\"Customer\"},{\"sequenceNumber\":2,\"key\":\"submission_system\",\"tenantTerm\":\"submission system\",\"frontiersDefaultTerm\":\"submission system\",\"category\":\"Product\"},{\"sequenceNumber\":3,\"key\":\"public_pages\",\"tenantTerm\":\"public pages\",\"frontiersDefaultTerm\":\"public pages\",\"category\":\"Product\"},{\"sequenceNumber\":4,\"key\":\"my_frontiers\",\"tenantTerm\":\"my frontiers\",\"frontiersDefaultTerm\":\"my frontiers\",\"category\":\"Product\"},{\"sequenceNumber\":5,\"key\":\"digital_editorial_office\",\"tenantTerm\":\"digital editorial office\",\"frontiersDefaultTerm\":\"digital editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":6,\"key\":\"deo\",\"tenantTerm\":\"DEO\",\"frontiersDefaultTerm\":\"DEO\",\"category\":\"Product\"},{\"sequenceNumber\":7,\"key\":\"digital_editorial_office_for_chiefs\",\"tenantTerm\":\"digital editorial office for chiefs\",\"frontiersDefaultTerm\":\"digital editorial office for chiefs\",\"category\":\"Product\"},{\"sequenceNumber\":8,\"key\":\"digital_editorial_office_for_eof\",\"tenantTerm\":\"digital editorial office for eof\",\"frontiersDefaultTerm\":\"digital editorial office for eof\",\"category\":\"Product\"},{\"sequenceNumber\":9,\"key\":\"editorial_office\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":10,\"key\":\"eof\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"Product\"},{\"sequenceNumber\":11,\"key\":\"research_topic_management\",\"tenantTerm\":\"research topic management\",\"frontiersDefaultTerm\":\"research topic management\",\"category\":\"Product\"},{\"sequenceNumber\":12,\"key\":\"review_forum\",\"tenantTerm\":\"review forum\",\"frontiersDefaultTerm\":\"review forum\",\"category\":\"Product\"},{\"sequenceNumber\":13,\"key\":\"accounting_office\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"Product\"},{\"sequenceNumber\":14,\"key\":\"aof\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"Product\"},{\"sequenceNumber\":15,\"key\":\"publishing_office\",\"tenantTerm\":\"publishing office\",\"frontiersDefaultTerm\":\"publishing office\",\"category\":\"Product\"},{\"sequenceNumber\":16,\"key\":\"production_office\",\"tenantTerm\":\"production office forum\",\"frontiersDefaultTerm\":\"production office forum\",\"category\":\"Product\"},{\"sequenceNumber\":17,\"key\":\"pof\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"Product\"},{\"sequenceNumber\":18,\"key\":\"book_office_forum\",\"tenantTerm\":\"book office forum\",\"frontiersDefaultTerm\":\"book office forum\",\"category\":\"Product\"},{\"sequenceNumber\":19,\"key\":\"bof\",\"tenantTerm\":\"BOF\",\"frontiersDefaultTerm\":\"BOF\",\"category\":\"Product\"},{\"sequenceNumber\":20,\"key\":\"aira\",\"tenantTerm\":\"AIRA\",\"frontiersDefaultTerm\":\"AIRA\",\"category\":\"Product\"},{\"sequenceNumber\":21,\"key\":\"editorial_board_management\",\"tenantTerm\":\"editorial board management\",\"frontiersDefaultTerm\":\"editorial board management\",\"category\":\"Product\"},{\"sequenceNumber\":22,\"key\":\"ebm\",\"tenantTerm\":\"EBM\",\"frontiersDefaultTerm\":\"EBM\",\"category\":\"Product\"},{\"sequenceNumber\":23,\"key\":\"domain\",\"tenantTerm\":\"domain\",\"frontiersDefaultTerm\":\"domain\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":24,\"key\":\"journal\",\"tenantTerm\":\"journal\",\"frontiersDefaultTerm\":\"journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":25,\"key\":\"section\",\"tenantTerm\":\"section\",\"frontiersDefaultTerm\":\"section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":26,\"key\":\"domains\",\"tenantTerm\":\"domains\",\"frontiersDefaultTerm\":\"domains\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":27,\"key\":\"specialty_section\",\"tenantTerm\":\"specialty section\",\"frontiersDefaultTerm\":\"specialty section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":28,\"key\":\"specialty_journal\",\"tenantTerm\":\"specialty journal\",\"frontiersDefaultTerm\":\"specialty journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":29,\"key\":\"journals\",\"tenantTerm\":\"journals\",\"frontiersDefaultTerm\":\"journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":30,\"key\":\"sections\",\"tenantTerm\":\"sections\",\"frontiersDefaultTerm\":\"sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":31,\"key\":\"specialty_sections\",\"tenantTerm\":\"specialty sections\",\"frontiersDefaultTerm\":\"specialty sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":32,\"key\":\"specialty_journals\",\"tenantTerm\":\"specialty journals\",\"frontiersDefaultTerm\":\"specialty journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":33,\"key\":\"manuscript\",\"tenantTerm\":\"manuscript\",\"frontiersDefaultTerm\":\"manuscript\",\"category\":\"Core\"},{\"sequenceNumber\":34,\"key\":\"manuscripts\",\"tenantTerm\":\"manuscripts\",\"frontiersDefaultTerm\":\"manuscripts\",\"category\":\"Core\"},{\"sequenceNumber\":35,\"key\":\"article\",\"tenantTerm\":\"article\",\"frontiersDefaultTerm\":\"article\",\"category\":\"Core\"},{\"sequenceNumber\":36,\"key\":\"articles\",\"tenantTerm\":\"articles\",\"frontiersDefaultTerm\":\"articles\",\"category\":\"Core\"},{\"sequenceNumber\":37,\"key\":\"article_type\",\"tenantTerm\":\"article type\",\"frontiersDefaultTerm\":\"article type\",\"category\":\"Core\"},{\"sequenceNumber\":38,\"key\":\"article_types\",\"tenantTerm\":\"article types\",\"frontiersDefaultTerm\":\"article types\",\"category\":\"Core\"},{\"sequenceNumber\":39,\"key\":\"author\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":40,\"key\":\"authors\",\"tenantTerm\":\"authors\",\"frontiersDefaultTerm\":\"authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":41,\"key\":\"authoring\",\"tenantTerm\":\"authoring\",\"frontiersDefaultTerm\":\"authoring\",\"category\":\"Core\"},{\"sequenceNumber\":42,\"key\":\"authored\",\"tenantTerm\":\"authored\",\"frontiersDefaultTerm\":\"authored\",\"category\":\"Core\"},{\"sequenceNumber\":43,\"key\":\"accept\",\"tenantTerm\":\"accept\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":44,\"key\":\"accepted\",\"tenantTerm\":\"accepted\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":45,\"key\":\"assistant_field_chief_editor\",\"tenantTerm\":\"Assistant Field Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editor\",\"description\":\"An editorial role on a Field Journal that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":46,\"key\":\"assistant_specialty_chief_editor\",\"tenantTerm\":\"Assistant Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":47,\"key\":\"assistant_specialty_chief_editors\",\"tenantTerm\":\"Assistant Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":48,\"key\":\"associate_editor\",\"tenantTerm\":\"Associate Editor\",\"frontiersDefaultTerm\":\"Associate Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":49,\"key\":\"specialty_chief_editor\",\"tenantTerm\":\"Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":50,\"key\":\"specialty_chief_editors\",\"tenantTerm\":\"Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":51,\"key\":\"chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":52,\"key\":\"chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":53,\"key\":\"call_for_participation\",\"tenantTerm\":\"call for participation\",\"frontiersDefaultTerm\":\"call for participation\",\"category\":\"Process\"},{\"sequenceNumber\":54,\"key\":\"citation\",\"tenantTerm\":\"citation\",\"frontiersDefaultTerm\":\"citation\",\"category\":\"Misc.\"},{\"sequenceNumber\":55,\"key\":\"citations\",\"tenantTerm\":\"citations\",\"frontiersDefaultTerm\":\"citations\",\"category\":\"Misc.\"},{\"sequenceNumber\":56,\"key\":\"contributor\",\"tenantTerm\":\"contributor\",\"frontiersDefaultTerm\":\"contributor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":57,\"key\":\"contributors\",\"tenantTerm\":\"contributors\",\"frontiersDefaultTerm\":\"contributors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":58,\"key\":\"corresponding_author\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":59,\"key\":\"corresponding_authors\",\"tenantTerm\":\"corresponding authors\",\"frontiersDefaultTerm\":\"corresponding authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":60,\"key\":\"decline\",\"tenantTerm\":\"decline\",\"frontiersDefaultTerm\":\"decline\",\"category\":\"Process\"},{\"sequenceNumber\":61,\"key\":\"declined\",\"tenantTerm\":\"declined\",\"frontiersDefaultTerm\":\"declined\",\"category\":\"Process\"},{\"sequenceNumber\":62,\"key\":\"reject\",\"tenantTerm\":\"reject\",\"frontiersDefaultTerm\":\"reject\",\"category\":\"Process\"},{\"sequenceNumber\":63,\"key\":\"rejected\",\"tenantTerm\":\"rejected\",\"frontiersDefaultTerm\":\"rejected\",\"category\":\"Process\"},{\"sequenceNumber\":64,\"key\":\"publish\",\"tenantTerm\":\"publish\",\"frontiersDefaultTerm\":\"publish\",\"category\":\"Core\"},{\"sequenceNumber\":65,\"key\":\"published\",\"tenantTerm\":\"published\",\"frontiersDefaultTerm\":\"published\",\"category\":\"Core\"},{\"sequenceNumber\":66,\"key\":\"publication\",\"tenantTerm\":\"publication\",\"frontiersDefaultTerm\":\"publication\",\"category\":\"Core\"},{\"sequenceNumber\":67,\"key\":\"peer_review\",\"tenantTerm\":\"peer review\",\"frontiersDefaultTerm\":\"peer review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":68,\"key\":\"peer_reviewed\",\"tenantTerm\":\"peer reviewed\",\"frontiersDefaultTerm\":\"peer reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":69,\"key\":\"initial_validation\",\"tenantTerm\":\"initial validation\",\"frontiersDefaultTerm\":\"initial validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":70,\"key\":\"editorial_assignment\",\"tenantTerm\":\"editorial assignment\",\"frontiersDefaultTerm\":\"editorial assignment\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":71,\"key\":\"independent_review\",\"tenantTerm\":\"independent review\",\"frontiersDefaultTerm\":\"independent review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":72,\"key\":\"interactive_review\",\"tenantTerm\":\"interactive review\",\"frontiersDefaultTerm\":\"interactive review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":73,\"key\":\"review\",\"tenantTerm\":\"review\",\"frontiersDefaultTerm\":\"review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":74,\"key\":\"reviewing\",\"tenantTerm\":\"reviewing\",\"frontiersDefaultTerm\":\"reviewing\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":75,\"key\":\"reviewer\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":76,\"key\":\"reviewers\",\"tenantTerm\":\"reviewers\",\"frontiersDefaultTerm\":\"reviewers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":77,\"key\":\"review_finalized\",\"tenantTerm\":\"review finalized\",\"frontiersDefaultTerm\":\"review finalized\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":78,\"key\":\"final_decision\",\"tenantTerm\":\"final decision\",\"frontiersDefaultTerm\":\"final decision\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":79,\"key\":\"final_validation\",\"tenantTerm\":\"final validation\",\"frontiersDefaultTerm\":\"final validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":80,\"key\":\"ae_accept_manuscript\",\"tenantTerm\":\"recommend to accept manuscript\",\"frontiersDefaultTerm\":\"accept manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":81,\"key\":\"fee\",\"tenantTerm\":\"fee\",\"frontiersDefaultTerm\":\"fee\",\"category\":\"Accounting\"},{\"sequenceNumber\":82,\"key\":\"fees\",\"tenantTerm\":\"fees\",\"frontiersDefaultTerm\":\"fees\",\"category\":\"Accounting\"},{\"sequenceNumber\":83,\"key\":\"guest_associate_editor\",\"tenantTerm\":\"Guest Associate Editor\",\"frontiersDefaultTerm\":\"Guest Associate Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":84,\"key\":\"guest_associate_editors\",\"tenantTerm\":\"Guest Associate Editors\",\"frontiersDefaultTerm\":\"Guest Associate Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":85,\"key\":\"in_review\",\"tenantTerm\":\"in review\",\"frontiersDefaultTerm\":\"in review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":86,\"key\":\"institutional_member\",\"tenantTerm\":\"institutional partner\",\"frontiersDefaultTerm\":\"institutional partner\",\"category\":\"Accounting\"},{\"sequenceNumber\":87,\"key\":\"institutional_membership\",\"tenantTerm\":\"institutional partnership\",\"frontiersDefaultTerm\":\"institutional partnership\",\"category\":\"Accounting\"},{\"sequenceNumber\":88,\"key\":\"article_processing_charge\",\"tenantTerm\":\"article processing charge\",\"frontiersDefaultTerm\":\"article processing charge\",\"category\":\"Accounting\"},{\"sequenceNumber\":89,\"key\":\"article_processing_charges\",\"tenantTerm\":\"article processing charges\",\"frontiersDefaultTerm\":\"article processing charges\",\"category\":\"Accounting\"},{\"sequenceNumber\":90,\"key\":\"apcs\",\"tenantTerm\":\"APCs\",\"frontiersDefaultTerm\":\"APCs\",\"category\":\"Accounting\"},{\"sequenceNumber\":91,\"key\":\"apc\",\"tenantTerm\":\"APC\",\"frontiersDefaultTerm\":\"APC\",\"category\":\"Accounting\"},{\"sequenceNumber\":92,\"key\":\"received\",\"tenantTerm\":\"received\",\"frontiersDefaultTerm\":\"received\",\"description\":\"Date manuscript was received on.\",\"category\":\"Core\"},{\"sequenceNumber\":93,\"key\":\"transferred\",\"tenantTerm\":\"transferred\",\"frontiersDefaultTerm\":\"transferred\",\"category\":\"Core\"},{\"sequenceNumber\":94,\"key\":\"transfer\",\"tenantTerm\":\"transfer\",\"frontiersDefaultTerm\":\"transfer\",\"category\":\"Core\"},{\"sequenceNumber\":95,\"key\":\"research_topic\",\"tenantTerm\":\"research topic\",\"frontiersDefaultTerm\":\"research topic\",\"category\":\"Core\"},{\"sequenceNumber\":96,\"key\":\"research_topics\",\"tenantTerm\":\"research topics\",\"frontiersDefaultTerm\":\"research topics\",\"category\":\"Core\"},{\"sequenceNumber\":97,\"key\":\"topic_editor\",\"tenantTerm\":\"Topic Editor\",\"frontiersDefaultTerm\":\"Topic Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":98,\"key\":\"review_editor\",\"tenantTerm\":\"Community Reviewer\",\"frontiersDefaultTerm\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":99,\"key\":\"title\",\"tenantTerm\":\"title\",\"frontiersDefaultTerm\":\"title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":100,\"key\":\"running_title\",\"tenantTerm\":\"running title\",\"frontiersDefaultTerm\":\"running title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":101,\"key\":\"submit\",\"tenantTerm\":\"submit\",\"frontiersDefaultTerm\":\"submit\",\"category\":\"Process\"},{\"sequenceNumber\":102,\"key\":\"submitted\",\"tenantTerm\":\"submitted\",\"frontiersDefaultTerm\":\"submitted\",\"category\":\"Process\"},{\"sequenceNumber\":103,\"key\":\"submitting\",\"tenantTerm\":\"submitting\",\"frontiersDefaultTerm\":\"submitting\",\"category\":\"Process\"},{\"sequenceNumber\":104,\"key\":\"t_e\",\"tenantTerm\":\"TE\",\"frontiersDefaultTerm\":\"TE\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":105,\"key\":\"topic\",\"tenantTerm\":\"topic\",\"frontiersDefaultTerm\":\"topic\",\"category\":\"Process\"},{\"sequenceNumber\":106,\"key\":\"topic_summary\",\"tenantTerm\":\"topic summary\",\"frontiersDefaultTerm\":\"topic summary\",\"category\":\"Process\"},{\"sequenceNumber\":107,\"key\":\"figure\",\"tenantTerm\":\"figure\",\"frontiersDefaultTerm\":\"figure\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":108,\"key\":\"figures\",\"tenantTerm\":\"figures\",\"frontiersDefaultTerm\":\"figures\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":109,\"key\":\"editorial_file\",\"tenantTerm\":\"editorial file\",\"frontiersDefaultTerm\":\"editorial file\",\"category\":\"Core\"},{\"sequenceNumber\":110,\"key\":\"editorial_files\",\"tenantTerm\":\"editorial files\",\"frontiersDefaultTerm\":\"editorial files\",\"category\":\"Core\"},{\"sequenceNumber\":111,\"key\":\"e_book\",\"tenantTerm\":\"e-book\",\"frontiersDefaultTerm\":\"e-book\",\"category\":\"Core\"},{\"sequenceNumber\":112,\"key\":\"organization\",\"tenantTerm\":\"organization\",\"frontiersDefaultTerm\":\"organization\",\"category\":\"Core\"},{\"sequenceNumber\":113,\"key\":\"institution\",\"tenantTerm\":\"institution\",\"frontiersDefaultTerm\":\"institution\",\"category\":\"Core\"},{\"sequenceNumber\":114,\"key\":\"reference\",\"tenantTerm\":\"reference\",\"frontiersDefaultTerm\":\"reference\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":115,\"key\":\"references\",\"tenantTerm\":\"references\",\"frontiersDefaultTerm\":\"references\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":116,\"key\":\"sce\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"description\":\"Abbreviation for Specialty Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":117,\"key\":\"submission\",\"tenantTerm\":\"submission\",\"frontiersDefaultTerm\":\"submission\",\"category\":\"Process\"},{\"sequenceNumber\":118,\"key\":\"submissions\",\"tenantTerm\":\"submissions\",\"frontiersDefaultTerm\":\"submissions\",\"category\":\"Process\"},{\"sequenceNumber\":119,\"key\":\"editing\",\"tenantTerm\":\"editing\",\"frontiersDefaultTerm\":\"editing\",\"category\":\"Process\"},{\"sequenceNumber\":120,\"key\":\"in_preparation\",\"tenantTerm\":\"in preparation\",\"frontiersDefaultTerm\":\"in preparation\",\"category\":\"Process\"},{\"sequenceNumber\":121,\"key\":\"country_region\",\"tenantTerm\":\"country/region\",\"frontiersDefaultTerm\":\"country/region\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":122,\"key\":\"countries_regions\",\"tenantTerm\":\"countries/regions\",\"frontiersDefaultTerm\":\"countries/regions\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":123,\"key\":\"specialty\",\"tenantTerm\":\"specialty\",\"frontiersDefaultTerm\":\"specialty\",\"category\":\"Core\"},{\"sequenceNumber\":124,\"key\":\"specialties\",\"tenantTerm\":\"specialties\",\"frontiersDefaultTerm\":\"specialties\",\"category\":\"Core\"},{\"sequenceNumber\":125,\"key\":\"associate_editors\",\"tenantTerm\":\"Associate Editors\",\"frontiersDefaultTerm\":\"Associate Editors\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":126,\"key\":\"reviewed\",\"tenantTerm\":\"reviewed\",\"frontiersDefaultTerm\":\"reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":127,\"key\":\"institutional_members\",\"tenantTerm\":\"institutional partners\",\"frontiersDefaultTerm\":\"institutional partners\",\"category\":\"Accounting\"},{\"sequenceNumber\":128,\"key\":\"institutional_memberships\",\"tenantTerm\":\"institutional partnerships\",\"frontiersDefaultTerm\":\"institutional partnerships\",\"category\":\"Accounting\"},{\"sequenceNumber\":129,\"key\":\"assistant_field_chief_editors\",\"tenantTerm\":\"Assistant Field Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":130,\"key\":\"publications\",\"tenantTerm\":\"publications\",\"frontiersDefaultTerm\":\"publications\",\"category\":\"Process\"},{\"sequenceNumber\":131,\"key\":\"ae_accepted\",\"tenantTerm\":\"recommended acceptance\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":132,\"key\":\"field_journal\",\"tenantTerm\":\"field journal\",\"frontiersDefaultTerm\":\"field journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":133,\"key\":\"field_journals\",\"tenantTerm\":\"field journals\",\"frontiersDefaultTerm\":\"field journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":134,\"key\":\"program_manager\",\"tenantTerm\":\"program manager\",\"frontiersDefaultTerm\":\"program manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":135,\"key\":\"journal_manager\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":136,\"key\":\"journal_specialist\",\"tenantTerm\":\"journal specialist\",\"frontiersDefaultTerm\":\"journal specialist\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":137,\"key\":\"program_managers\",\"tenantTerm\":\"program managers\",\"frontiersDefaultTerm\":\"program managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":138,\"key\":\"journal_managers\",\"tenantTerm\":\"journal managers\",\"frontiersDefaultTerm\":\"journal managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":139,\"key\":\"journal_specialists\",\"tenantTerm\":\"journal specialists\",\"frontiersDefaultTerm\":\"journal specialists\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":140,\"key\":\"cover_letter\",\"tenantTerm\":\"manuscript contribution to the field\",\"frontiersDefaultTerm\":\"manuscript contribution to the field\",\"category\":\"Process\"},{\"sequenceNumber\":141,\"key\":\"ae_accepted_manuscript\",\"tenantTerm\":\"recommended to accept manuscript\",\"frontiersDefaultTerm\":\"accepted manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":142,\"key\":\"recommend_for_rejection\",\"tenantTerm\":\"recommend for rejection\",\"frontiersDefaultTerm\":\"recommend for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":143,\"key\":\"recommended_for_rejection\",\"tenantTerm\":\"recommended for rejection\",\"frontiersDefaultTerm\":\"recommended for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":144,\"key\":\"ae\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"description\":\"Associate Editor - board member\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":145,\"key\":\"re\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"description\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":146,\"key\":\"rev\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"description\":\"Reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":147,\"key\":\"aut\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"description\":\"Author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":148,\"key\":\"coraut\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"description\":\"Corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":149,\"key\":\"saut\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"description\":\"Submitting author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":150,\"key\":\"coaut\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"description\":\"co-author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":151,\"key\":\"tsof\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"description\":\"Typesetter\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":152,\"key\":\"typesetting_office\",\"tenantTerm\":\"typesetting office\",\"frontiersDefaultTerm\":\"typesetting office\",\"category\":\"Product\"},{\"sequenceNumber\":153,\"key\":\"config\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"description\":\"Configuration office role\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":154,\"key\":\"jm\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"description\":\"Journal Manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":155,\"key\":\"rte\",\"tenantTerm\":\"RTE\",\"frontiersDefaultTerm\":\"RTE\",\"description\":\"Research topic editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":156,\"key\":\"organizations\",\"tenantTerm\":\"organizations\",\"frontiersDefaultTerm\":\"organizations\",\"category\":\"Core\"},{\"sequenceNumber\":157,\"key\":\"publishing\",\"tenantTerm\":\"publishing\",\"frontiersDefaultTerm\":\"publishing\",\"category\":\"Core\"},{\"sequenceNumber\":158,\"key\":\"acceptance\",\"tenantTerm\":\"acceptance\",\"frontiersDefaultTerm\":\"acceptance\",\"category\":\"Process\"},{\"sequenceNumber\":159,\"key\":\"preferred_associate_editor\",\"tenantTerm\":\"preferred associate editor\",\"frontiersDefaultTerm\":\"preferred associate editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":160,\"key\":\"topic_editors\",\"tenantTerm\":\"Topic Editors\",\"frontiersDefaultTerm\":\"Topic Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":161,\"key\":\"institutions\",\"tenantTerm\":\"institutions\",\"frontiersDefaultTerm\":\"institutions\",\"category\":\"Core\"},{\"sequenceNumber\":162,\"key\":\"author(s)\",\"tenantTerm\":\"author(s)\",\"frontiersDefaultTerm\":\"author(s)\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":163,\"key\":\"figure(s)\",\"tenantTerm\":\"figure(s)\",\"frontiersDefaultTerm\":\"figure(s)\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":164,\"key\":\"co-authors\",\"tenantTerm\":\"co-authors\",\"frontiersDefaultTerm\":\"co-authors\",\"description\":\"co-authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":165,\"key\":\"editorial_board_members\",\"tenantTerm\":\"editorial board members\",\"frontiersDefaultTerm\":\"editorial board members\",\"description\":\"editorial board members\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":166,\"key\":\"editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"editorial board\",\"category\":\"Product\"},{\"sequenceNumber\":167,\"key\":\"co-authorship\",\"tenantTerm\":\"co-authorship\",\"frontiersDefaultTerm\":\"co-authorship\",\"description\":\"co-authorship\",\"category\":\"Misc.\"},{\"sequenceNumber\":168,\"key\":\"role_id_1\",\"tenantTerm\":\"registration office\",\"frontiersDefaultTerm\":\"registration office\",\"category\":\"User Role\"},{\"sequenceNumber\":169,\"key\":\"role_id_2\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"User Role\"},{\"sequenceNumber\":170,\"key\":\"role_id_7\",\"tenantTerm\":\"field chief editor\",\"frontiersDefaultTerm\":\"field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":171,\"key\":\"role_id_8\",\"tenantTerm\":\"assistant field chief editor\",\"frontiersDefaultTerm\":\"assistant field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":172,\"key\":\"role_id_9\",\"tenantTerm\":\"specialty chief editor\",\"frontiersDefaultTerm\":\"specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":173,\"key\":\"role_id_10\",\"tenantTerm\":\"assistant specialty chief editor\",\"frontiersDefaultTerm\":\"assistant specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":174,\"key\":\"role_id_11\",\"tenantTerm\":\"associate editor\",\"frontiersDefaultTerm\":\"associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":175,\"key\":\"role_id_12\",\"tenantTerm\":\"guest associate editor\",\"frontiersDefaultTerm\":\"guest associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":176,\"key\":\"role_id_13\",\"tenantTerm\":\"review editor\",\"frontiersDefaultTerm\":\"review editor\",\"category\":\"User Role\"},{\"sequenceNumber\":177,\"key\":\"role_id_14\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":178,\"key\":\"role_id_15\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"User Role\"},{\"sequenceNumber\":179,\"key\":\"role_id_16\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"User Role\"},{\"sequenceNumber\":180,\"key\":\"role_id_17\",\"tenantTerm\":\"submitting author\",\"frontiersDefaultTerm\":\"submitting author\",\"category\":\"User Role\"},{\"sequenceNumber\":181,\"key\":\"role_id_18\",\"tenantTerm\":\"co-author\",\"frontiersDefaultTerm\":\"co-author\",\"category\":\"User Role\"},{\"sequenceNumber\":182,\"key\":\"role_id_20\",\"tenantTerm\":\"production office\",\"frontiersDefaultTerm\":\"production office\",\"category\":\"User Role\"},{\"sequenceNumber\":183,\"key\":\"role_id_22\",\"tenantTerm\":\"typesetting office (typesetter)\",\"frontiersDefaultTerm\":\"typesetting office (typesetter)\",\"category\":\"User Role\"},{\"sequenceNumber\":184,\"key\":\"role_id_24\",\"tenantTerm\":\"registered user\",\"frontiersDefaultTerm\":\"registered user\",\"category\":\"User Role\"},{\"sequenceNumber\":185,\"key\":\"role_id_35\",\"tenantTerm\":\"job office\",\"frontiersDefaultTerm\":\"job office\",\"category\":\"User Role\"},{\"sequenceNumber\":186,\"key\":\"role_id_41\",\"tenantTerm\":\"special event administrator\",\"frontiersDefaultTerm\":\"special event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":187,\"key\":\"role_id_42\",\"tenantTerm\":\"special event reviewer\",\"frontiersDefaultTerm\":\"special event reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":188,\"key\":\"role_id_43\",\"tenantTerm\":\"submit abstract\",\"frontiersDefaultTerm\":\"submit abstract\",\"category\":\"User Role\"},{\"sequenceNumber\":189,\"key\":\"role_id_52\",\"tenantTerm\":\"events office\",\"frontiersDefaultTerm\":\"events office\",\"category\":\"User Role\"},{\"sequenceNumber\":190,\"key\":\"role_id_53\",\"tenantTerm\":\"event administrator\",\"frontiersDefaultTerm\":\"event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":191,\"key\":\"role_id_89\",\"tenantTerm\":\"content management office\",\"frontiersDefaultTerm\":\"content management office\",\"category\":\"User Role\"},{\"sequenceNumber\":192,\"key\":\"role_id_98\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"User Role\"},{\"sequenceNumber\":193,\"key\":\"role_id_99\",\"tenantTerm\":\"projects\",\"frontiersDefaultTerm\":\"projects\",\"category\":\"User Role\"},{\"sequenceNumber\":194,\"key\":\"role_id_103\",\"tenantTerm\":\"configuration office\",\"frontiersDefaultTerm\":\"configuration office\",\"category\":\"User Role\"},{\"sequenceNumber\":195,\"key\":\"role_id_104\",\"tenantTerm\":\"beta user\",\"frontiersDefaultTerm\":\"beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":196,\"key\":\"role_id_106\",\"tenantTerm\":\"wfconf\",\"frontiersDefaultTerm\":\"wfconf\",\"category\":\"User Role\"},{\"sequenceNumber\":197,\"key\":\"role_id_107\",\"tenantTerm\":\"rt management beta user\",\"frontiersDefaultTerm\":\"rt management beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":198,\"key\":\"role_id_108\",\"tenantTerm\":\"deo beta user\",\"frontiersDefaultTerm\":\"deo beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":199,\"key\":\"role_id_109\",\"tenantTerm\":\"search beta user\",\"frontiersDefaultTerm\":\"search beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":200,\"key\":\"role_id_110\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"User Role\"},{\"sequenceNumber\":201,\"key\":\"role_id_111\",\"tenantTerm\":\"myfrontiers beta user\",\"frontiersDefaultTerm\":\"myfrontiers beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":202,\"key\":\"role_id_21\",\"tenantTerm\":\"copy editor\",\"frontiersDefaultTerm\":\"copy editor\",\"category\":\"User Role\"},{\"sequenceNumber\":203,\"key\":\"role_id_1_abr\",\"tenantTerm\":\"ROF\",\"frontiersDefaultTerm\":\"ROF\",\"category\":\"User Role\"},{\"sequenceNumber\":204,\"key\":\"role_id_2_abr\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"User Role\"},{\"sequenceNumber\":205,\"key\":\"role_id_7_abr\",\"tenantTerm\":\"FCE\",\"frontiersDefaultTerm\":\"FCE\",\"category\":\"User Role\"},{\"sequenceNumber\":206,\"key\":\"role_id_8_abr\",\"tenantTerm\":\"AFCE\",\"frontiersDefaultTerm\":\"AFCE\",\"category\":\"User Role\"},{\"sequenceNumber\":207,\"key\":\"role_id_9_abr\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"category\":\"User Role\"},{\"sequenceNumber\":208,\"key\":\"role_id_10_abr\",\"tenantTerm\":\"ASCE\",\"frontiersDefaultTerm\":\"ASCE\",\"category\":\"User Role\"},{\"sequenceNumber\":209,\"key\":\"role_id_11_abr\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"category\":\"User Role\"},{\"sequenceNumber\":210,\"key\":\"role_id_12_abr\",\"tenantTerm\":\"GAE\",\"frontiersDefaultTerm\":\"GAE\",\"category\":\"User Role\"},{\"sequenceNumber\":211,\"key\":\"role_id_13_abr\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"category\":\"User Role\"},{\"sequenceNumber\":212,\"key\":\"role_id_14_abr\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"category\":\"User Role\"},{\"sequenceNumber\":213,\"key\":\"role_id_15_abr\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":214,\"key\":\"role_id_16_abr\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":215,\"key\":\"role_id_17_abr\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":216,\"key\":\"role_id_18_abr\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":217,\"key\":\"role_id_20_abr\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"User Role\"},{\"sequenceNumber\":218,\"key\":\"role_id_22_abr\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"category\":\"User Role\"},{\"sequenceNumber\":219,\"key\":\"role_id_24_abr\",\"tenantTerm\":\"RU\",\"frontiersDefaultTerm\":\"RU\",\"category\":\"User Role\"},{\"sequenceNumber\":220,\"key\":\"role_id_35_abr\",\"tenantTerm\":\"JOF\",\"frontiersDefaultTerm\":\"JOF\",\"category\":\"User Role\"},{\"sequenceNumber\":221,\"key\":\"role_id_41_abr\",\"tenantTerm\":\"SE-ADM\",\"frontiersDefaultTerm\":\"SE-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":222,\"key\":\"role_id_42_abr\",\"tenantTerm\":\"SE-REV\",\"frontiersDefaultTerm\":\"SE-REV\",\"category\":\"User Role\"},{\"sequenceNumber\":223,\"key\":\"role_id_43_abr\",\"tenantTerm\":\"SE-AUT\",\"frontiersDefaultTerm\":\"SE-AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":224,\"key\":\"role_id_52_abr\",\"tenantTerm\":\"EVOF\",\"frontiersDefaultTerm\":\"EVOF\",\"category\":\"User Role\"},{\"sequenceNumber\":225,\"key\":\"role_id_53_abr\",\"tenantTerm\":\"EV-ADM\",\"frontiersDefaultTerm\":\"EV-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":226,\"key\":\"role_id_89_abr\",\"tenantTerm\":\"COMOF\",\"frontiersDefaultTerm\":\"COMOF\",\"category\":\"User Role\"},{\"sequenceNumber\":227,\"key\":\"role_id_98_abr\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"User Role\"},{\"sequenceNumber\":228,\"key\":\"role_id_99_abr\",\"tenantTerm\":\"Projects\",\"frontiersDefaultTerm\":\"Projects\",\"category\":\"User Role\"},{\"sequenceNumber\":229,\"key\":\"role_id_103_abr\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"category\":\"User Role\"},{\"sequenceNumber\":230,\"key\":\"role_id_104_abr\",\"tenantTerm\":\"BETA\",\"frontiersDefaultTerm\":\"BETA\",\"category\":\"User Role\"},{\"sequenceNumber\":231,\"key\":\"role_id_106_abr\",\"tenantTerm\":\"WFCONF\",\"frontiersDefaultTerm\":\"WFCONF\",\"category\":\"User Role\"},{\"sequenceNumber\":232,\"key\":\"role_id_107_abr\",\"tenantTerm\":\"RTBETA\",\"frontiersDefaultTerm\":\"RTBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":233,\"key\":\"role_id_108_abr\",\"tenantTerm\":\"DEOBETA\",\"frontiersDefaultTerm\":\"DEOBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":234,\"key\":\"role_id_109_abr\",\"tenantTerm\":\"SEARCHBETA\",\"frontiersDefaultTerm\":\"SEARCHBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":235,\"key\":\"role_id_110_abr\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"category\":\"User Role\"},{\"sequenceNumber\":236,\"key\":\"role_id_111_abr\",\"tenantTerm\":\"MFBETA\",\"frontiersDefaultTerm\":\"MFBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":237,\"key\":\"role_id_21_abr\",\"tenantTerm\":\"COPED\",\"frontiersDefaultTerm\":\"COPED\",\"category\":\"User Role\"},{\"sequenceNumber\":238,\"key\":\"reviewer_editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"This is the label for the review editorial board\",\"category\":\"Label\"},{\"sequenceNumber\":239,\"key\":\"field_chief_editor\",\"tenantTerm\":\"Field Chief Editor\",\"frontiersDefaultTerm\":\"Field Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":240,\"key\":\"field_chief_editors\",\"tenantTerm\":\"Field Chief Editors\",\"frontiersDefaultTerm\":\"Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":241,\"key\":\"editor\",\"tenantTerm\":\"editor\",\"frontiersDefaultTerm\":\"editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":242,\"key\":\"editors\",\"tenantTerm\":\"editors\",\"frontiersDefaultTerm\":\"editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":243,\"key\":\"board\",\"tenantTerm\":\"board\",\"frontiersDefaultTerm\":\"board\",\"category\":\"Label\"},{\"sequenceNumber\":244,\"key\":\"boards\",\"tenantTerm\":\"boards\",\"frontiersDefaultTerm\":\"boards\",\"category\":\"Label\"},{\"sequenceNumber\":245,\"key\":\"article_collection\",\"tenantTerm\":\"article collection\",\"frontiersDefaultTerm\":\"article collection\",\"category\":\"Label\"},{\"sequenceNumber\":246,\"key\":\"article_collections\",\"tenantTerm\":\"article collections\",\"frontiersDefaultTerm\":\"article collections\",\"category\":\"Label\"},{\"sequenceNumber\":247,\"key\":\"handling_editor\",\"tenantTerm\":\"handling editor\",\"frontiersDefaultTerm\":\"associate editor\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":248,\"key\":\"handling_editors\",\"tenantTerm\":\"handling editors\",\"frontiersDefaultTerm\":\"associate editors\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":249,\"key\":\"ae_accept\",\"tenantTerm\":\"recommend acceptance\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":250,\"key\":\"rtm\",\"tenantTerm\":\"RTM\",\"frontiersDefaultTerm\":\"RTM\",\"category\":\"Product\"},{\"sequenceNumber\":251,\"key\":\"frontiers_media_sa\",\"tenantTerm\":\"Frontiers Media S.A\",\"frontiersDefaultTerm\":\"Frontiers Media S.A\",\"category\":\"Customer\"},{\"sequenceNumber\":252,\"key\":\"review_editors\",\"tenantTerm\":\"Community Reviewers\",\"frontiersDefaultTerm\":\"Review Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":253,\"key\":\"journal_card_chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":254,\"key\":\"journal_card_chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":255,\"key\":\"call_for_papers\",\"tenantTerm\":\"Call for papers\",\"frontiersDefaultTerm\":\"Call for papers\",\"category\":\"Label\"},{\"sequenceNumber\":256,\"key\":\"calls_for_papers\",\"tenantTerm\":\"Calls for papers\",\"frontiersDefaultTerm\":\"Calls for papers\",\"category\":\"Label\"},{\"sequenceNumber\":257,\"key\":\"supervising_editor\",\"tenantTerm\":\"Supervising Editor\",\"frontiersDefaultTerm\":\"Supervising Editor\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editor\"},{\"sequenceNumber\":258,\"key\":\"supervising_editors\",\"tenantTerm\":\"Supervising Editors\",\"frontiersDefaultTerm\":\"Supervising Editors\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editors\"},{\"sequenceNumber\":259,\"key\":\"reviewer_endorse\",\"tenantTerm\":\"endorse\",\"frontiersDefaultTerm\":\"endorse\",\"category\":\"Label\"},{\"sequenceNumber\":260,\"key\":\"reviewer_endorsed\",\"tenantTerm\":\"endorsed\",\"frontiersDefaultTerm\":\"endorsed\",\"category\":\"Label\"},{\"sequenceNumber\":261,\"key\":\"reviewer_endorse_publication\",\"tenantTerm\":\"endorse publication\",\"frontiersDefaultTerm\":\"endorse publication\",\"category\":\"Label\"},{\"sequenceNumber\":262,\"key\":\"reviewer_endorsed_publication\",\"tenantTerm\":\"endorsed publication\",\"frontiersDefaultTerm\":\"endorsed publication\",\"category\":\"Label\"},{\"sequenceNumber\":263,\"key\":\"editor_role\",\"tenantTerm\":\"editor role\",\"frontiersDefaultTerm\":\"Editor Role\",\"category\":\"Label\"},{\"sequenceNumber\":264,\"key\":\"editor_roles\",\"tenantTerm\":\"editor roles\",\"frontiersDefaultTerm\":\"Editor Roles\",\"category\":\"Label\"},{\"sequenceNumber\":265,\"key\":\"editorial_role\",\"tenantTerm\":\"editorial role\",\"frontiersDefaultTerm\":\"Editorial Role\",\"category\":\"Label\"},{\"sequenceNumber\":266,\"key\":\"editorial_roles\",\"tenantTerm\":\"editorial roles\",\"frontiersDefaultTerm\":\"Editorial Roles\",\"category\":\"Label\"},{\"sequenceNumber\":267,\"key\":\"call_for_paper\",\"tenantTerm\":\"Call for paper\",\"frontiersDefaultTerm\":\"Call for paper\",\"category\":\"Label\"},{\"sequenceNumber\":268,\"key\":\"research_topic_abstract\",\"tenantTerm\":\"manuscript summary\",\"frontiersDefaultTerm\":\"manuscript summary\",\"category\":\"Process\"},{\"sequenceNumber\":269,\"key\":\"research_topic_abstracts\",\"tenantTerm\":\"manuscript summaries\",\"frontiersDefaultTerm\":\"manuscript summaries\",\"category\":\"Process\"},{\"sequenceNumber\":270,\"key\":\"submissions_team_manager\",\"tenantTerm\":\"Journal Manager\",\"frontiersDefaultTerm\":\"Content Manager\",\"category\":\"Process\"},{\"sequenceNumber\":271,\"key\":\"submissions_team\",\"tenantTerm\":\"Journal Team\",\"frontiersDefaultTerm\":\"Content Team\",\"category\":\"Process\"},{\"sequenceNumber\":272,\"key\":\"topic_coordinator\",\"tenantTerm\":\"topic coordinator\",\"frontiersDefaultTerm\":\"topic coordinator\",\"category\":\"Process\"},{\"sequenceNumber\":273,\"key\":\"topic_coordinators\",\"tenantTerm\":\"topic coordinators\",\"frontiersDefaultTerm\":\"topic coordinators\",\"category\":\"Process\"},{\"sequenceNumber\":274,\"key\":\"frontiers_journal_team\",\"tenantTerm\":\"frontiers journal team\",\"frontiersDefaultTerm\":\"frontiers journal team\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":275,\"key\":\"research_topic_ic_submission\",\"tenantTerm\":\"RT:IC Submission\",\"frontiersDefaultTerm\":\"RT:IC Submission\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":276,\"key\":\"research_topic_ic_submission_participant\",\"tenantTerm\":\"RT:IC Submission participant\",\"frontiersDefaultTerm\":\"RT:IC Submission participant\",\"category\":\"Label (Role)\"}]}'\n",impactGtmId:"GTM-NJF2ML9B",impactGtmAuth:"fYo-7NoDm9w37QgFMs03SA",impactGtmPreview:"env-1",impactGoogleMapsApiKey:"AIzaSyCTEhX2EU8PWfi86GW9FI00FTcyKk6Ifr8",qualtricsV4ToV3:"'{\"enabled\":true,\"interceptId\":\"SI_er0E2ze69Oz8Yn4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsUmux:"'{\"enabled\":false,\"interceptId\":\"SI_89fPHY3eTxQBwtU\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsContinuousBrand:"'{\"enabled\":true,\"interceptId\":\"SI_9ZuT94UT81FcRh4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",defaultArticleTemplate:"v3"},app:{baseURL:"/",buildId:"ed555f16-85f7-4f41-8f2f-451827c59120",buildAssetsDir:"ap-2024/_nuxt",cdnURL:""}}</script>
<script src="https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6" type="text/javascript" async></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML" type="text/javascript" async></script>
<script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js" type="text/javascript" async></script>
<script src="https://api.altmetric.com/v1/doi/10.3389/fonc.2020.00295?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15" type="text/javascript" async></script>
<script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript" async></script></body></html>